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Introduction 
Over the last three decades, haematopoietic stem cell transplantation (HCT) 
has become an important treatment modality for a wide range of life-
threatening haematological and immunological disorders in both children and 
adults, with over 25,000 transplants in Europe in the year 2003 1. With an 
increasing number of long-term survivors, the long-term consequences of HCT 
become increasingly important. Late effects may result from the disease for 
which HCT is performed (including its initial treatment), from toxicity of the 
conditioning regimens, and (in allogeneic HCT) from chronic graft-versus-host-
disease (cGVHD). 
Chronic GVHD 
cGVHD is the prime cause of transplant related mortality and contributes both 
directly and indirectly to many late complications 2;3. The incidence of cGVHD 
is increasing due to the increase of alternative donors (e.g. haplo-identical 
family members and matched unrelated donors), alternative sources of 
haematopoietic stem cells (peripheral blood stem cells instead of bone 
marrow), and use of donor lymphocyte infusions for treatment of relapse or 
prophylaxis to prevent relapse in patients at high risk for relapse of their 
malignancy 4. Although a wide range of organs can be affected by cGVHD (e.g. 
skin, hair, nails, eyes, mouth, gastro-intestinal tract, liver and respiratory tract), 
endocrine organs are usually not directly affected. Treatment of GVHD with 
high doses of glucocorticosteroids, however, will have its impact on growth, 
adrenal function and bone mineral density. 
Conditioning regimens 
Successful engraftment of allogeneic haematopoietic stem cells will not occur 
in the presence of a competent immune system. Therefore, most recipients will 
have to be 'conditioned' for HCT. This conditioning aims at induction of space 
for progenitor cells to engraft and immunosuppression to accept the allogeneic 
graft 5. It may be myeloablative (i.e. eradicating the host’s haematopoietic 
General introduction 
 3 
system), or immunoablative (i.e. only suppressing the host’s immune 
alloreactivity, nowadays called ‘reduced intensity conditioning’). It is effectuated 
by high doses of chemotherapy, often combined with total-body irradiation 
(TBI) and sometimes with anti-T-cell antibodies. In the first decade of HCT, 
most myeloablative conditioning regimens consisted of single-fraction TBI and 
high dose cyclophosphamide (120 mg/kg). In an attempt to reduce late effects 
from radiation-induced toxicity, most centres have replaced single fraction TBI 
(radiation dose 7-10 Gy) by fractionated TBI (total radiation dose 10-16 Gy, 
fraction size 1.2-3.0 Gy, fraction interval 6-24 hours). In addition, radiation-free 
conditioning regimens were introduced, containing high doses of busulphan 
(16-20 mg/kg) or treosulphan (30-42 mg/m2), combined with cyclophosphamide 
(120-200 mg/kg), or Melphalan (140 mg/m2). Sometimes other 
chemotherapeutic agents are added for an additional anti-leukaemic effect 
(e.g. cytosine-arabinoside or etoposide).  
Chemotherapy and late effects after HCT 
Most late effects of chemotherapeutic agents used in conditioning regimens 
result from alkylating agents, such as cyclophosphamide (Cy) and busulphan 
(Bu). The most important late effect of high doses of these agents is gonadal 
damage, contributing to azoospermia in boys and premature ovarian failure in 
girls. In addition, alkylating agents may cause lung damage, resulting in 
interstitial pneumonitis and pulmonary fibrosis. Busulphan, used in radiation-
free conditioning regimens, may give rise to cataract formation in some 
patients 6;7, although far less frequent than after TBI-based conditioning for 
HCT. All alkylating agents increase the risk of secondary tumours. 
Radiotherapy and late effects after HCT 
TBI is one of the most important causes of late effects after HCT. TBI 
contributes to non-endocrine late effects such as interstitial pneumonitis and 
pulmonary fibrosis, renal dysfunction, cataract, dental dysplasia, decreased 
salivary function, and secondary tumours 8;9. Endocrine late effects of TBI 
include damage to the growth plate, growth hormone deficiency (GHD), 
gonadal failure, and primary hypothyroidism 2;10. TBI increases the risk of 
secondary tumours, with a latency period of 10 years or more in most cases. 
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Radiobiology of TBI 
In this section, the different types of radiation damage and the rationale behind 
fractionation are briefly discussed. Radiation damage can be divided in 
stochastic and non-stochastic effects. Stochastic effects are effects that occur 
on a random basis with the chance of occurrence (but not the severity) 
increasing with dose (e.g. secondary tumours). These effects typically have no 
threshold value. Non-stochastic effects, also called deterministic effects, are 
those in which the severity of the effect varies with the dose and for which a 
threshold value does exist. Deterministic effects of ionising radiation depend on 
total dose, fraction size, and fraction interval and dose rate (i.e. the radiation 
dose received in a given time).  
 
The basis of fractionation can be explained by the five R’s of radiotherapy: 
 
- Radiosensitivity (different cell types have different radiosensitivity) 
- Repair (cell types differ in their capacity for repair of sub-lethal 
radiation damage) 
- Repopulation (between doses repopulation takes place) 
- Redistribution (effects of radiation on individual cells depend on their 
position in the cell cycle; between fractions, cells are ‘redistributed’ 
among different phases of the cell cycle. Cells that were in a 
relatively radioresistant state at time of first exposure may have 
become more radiosensitive during subsequent exposure to 
radiation)  
- Reoxygenation (in hypoxic state, cells are relatively radioresistant; 
reoxygenation of hypoxic tissues make cells more sensitive to 
subsequent doses of radiation) 
 
Cell survival curves represent the relation between radiation dose and 
surviving fraction of cells. They are described by a combined linear and 
quadratic model, determined by radiation dose and the first two R’s of 
radiotherapy:  radiosensitivity (α, linear relation to dose) and capacity for 
cellular repair (β, quadratic relation to dose) 11.  
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S(D): the fraction of cells surviving a dose D;  
α: a constant describing the initial slope of the cell survival curve;  
β: a smaller constant describing the quadratic component of cell killing. 
 
Tissues that are relatively radioresistant and/or have a high capacity for cellular 
repair have a low α/β ratio, whereas those that are radiosensitive and/or have a 
low capacity of repair have a high α/β ratio. Fractionation of the total radiation 
dose in fractions of 1.2-3.0 Gy with an interval of at least 6 hours, will lead to 
much greater reduction of radiation damage in tissues with low α/β ratios 
compared to tissues with high α/β ratios. Therefore, if a tumour has a high α/β 
ratio, fractionation can result in reduction of radiation damage to normal 
tissues, which allows for higher total doses without increasing normal tissue 
damage 12. Some haematological malignancies, however, are not very 
radiosensitive, resulting in reduced tumour kill if fractionation is applied. In a 
study by Cosset et al., fraction size sensitivity  (i.e. influence of fraction size on 
tumour survival) was high in chronic myeloid leukaemia (CML), variable in 
acute lymphoblastic leukaemia (ALL) and low in acute non-lymphoblastic 
leukaemia (ANLL) 13. Due to this diversity in radiosensitivity, one fractionation 
scheme (e.g. 6x2.0 Gy) will not fit all patients. This explains why outcomes 
from different TBI-schedules are similar in unselected patients populations due 
to diversity in radiosensitivity between the different tumours 14.   
Besides reducing tumour kill in some tumours, fractionation reduces the 
immunosuppressive effects of TBI. Therefore, fractionation of total TBI dose is 
associated with a higher incidence in graft failure, especially in patients 
receiving T-cell depleted grafts. To reduce these negative effects of 
fractionation on tumour kill and immunosuppression, total dose is usually 
higher in fractionated TBI (12-15 Gy) compared to single fraction TBI (7-10 
Gy). This increase in total TBI dose reduces the possible beneficial effects of 
fractionation. Two large single-centre, prospective randomised studies 
comparing 10 Gy single fraction TBI to fractionated TBI (12 or 14.85 Gy) did 
not find any difference in the main outcome parameters (i.e. overall survival, 
relapse-free survival and interstitial pneumonitis) 15;16. The most common late 
)( 2)( DDeDS βα +−=
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effects of TBI in children are gonadal failure and growth plate damage. As 
these organs have high α/β ratios, the benefit of fractionation is probably 
limited.  
Endocrine late effects after HCT 
Gonadal function, puberty and fertility 
Of the hypothalamus-pituitary-gonadal axis, the gonads are the most sensitive 
to chemotherapy and radiation. Both radiation and alkylating agents may 
induce gonadal failure, busulphan being one of the most gonadotoxic 
chemotherapeutic agents. 
In boys, the testicular germinal epithelium is much more vulnerable to both 
radiation and chemotherapy than Leydig cells are 17. As a result, the vast 
majority of boys will have severely reduced fertility due to damage to the 
germinal epithelium, but their pubertal development is normal. On the other 
hand, recovery of spermatogenesis has been reported in a small number of 
patients after TBI 18-21. 
After TBI-based conditioning for HCT in girls, the risk of ovarian failure 
increases with age at TBI as well as with time since TBI 22;23. This relation 
between ovarian failure and age of TBI is less well-established after Bu/Cy 
based conditioning 10. As a result of radiation damage to the uterus 24;25, 
pregnancies in women with a history of TBI are at high risk of complications. 
The combined results of two large studies report spontaneous abortion in 25%, 
preterm delivery in 53% and low birth weight (<2.5 kg) in 56% 19;21. 
At the hypothalamic-pituitary level, radiation doses >18 Gy are required to 
induce precocious puberty (most often seen in girls) 26-28, and even higher 
doses (>24 Gy) are needed to induce hypogonadotrophic hypogonadism 29;30. 
Therefore, precocious puberty and hypogonado-trophic hypogonadism are 
almost exclusively seen in patients who had received prophylactic cranial 
irradiation prior to HCT. 
Thyroid function  
Thyroid dysfunction is reported after TBI-based conditioning as well as after 
radiation free conditioning. Of the hypothalamic-pituitary-thyroid axis, the 
thyroid gland is by far the most sensitive to radiation and chemotherapy, and 
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therefore hypothyroidism will be the result of damage to the thyroid gland itself. 
In most cases a compensated primary hypothyroidism is seen, characterized 
by an increase of thyroid stimulating hormone (TSH) in combination with a 
normal serum free thyroxine (FT4) level. Overt hypothyroidism with decreased 
FT4 is rare. The incidence of thyroid dysfunction increases with 1) time since 
HCT, 2) younger ages at time of TBI and 3) increasing TBI doses. In addition, 
thyroid dysfunction appears to be more common after unfractionated TBI (up to 
45%) compared to fractionated TBI (15%) 10.  
Growth and growth hormone secretion 
Impaired growth is an important complication of HCT, which occurs in the vast 
majority of children conditioned with TBI, but only rarely after conditioning with 
Bu-Cy. Major causes of impaired growth are chronic GVHD and its treatment 
with glucocorticosteroids, damage to the epiphyseal growth plate, impairment 
of GH secretion, hypothyroidism and hypogonadism. Growth impairment is 
most prominent during puberty, with a blunted pubertal growth spurt in most 
patients 31. 
Other endocrine functions 
The remaining endocrine tissues (e.g. adrenal glands, parathyroid glands, 
pancreas and adipose tissue) are relatively resistant to radiation and 
chemotherapy. Therefore, direct late effects of either radiation or 
chemotherapy on these organs are exceptional.  
Outline of this thesis 
Chapter 2 describes the late effects of TBI as a single toxic agent in rhesus 
monkeys on growth, thyroid gland and pituitary gland. Anthropometrical data 
were collected; thyroid and pituitary glands were examined; serum levels of 
thyroid stimulating hormone, free thyroxin, insulin-like growth factor-I and its 
binding protein-3 were measured. In humans, the exact role of TBI is difficult to 
assess due to the superimposed and/or synergistic effects of other factors 
present in clinical settings (e.g. cytostatics, antimicrobial drugs, GVHD, steroids 
and the underlying disease itself). The rhesus monkeys in this study received 
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TBI as single toxic agent and therefore provide a unique opportunity to study 
effects of TBI. 
Chapter 3 is a report on the effect of irradiation on longitudinal growth, growth 
plate architecture and the expression of parathyroid hormone related peptide 
(PTHrP) and Indian hedgehog (IHh) in tibial growth plates of rats. PTHrP and 
IHh are key regulators of pace and synchrony of chondrocyte differentiation, 
and irradiation will disturb both these processes. 
In chapter 4 results of a cross-sectional study on both endocrine and non-
endocrine late effects of HCT during childhood are presented in a population of 
adult survivors of childhood HCT. Effects on growth, gonadal function, thyroid 
function, bone mineral density, lung function, renal function, eyes and skin 
were evaluated. 
Chapter 5 reports the results of the largest multi-centre study on factors that 
play a role in the final height outcome of patients who underwent HCT during 
childhood. The study includes data on 181 patients with aplastic anaemia, 
leukaemia, and lymphoma who had HCT before puberty and who had reached 
final height. 
In chapter 6 pubertal development and growth after TBI-based conditioning for 
allogeneic HCT for haematological malignancies is described in children who 
received HCT in our centre. 
Chapter 7 describes patterns of growth and body proportions in children 
receiving TBI for HCT in our centre before onset of puberty. It is one of the 
largest single-centre studies on growth and final height after TBI-based 
conditioning for HCT, and the first study to analyse the effects of unfractionated 
TBI on body proportions in boys and girls separately, thereby identifying sex-
differences in development of body proportions after single dose TBI. For each 
sex, a model of growth after TBI is presented, in which effects of time since 
HCT, age at HCT, and puberty are the major determinants of changes in height 
SDS. 
In chapter 8 results of a study on growth hormone secretion and the effects of 
GH therapy on growth after TBI-based conditioning for HCT in our centre are 
reported. In the study, the model for growth after TBI (as described in chapter 
7) is used to estimate the net effect of GH therapy. The study is one of the few 
studies on the effect of GH therapy after TBI that report final height, and the 
only study in which most children treated with GH were not considered GH 
deficient. 
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Chapter 9 describes the effects of radiation-free Bu/Cy based conditioning on 
growth and endocrine function in children without a history of irradiation. In 
contrast to most other reports, individual growth curves were analysed in 
addition to group analyses, and impaired growth was encountered in a 
significant proportion of patients.  
In chapter 10 Quality of life is investigated in adult survivors of childhood HCT, 
using both generic and disease-specific questionnaires. In addition coping 
strategies are investigated. 
Finally, the results and implications of the different studies are discussed in 
chapter 11 and summarised in chapter 12, followed by a summary in Dutch in 
chapter 13. 
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Abstract 
Aim: To investigate the effect of total-body irradiation (TBI) on growth, thyroid 
and pituitary gland in primates.  
 
Materials and methods: Thirty-seven rhesus monkeys (mean age 3.1 ± 0.6 
years) received either a low-dose (4 - 6 Gy) TBI (n = 26) or high-dose (7 - 12 
Gy) TBI (n = 11) and were sacrificed together with 8 age-matched controls after 
a post-irradiation interval of 5.9 ± 1.5 years. Anthropometric data were 
collected; thyroid and pituitary glands were examined; serum levels of thyroid 
stimulating hormone (TSH), free thyroxin (FT4), insulin-like growth factor-I 
(IGF-1) and its binding protein-3 (IGFBP-3) were measured.  
 
Results: Decrease in final height due to irradiation could not be demonstrated. 
There was a dose-dependent decrease in body weight, ponderal index, 
skinfold thickness and thyroid weight. The latter was not accompanied by 
elevation of TSH or decrease in FT4. Structural changes in the thyroid gland 
were found in 50% of the irradiated animals. Levels of IGF-I and IGFBP-3 did 
not differ between the dose groups, but the high-dose group had a lower IGF- 
l/IGFBP-3 ratio.  
 
Conclusions: Total body irradiation had a negative effect on body fat. There 
was no evidence of (compensated) hypothyroidism, but dose-dependent 
decrease in thyroid weight and changes in follicular structure suggest some 
effect of TBI on the thyroid gland. The decreased IGFI/IGFBP-3 ratio in the 
high-dose group can indicate that the somatotrophic axis was mildly affected 
by TBI. These results show that TBI can have an effect on the physical build 
and thyroid gland of primates even in the absence of cytostatic agents or 
immunosuppressive drugs.  
Effects of TBI on growth, thyroid and pituitary gland in monkeys 
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Introduction 
Total-body irradiation (TBI) is frequently used in combination with high-dose 
chemotherapy in conditioning regimens for haematopoietic stem cell 
transplantation (HCT). Unfortunately this aggressive conditioning has negative 
effects on several organs including those of the endocrine system 1. Examples 
of negative effects on endocrine organs are decreased fertility and 
hypogonadism, (compensated) hypothyroidism, and growth hormone 
deficiency (GHD), respectively 2. In children, TBI and HCT often result in 
impaired growth and reduction of final height 3;4. Although TBI is considered to 
be an important etiologic factor in these disorders, its exact role is difficult to 
assess due to the superimposed and/or synergistic effects of other factors 
used in clinical settings (e.g. cytostatics, antimicrobial drugs, GVHD, 
corticosteroids and the underlying disease itself). Therefore, studies in animals 
without (previous treatment of) an underlying disease are helpful in the 
investigation of TBI as a single toxic factor. Radiation experiments in primates 
are of relevance since the response to radiation in monkeys does not seem to 
be significantly different from that in man. This has been demonstrated for 
acute effects on the haematopoietic system 5 and late effects such as tumour 
induction 6. Furthermore an outbred species such as the rhesus monkey 
(Macaca mulatta) is more representative as an animal model to assess the 
effect of TBI as a single toxic factor than are inbred rodents. Results of the 
effect of TBI, without interference of other medication such as cytostatics or 
immuno-suppressive drugs, on the eye 7 and on hepatic and renal function 8 
are already available. This article describes the effect of TBI as a single toxic 
factor on both the thyroid gland and somatotrophic axis.  
Materials and methods  
Animal population  
Between 1963 and 1989 approximately 100 rhesus monkeys received TBI in 
the Biomedical Primate Research Centre (BPRC) of Rijswijk, the Netherlands, 
in experiments on both the efficacy of the HCT procedure and the late effects 
of TBI. In a terminal experiment 37 irradiated animals and 20 control animals 
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were sacrificed. Anthropometric measurements were taken and after 
anaesthesia (using ketamin and vetrancyl) the animals were heparinised and 
euthanised. Tissue samples gathered during autopsy were distributed to 
several research institutes interested in late effects of TBI. We were able to 
obtain blood samples and tissue samples of the thyroid and pituitary gland. The 
mean age of the irradiated animals was 8.9 ± 1.6 years (range 6.2 - 11.8). 
There were eight age-matched control animals with a mean age of 8.9 ± 2.0 
years (range 6.8 - 12.5). The mean age of the control animals that were 
excluded from the analyses was 24.9 ± 5.8 years (range 17.8 - 34.8). Total 
body irradiation was given at a mean age of 3.1 ± 0.6 years (range 2.0 - 4.6), 
which means that most of the animals had just entered puberty at the time of 
the TBI. Age at time of irradiation did not differ between the low-dose group 
(LD) and the high-dose group (HD). The post-irradiation interval (overall 5.9 ± 
1.5 years) was longer in the high-dose group compared to the low-dose group: 
median 6.8 (4.8 - 8.3) years versus 5.7 (3.3 - 7.4) years (P = 0.003). All 
animals involved in the present study were bred within the BPRC colony and 
kept under identical housing conditions. They were fed commercial food pellets 
(Hopefarms) and a diet of fresh fruit and vegetables. The animals were 
procured, maintained and used in accordance with Dutch law and regulations, 
the Animal Care and Use Committee and the Animal Ethical Committee 
approved all experiments.  
Irradiation and additional treatments  
The total-body irradiations were performed at an instantaneous dose-rate of 
0.3 Gy min-1 with either 300 kV or 6 MV X-rays. Monkeys were irradiated in a 
specially designed cage that was slowly rotated along its longitudinal axis in 
the beam in order to obtain an optimal dose distribution over the animal. At a 
later stage the animals were irradiated bilaterally. Radiation doses received by 
the monkeys are expressed as absorbed dose in soft tissue averaged over the 
animal 9. Three groups of animals were distinguished: control animals (n = 8), 
animals that received a relatively low TBI dose (4 - 6 Gy as a single fraction; n 
= 26), and those which received a high TBI dose (7 - 8.5 Gy as a single 
fraction; n = 8, or 12 Gy in two single fractions on two consecutive days; n = 3). 
The animal characteristics in the different dose groups are presented in table 1.  
Both the TBI doses and dose rate correspond well with those used in our clinic 
in several hundred patients transplanted at our centre since 1965. Patients 
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transplanted for severe aplastic anaemia, immune-deficiency syndromes or 
haemoglobinopathies received 4 - 5 Gy single fraction TBI. Patients with 
haematological malignancies receive either 7 - 8 Gy as a single fraction, or 12 
Gy in two single fractions on two consecutive days (instantaneous dose rates 
used are always 0.25 ± 0.05 Gy min-1). 
 
 
Table 1. Number of male and female monkeys in subsequent dose categories 
TBI dose Males Females 
Control animals (n=8) 2 6 
Low-dose TBI (n=26)   
 4.0 Gy 3 - 
 5.0 - 5.3 Gy 15 5 
 6.0 Gy 3 - 
High-dose TBI (n=11)   
 7.0 Gy 1 - 
 8.0 Gy 2 1 
 8.5 Gy 3 1 
 2 x 6.0 Gy 2 1 
 
 
After TBI seven animals (all LD) received supportive care only, the other 
animals received additional treatment to enhance the recovery of bone marrow. 
Additional treatment consisted of either cytokines only (n = 18, one HD), or 
HCT (n = 5, all HD), or both HCT and cytokines (n = 7, five HD). Cytokines 
used were human granulocyte macrophage colony-stimulating factor (GM-
CSF), rhesus monkey interleukin-3 (IL-3) or rhesus monkey interleukin-6 (IL-6) 
for approximately 14 days. 
Morphological, functional and histological assessments  
Anthropometrical measurements consisted of body weight, subscapular 
skinfold thickness, upper leg length and lower leg length, sitting height and 
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head circumference. All measurements were done according to standard 
protocols10. Total length was estimated by adding sitting height, upper leg 
length and lower leg length. Ponderal index was calculated as (body weight x 
100) / sitting height11. Thyroid status was evaluated by determining thyroid 
weight, serum levels of free thyroxin (FT4) and thyroid stimulating hormone 
(TSH). Both FT4 and TSH were assayed at the Leiden University Medical 
Centre; FT4 was measured by radio-immunoassay (RIA) and TSH by immuno-
radiometric assay (IRMA), (both from DPC, Los Angeles CA). The thyroid 
glands of 26 irradiated (seven high-dose TBI) and eight control animals were 
sectioned and stained at the Veterinary Faculty of Utrecht University with 
haematoxylin-eosin (HE), periodic-acid-Schiff (PAS), and immunohistochemical 
staining using antibodies against calcitonin. The somatotrophic axis was 
evaluated by measuring serum levels of insulin-like growth factor-1 (IGF-l) and 
its binding protein 3 (IGFBP-3) (assayed at the Wilhelmina Children's Hospital, 
Utrecht12). Sections of the pituitary glands were stained with HE, PAS, orange-
G and immunohistochemical staining using antibodies against growth 
hormone.  
Statistical analyses  
Results are expressed as mean (SD) or median (range) as indicated. The 
results of the different dose groups were compared by non-parametric tests 
(Mann-Whitney U test and Kruskal-Wallis H test). Dose dependency was 
analysed by Spearman's correlation for both sexes separately. Linear 
regression analysis with calculation of partial correlation coefficients was done 
on the total group of all animals controlling for possible confounding factors 
such as sex, age and body weight. All analyses were performed using two-
sided tests.  
Results 
Anthropometric measurements  
Because of the differences between both sexes, separate analyses were done 
for each sex. Table 2 shows the results of the anthropometric measurements.  
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Table 2. Auxological results in the different dose groups. Data presented as mean (SD). 
  MALES  FEMALES 
  Reference 
 
Control 
(n=2) 
Low-dose
(n=21) 
High-dose
(n=8) 
 Reference
 
Control 
(n=6) 
Low-dose
(n=5) 
High-dose 
(n=3) 
Body weight (kg)* 
 
10.8 7.8 (0.5) 7.0 (1.2) 5.9 (0.8)  8.7 4.9 (0.8) 4.5 (0.7) 3.8 (0.5) 
Ponderal index** 
 
19.0 14.0 (1.6) 12.9 (1.7) 11.3 (1.3)  16.8 10.2 (1.0) 9.3 (1.1) 8.0 (0.7) 
Skinfold  (cm)* 
 
4.1 4.0 (1.4) 3.5 (1.4) 2.6 (0.8)  5.4 4.3 (0.8) 2.5 (0.7) 2.3 (1.2) 
Sitting height (cm)* 
 
56.8 56.1 (2.8) 53.8 (3.0) 52.4 (2.3)  51.9 47.5 (3.5) 48.2 (1.4) 47.3 (2.6) 
Upper leg length (cm) 
 
n.a. 18.5 (2.3) 18.5 (1.3) 18.1 (0.9)  n.a. 15.0 (1.0) 15.5 (0.6) 15.9 (1.2) 
Lower leg length (cm) 
 
n.a. 21.8 (0.4) 21.0 (1.5) 20.6 (1.5)  n.a. 17.9 (0.7) 18.1 (0.8) 19.3 (1.3) 
Head circumference (cm) 
 
n.a. 29.5 (0.1) 30.1 (1.9) 28.9 (1.7)  n.a. 26.4 (2.0) 26.8 (0.8) 26.4 (1.3) 
Estimated height (cm) 
 
n.a. 96.3 (0.1) 93.3 (5.1) 91.1 (3.1)  n.a. 80.4 (4.0) 81.7 (2.2) 82.5 (4.7) 
*  Reference values are means, based on data from Schwartz and Kemnitz13 on 6-14 year old 
 animals. 
** Calculated from mean values of body weight and sitting height derived from data of Schwartz  and 
 Kemnitz13. 
n.a. Not available. 
 
 
 
Comparison of the results for the different dose groups revealed a decrease 
with increasing TBI doses in body weight in males P = 0.036), a decrease in 
ponderal index in both males (P = 0.045) and females (P = 0.033), and a 
decrease in subscapular skinfold thickness in females (P = 0.018). Radiation-
dose dependency was confirmed by correlation analyses for body weight 
(males: r = -0.37; P = 0.042 and females: r = -0.57; P = 0.033), for ponderal 
index (males: r = -0.37; P = 0.039 and females: r = -0.69; P = 0.006), and for 
skinfold thickness in females (r = -0.65; P = 0.013). After controlling for the 
effects of sex and age, the partial correlation coefficient between body weight 
and TBI dose was r = -0.51 (P = 0.001), between ponderal index and TBI dose 
r = -0.55 (P < 0.001) and between skinfold thickness and TBI dose r = -0.39 (P 
= 0.011). The other parameters, including sitting height and estimated total 
length did not show significant differences between the dose groups, nor were 
there indications for radiation-dose dependency of those parameters.  
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Functional and morphological evaluation of the thyroid gland  
The mean thyroid weight decreased with increasing TBI dose (table 3; P < 
0.001). There was a negative correlation between thyroid weight and TBI dose 
(r = -0.59; P < 0.001), which remained after controlling for body weight (partial r 
= -0.51; P = 0.001). Free T4 and TSH levels did not differ between the various 
dose groups. Table 3 (upper part) summarises the results of the thyroid 
evaluation.  
 
 
Table 3. Results of thyroid and somatotrophic evaluation. Organ weights as mean 
(SD); serum parameters as median (range). 
 Control Low-dose TBI High-dose TBI 
Weight thyroid (g) 0.59   (0.16) 0.47   (0.16) 0.30   (0.10) 
TSH (mIU/L) 0.14 (0.01-2.41) 0.35 (0.37-1.72) 0.42 (0.12-2.44) 
Free T4 (pmol/L) 4.2 (1.8-13.1) 6.9 (2.2-18.1) 5.8 (3.3-10.0) 
    
Weight pituitary (g) 0.096   (0.024) 0.084   (0.018) 0.082   (0.017) 
IGF-1 (mg/L) 0.37 (0.23-0.62) 0.40 (0.21-0.88) 0.32 (0.22-0.57) 
IGFBP3 (mg/L) 1.55 (1.01-3.74) 1.88 (1.17-2.44) 1.71 (1.30-2.03) 
IGF-1/IGFBP3 ratio 0.19 (0.16-0.34) 0.21 (0.12-0.47) 0.17 (0.12-0.23) 
 
 
On histological examination 13 of the 26 irradiated monkeys (six out of seven 
in the high-dose group and seven out of 19 in the low-dose group) had small 
follicles (which were lined with higher cuboidal epithelium) compared to the 
non-irradiated animals. An example of these differences is shown in figure 1. 
Animals with these structural changes had a lower thyroid weight compared to 
animals without these changes (mean: 0.522 versus 0.354 g; P = 0.004) and 
there was a correlation between TBI dose and the presence of structural 
changes (r = 0.54, P = 0.001). One irradiated monkey (TBI dose 5.0 Gy) had a 
macrofollicular goitre with focally distinct papillary hyperplasia. The papillae 
and some newly formed follicles had high columnar cells and many resorption 
vacuoles were present. The distended follicles had flat epithelial cells. No other 
histological abnormalities were found in the thyroid sections. 
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Figure 1. Example of the typical thyroid abnormalities found in irradiated monkeys (left 
side) compared to the normal thyroid tissue of a non-irradiated monkey (right side). 
Note the decrease in follicle size lined with higher cuboidal epithelium in the irradiated 
animal (staining: Haematoxylin-Eosin; magnification: a & b: 10x5; c & d: 10x40). 
 
Functional and morphological evaluation of the somatotrophic axis  
Results of evaluation of the somatotrophic axis and the pituitary gland are 
included in table 3 (lower part). Pituitary weight did not differ between the 
various dose groups. No correlation was found between TBI dose and pituitary 
weight even after controlling for body weight and sex. The plasma levels of 
IGF-I and IGFBP-3 did not differ between different dose groups. However, the 
ratio of IGF-l and IGFBP-3 was higher in the low-dose group compared to the 
high-dose group (P = 0.047). On histological examination no abnormalities 
were found in the pituitary glands apart from an area with hyperplasia of 
prolactin-producing cells in one irradiated monkey (TBI dose 8.5 Gy).  
Discussion  
Studies on the effect of TBI in HCT patients are complicated by confounding 
variables such as the initial disease, the use of cytostatics in both initial 
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treatment and conditioning regimens, the complications of allogeneic marrow 
transplantation and the effects caused by post-HCT medication (e.g. 
corticosteroids, cyclosporine A and antibiotics). The animals in this study 
therefore offer a unique possibility to investigate the effects of TBI as a single 
toxic agent in primates. Compared to the measurement data published by other 
authors11;13 the animals used as controls in this study had a relatively low body 
weight and ponderal index, and the females had low sitting heights and 
subscapular skinfold thickness. In spite of this, though, body weight, ponderal 
index and subscapular skinfold thickness were clearly influenced by TBI: the 
high-dose irradiated animals were skinny compared to age-matched non-
irradiated animals. A possible explanation for these changes are provided by 
Griffiths et al.14. They describe alterations in gastrointestinal regulatory 
peptides in the irradiated monkeys, which could have resulted in anorexia. In 
contrast to the observations in children after TBI and HCT, no effect of TBI on 
growth could be found in the present study. The loss of height potential in 
children is most prominent during puberty, as many patients have an impaired 
pubertal growth spurt3;15. Rhesus monkeys exhibit only a small pubertal growth 
spurt compared to humans16, and therefore, impairment of this growth spurt 
would not have major effects on final height. Sonneveld and van Bekkum17, 
however, showed that TBI (as single toxic agent) can cause inhibition of growth 
in rhesus monkeys from the same colony as the animals in the present study. 
Radiation doses of 7.5 Gy or higher were required and the effect was more 
pronounced in animals irradiated before the age of 40 months. The relatively 
low-doses used in most animals in our study and the relatively high ages at the 
time of irradiation could explain the lack of growth impairment (at the age of 
three the animals have attained approximately 90% of their adult sitting 
height)10. The difference in thyroid weight between the various dose-groups 
and the negative correlation between thyroid weight and TBI dose suggest an 
effect of TBI on the thyroid gland. Small follicles lined with higher epithelium, as 
found in thyroid glands of irradiated animals, are usually associated with a high 
activity of the follicular epithelial cells. We speculate that, in some animals, 
radiation has induced damage to thyrocytes which is compensated by their 
increased activity. This increased activity may have resulted in a decreased 
colloid content, which, in conjunction to a possible reduction in cell number, 
could explain the decrease in thyroid weight. In humans receiving a TBI and 
HCT for haematological malignancies, (compensated) hypothyroidism occurs 
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in 15 - 50% of the patients18. The incidence of radiation-induced 
(compensated) hypothyroidism depends on radiation dose, fractionation 
schedule and post-irradiation interval19. The small number of animals in the 
high-dose group and the limited post-irradiation interval could explain why we 
did not find hypothyroidism. The incidence of malignant tumours of the thyroid 
gland is increased after irradiation20, and young patients with papillary thyroid 
carcinoma often have a history of irradiation of the thyroid gland21;22. After HCT 
and TBI, patients are at risk for secondary malignancies23;24, and although 
most of those are of haematological origin25;26 the incidence of thyroid 
carcinomas is also increased23. In this study no evidence for malignant thyroid 
tumours was found in any of the irradiated monkeys. This could, however, be 
caused by the relatively short post-irradiation interval, as radiation induced 
(thyroid) malignancies in monkeys (as in humans) generally occur after a 
latency period of ten years or more6. After irradiation of the hypothalamus-
pituitary axis a decreased secretion of hormones from the anterior lobe of the 
pituitary can occur. In most cases growth hormone is the first of these 
hormones to be decreased in the circulation. Radiation induced growth 
hormone deficiency (GHD) is dose dependent and the incidence increases with 
increasing post-irradiation intervals27;28. The animals in the high-dose group 
were therefore more likely to suffer from GHD than those in the low-dose 
group. However, the diagnosis of GHD is difficult and requires stimulation tests 
or evaluation of GH secretion patterns by frequent sampling, which could not 
be performed in the present study. Growth hormone deficiency is reflected by 
decreased serum levels of IGF-1 and IGFBP-329. Even in man, however, the 
normal ranges of IGF-l and IGFBP-3 are wide and distinction between values 
of normal and GH-deficient subjects is difficult. Information on IGF-1 and 
IGFBP-3 levels in serum of normal rhesus monkeys is scarce, and values show 
considerable variations: Schwartz and Kemnitz13 describe mean IGF-l levels of 
approximately 100-350 ng/ml in young adult rhesus monkeys, whereas Liu et 
al.30 mention mean IGF-l levels of 600-1600 ng/ml. We therefore depended on 
our control animals as reference for normal values of IGF-l and IGFBP-3. 
Although the absolute levels of IGF-l and IGFBP-3 were not different between 
the radiation groups, the lower IGF-1/IGFBP-3 ratio of the animals in the high-
dose group suggests less circulating free IGF-I, which may indicate subtle 
changes in the somatotrophic axis by TBI. Histological examination did not 
reveal any changes in the pituitary gland; whether the hyperplasia of prolactin-
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producing cells is related to the TBI is unknown. In summary, we demonstrated 
an effect of TBI on body weight, ponderal index and skinfold thickness, but not 
on height. The histological changes and the decrease of thyroid weight with 
increasing TBI doses are indications for radiation-induced thyroid damage and 
compensatory reactions. Although the changes in body composition and the 
normal IGF-I and IGFBP-3 levels do not suggest radiation-induced GHD, there 
was a decreased IGF-I/IGFBP-3 ratio in the high-dose group, which could 
indicate a subtle effect of TBI on the somatotrophic axis. We therefore 
conclude that TBI-doses of 4-12 Gy with an instantaneous dose rate of 0.3 Gy 
min-1 can have an effect on the thyroid gland and on the physical build of 
primates even in the absence of cytostatic agents or immunosuppressive 
drugs.  
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EFFECT OF X-IRRADIATION ON GROWTH AND 
THE EXPRESSION OF PARATHYROID HORMONE-
RELATED PEPTIDE AND INDIAN HEDGEHOG IN 
THE TIBIAL GROWTH PLATE OF THE RAT 
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Abstract  
Aim: To study the effect of irradiation on the longitudinal growth and the 
expression of parathyroid hormone-related peptide (PTHrP) and Indian 
hedgehog (IHh) in tibial growth plates of rats.  
 
Materials and methods: At 3 weeks of age, 30 male rats received a single 
fraction of irradiation (8 Gy) to their right hind limb, and small groups of animals 
were sacrificed 1, 2, 3, 5, 7, 10, 15, and 26 weeks after irradiation. Weight and 
length of both irradiated and non-irradiated tibiae were measured, and sections 
of the tibiae were stained with HE. PTHrP and IHh were visualized using 
immunohistochemical techniques.  
 
Results: Radiation resulted in persistent growth delay of the irradiated tibiae, 
with a difference in length of more than 10% between the irradiated and the 
non-irradiated tibiae 15 weeks or more after irradiation. The growth plate 
architecture was disturbed, and the expression of both PTHrP and IHh was 
decreased in the irradiated tibiae.  
 
Conclusion: As PTHrP and IHh are key regulators of both the pace and the 
synchronisation of the differentiation of growth plate chondrocytes, the reduced 
expression of PTHrP and IHh may contribute to the changes found after 
irradiation. 
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Introduction  
In children treated for cancer, radiation has a direct effect on the epiphyses 
which results in disruption of growth plate architecture and contributes to the 
impaired growth by a yet unknown mechanism 1;2.  
Many tissues show changes in the expression of regulatory proteins in 
response to radiation damage, a phenomenon known as ‘humoral 
radiopathology’ 3. These humoral factors are often growth factors or other 
mediators of cell proliferation and differentiation (e.g., transforming growth 
factors, fibroblast growth factors, tumour necrosis factor, and others). Although 
the effects of irradiation on growth and growth plate architecture are 
extensively studied for over 50 years 4-8, little is known about the effects of 
irradiation on the expression of growth factors involved in the regulation of 
chondrogenesis in the epiphyseal growth plate.  
Parathyroid hormone-related peptide (PTHrP) and Indian hedgehog (Ihh) are 
paracrine/ autocrine factors that control the pace and synchrony of chondrocyte 
differentiation and are believed to co-ordinate the development of the growth 
plate and to influence growth rate 9.  
As radiation affects architecture and growth rate of the growth plates, we were 
interested in its effect on the expression patterns of PTHrP and IHh. Therefore, 
we studied the effect of local irradiation on longitudinal growth and on the 
expression of both PTHrP and IHh in rat tibial growth plates.  
Materials and Methods  
All animal experiments were approved by a local ethical committee and 
performed according to Dutch law and regulation.  
Irradiation  
At the age of 3 weeks, 30 male Wistar rats received a single dose of X-
irradiation (8.0 Gy) to the right hind limb (Philips X-ray generator, operating at 
250 kV and 15 mA, equipped with a Thoraeus filter which resulted in a dose 
rate of 1.6 Gy/min). The left hind limb served as an internal control. Irradiation 
was performed at the Department of Clinical Oncology, using a setup that was 
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previously used for irradiation of rat gastrocnemius muscle. Details on the 
irradiation procedure are described in an earlier report by Hermens et al. 10. 
The animals were anesthetised with a mixture of Aescoket® (50 mg/kg i.p.) and 
Rompun® (2 mg/kg i.p.) prior to irradiation. The right hind limbs were irradiated 
in posterior-anterior direction from the knee joint down. The rest of the body 
was protected with 2 mm thick lead plates. Special attention was given to the 
position of the testes, in order to prevent radiation damage. The focus–skin 
distance was 25 cm.  
Animal Housing and Sample Collection  
After irradiation, the animals were placed (2 per cage) in a light and 
temperature-controlled environment and were given standard laboratory chow 
and water ad libitum. At post-irradiation intervals of 1, 2, 3, 5, 7, and 10 weeks, 
groups of 4 animals were decapitated and both the irradiated and the non-
irradiated tibiae were dissected and stripped. The same was done at 15 and 26 
weeks with groups of 3 animals. Tibiae were weighed, and the tibial length was 
measured with a caliper. The tibiae were then split mid-saggittally in two equal 
halves and further processed for immunohistochemical analyses.  
Immunohistochemistry  
The detailed immunohistochemical procedures were previously described by 
Van der Eerden et al. 11. The aspect of a growth plate section varies with the 
plane of the section (exactly craniocaudal or angulated) as well as with the 
position of the section (central or more peripheral in the growth plate). To 
ensure comparable sections, much effort is put on splitting the tibiae exactly 
mid-saggitally in equal halves and on the embedding and positioning of the 
samples on the microtome. Furthermore, only the first 15 sections of each 
sample were used to prevent the use of peripherally cut sections.  
For PTHrP detection in the proximal tibial growth plates, the primary antibody 
was rabbit-derived polyclonal IgG raised against amino acids 34–53 of human 
PTHrP which is homologous to the PTHrP sequence in the rat (Oncogene 
Science, Cambridge, Mass., USA). For the detection of IHh, the primary 
antibody was goat-derived polyclonal IgG raised against the carboxy terminus 
of human IHh protein which cross-reacts with mouse and rat IHh (Santa Cruz 
Laboratories, Santa Cruz, Calif., USA). For optimal comparability, sections of 
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the irradiated and non-irradiated growth plates of animals of the same age 
were processed in the same experiment.  
Measurements and Statistical Analyses  
SPSS version 10.0 (SPSS, Chicago, Ill., USA) was used for statistical 
analyses. Differences in tibial length were analysed with regression models 
using a linear and 3rd-order curve fit. Histological measurements were done on 
digital micrographs of growth plate sections, using an image analysis program 
(Image-Pro Plus 3.0; MediaCybernetics, Silver Spring, Md., USA). We decided 
to use digital imaging, since blinding of the samples was not possible, due to 
the clearly visible differences between the irradiated and non-irradiated growth 
plates, making counting subjective.  
In each growth plate, we measured the mean width of the individual growth 
plate zones, the mean height of individual columns in the proliferative zone, the 
amount of intervening matrix (as percentage of total growth plate area), the 
number of cells in the late proliferative and early hypertrophic zone, and the 
number of PTHrP-positive and IHh-positive cells in this ‘transitional’ zone. In 
individual animals, the results of the irradiated growth plate were compared to 
those of the normal growth plate. As there were only 3 or 4 animals at each 
time point, the animals were then clustered into three age groups: young (1–3 
weeks after irradiation), middle-aged (5–10 weeks after irradiation), and old 
(15–26 weeks after irradiation). Differences between irradiated and non-
irradiated growth plates were analysed in each age group using A Wilcoxon 
signed-rank test.  
Results  
There were no visible effects of the irradiation in any of the animals, i.e., we did 
not observe functional impairment or skin lesions of the irradiated hind limb. In 
all animals, the irradiated tibia was shorter as compared with the non-irradiated 
tibia. This was noticed already 1 week after irradiation. Furthermore, the 
difference increased with increasing post-irradiation intervals, suggesting 
continuous growth delay (figure 1a).  
On histological examination, a clear disruption of the growth plate architecture 
was found at all times after irradiation (figure 2). The columns were less 
straight and less parallel to each other, and many columns did not extend 
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across the entire growth plate. The mean reduction in column height in the 
proliferative zone was 38% in the young animals (p = 0.002), 27% in the 
middle-aged animals (p = 0.04), and 13% in old animals (not significant). 
Furthermore, there were some clusters of cells that were not organised in 
columns, as well as clustered columns. The amount of intervening matrix was 
increased in the middle-aged (mean increase 26%; p = 0.03) and older animals 
(mean increase 17%; p = 0.04), but not in the younger animals. There were 
some cells with a hypertrophic appearance within the proliferative zone (see 
arrows in figures 2b and d) and some columns failed to complete the 
transformation from cartilage to bone, which resulted in cartilage islands within 
the trabecular bone (see arrowheads in figures 2f and 3f).  
Due to these structural changes, the different zones (i.e., resting, proliferative, 
hypertrophic, and calcifying zones) were less well defined, making it difficult to 
establish the exact width of each zone. We could not establish significant 
changes in the growth plate width nor in the width of individual zones (data not 
shown). 
Both the absolute and relative numbers of PTHrP-positive cells in the irradiated 
growth plates were reduced (figure 3a–f). This reduction was seen already 1 
week after irradiation and did not restore with increasing time interval after 
irradiation. The reduction was seen in both the stem cell zone and (most 
prominent) in late proliferating and early hypertrophic chondrocytes which were 
previously shown to express PTHrP 11. The mean relative reduction in PTHrP-
positive cells in the ‘transitional’ zone was 52% in the young animals (p = 0.02), 
43% in the middle-aged animals (p = 0.04), and 36% in the old animals (p = 
0.05). We saw a similar reduction in the number of IHh-positive cells in the 
irradiated tibiae (figure 3g–h). Since overall staining of IHh was very weak, 
computer-aided digital imaging and quantification turned out to be unreliable. 
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Figure 1.  a. Tibial length of irradiated (▲) and non-irradiated (♦) legs 0 to 26 weeks 
after irradiation. b. Individual differences in tibial length (control minus irradiated tibia) 
versus weeks after irradiation. 
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Figure 2. Morphological changes after irradiation.  
Irradiated tibiae are presented on the right-hand side. HE staining. a,b 2 weeks after 
irradiation. c,d 7 weeks after irradiation. e,f 15 weeks after irradiation. Note the 
disorganisation of the growth plate and the presence of hypertrophic cells (arrows in b 
and d) in the proliferative zone and the cartilage islands in metaphyseal bone 
(arrowheads in f). S = Stem cell zone; P = zone of proliferation; H = zone of 
hypertrophy. 
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Figure 3. Presence of PTHrP and IHh in the tibial growth plates at different times after irradiation. 
Irradiated tibiae are presented on the right-hand side. PTHrP and IHh levels are clearly reduced after 
irradiation. a,b PTHrP 2 weeks after irradiation. c,d PTHrP 7 weeks after irradiation. e,f PTHrP 15 
weeks after irradiation; note the islands of hypertrophic cells (with PTHrP staining) within the bone 
(arrowheads in f). g,h IHh 2 weeks after irradiation. S = Stem cell zone; P = zone of proliferation; H = 
zone of hypertrophy. 
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Discussion  
In our clinic, many haematopoietic stem cell transplant recipients who are 
treated for haematological malignancies show growth delay after a single 
fraction of 8.0 Gy of total-body irradiation 12. As this radiation dose is known to 
damage the growth plate architecture in many species, including rats 8;13, we 
decided to use this dose for our experiments. As could be expected, a single 
dose of 8.0 Gy to the right hind limb resulted in structural as well as functional 
damage (growth delay) to the epiphyseal growth plate. The difference in tibial 
length between the irradiated and non-irradiated limb increased during the 
whole follow-up period, suggesting that growth delay was persistent, and there 
was certainly no catch-up growth. This is in line with the human situation, 
where damage to the growth plates also results in persistent growth 
retardation.  
The increase in intervening matrix in the middle-aged and old animals suggests 
that growth retardation could be the result of exhaustion of germinal cells after 
radiation-induced cell death in the stem cell zone. The decreases in PTHrP and 
IHh, however, suggest that changes in paracrine/autocrine factors could also 
contribute to both growth delay and structural changes. PTHrP is a 
paracrine/autocrine factor, produced in most cell types in the body. Its functions 
include the regulation of cell cycle, differentiation, apoptosis, and 
developmental events 14. In prenatal growth plates, it delays the transition of 
chondrocytes from a proliferative towards a hypertrophic state and 
synchronises the rate of differentiation in the growth plate 15. If PTHrP is over-
expressed, the transition from proliferation to differentiation is impaired, 
resulting in prolonged proliferation and delayed differentiation 16. In the 
absence of PTHrP, however, this transition is accelerated, which leads to 
premature differentiation and growth delay 17. Therefore, both the PTHrP and 
the PTH/PTHrP-receptor-deficient mice show accelerated hypertrophy and 
mineralization in the cartilage. Furthermore, PTH/PTHrP receptor knockout 
mice show delayed vascular invasion, whereas the double homozygous PTHrP 
and PTH/PTHrP receptor knockout mice do not. Thus, PTHrP must slow 
vascular invasion by a mechanism independent of the PTH/PTHrP receptor 18. 
PTHrP expression is stimulated by IHh which is expressed in early 
hypertrophic chondrocytes 19. An increase in PTHrP slows down differentiation 
and results in a reduction of IHh-producing cells, thus forming a negative 
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feedback loop which co-ordinates the development of the growth plate and 
influences growth rate 20. All components of this feedback loop (i.e., PTHrP, 
IHh, and their respective receptors) are also present in the post-natal growth 
plate of the rat 11, and the feedback loop is, therefore, supposed to be 
functional after birth as well.  
A recently published in vitro study on irradiated avian growth plate 
chondrocytes 21 describes a dose-dependent decrease in both PTHrP mRNA 
and PTHrP protein (but not other autocrine and paracrine factors) 24 h after 
irradiation which was related to a radiation-induced increase in cytosolic 
calcium. In addition to these findings, we found in our in vivo experiments that 
PTHrP and IHh continue to be reduced after longer post-irradiation intervals 
(up to 26 weeks). Furthermore, radiation resulted in growth delay and 
disorganisation of the columnar structure of the growth plate, which could 
indicate impaired synchronisation of the processes of proliferation and 
differentiation in the growth plate. As PTHrP and IHh play a key regulatory role 
in these processes, it is not unlikely that the radiation-induced disturbances in 
growth plate differentiation are related to the changes in PTHrP and/or IHh 
expression we found after irradiation. In normal growth plates, however, 
premature differentiation mediated by a decrease in PTHrP expression would 
not only result in growth delay, but also in accelerated differentiation and 
increased bone formation, something we did not see in our experiment. This 
implies that differentiation is also impaired. Indeed, in vitro experiments in other 
species have shown a decrease in matrix production and mineralization after 
irradiation 22. There are several possible explanations for the reduced 
expression of PTHrP we found after irradiation: (1) irradiation may have 
disturbed the proliferation of chondrocytes which forces them into 
differentiation, achieved by a reduction in PTHrP expression, and (2) irradiation 
has impaired the differentiation of chondrocytes, and the decrease in PTHrP 
expression is an attempt to overcome this. Both explanations imply that 
decreased PTHrP expression is a regulatory mechanism, but they do not 
explain why the decreased expression of PTHrP did not increase IHh 
expression, as could be expected, if the negative feedback loop is present in 
postnatal growth plates. A third possibility is that the reduction in the 
expression of both PTHrP and IHh is just a consequence of the impaired 
function of differentiating chondrocytes, as (at least in other species) other 
Chapter 3 
38 
differentiation markers are also reduced after irradiation (e.g., alkaline 
phosphatase and collagen X) 22. 
Whatever the mechanism, however, a reduction in PTHrP and IHh is expected 
to have an effect on growth and differentiation. We, therefore, conclude that a 
reduced expression of both PTHrP and IHh may contribute to the disturbances 
in growth and growth plate architecture seen in rats after irradiation.  
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Introduction 
Over the past 35 years, haematopoietic stem cell transplantation (HCT) has 
become an important treatment modality for a wide range of life-threatening 
haematological and immunological disorders in both children and adults. 
Successful engraftment of allogeneic haematopoietic stem cells, however, will 
not occur in the presence of a competent immune system. Therefore, most 
recipients will have to be 'conditioned' for HCT. Moreover, when HCT is done 
to cure a haematological malignancy, intensive conditioning is needed, 
eradicating most of the host’s haematopoiesis. The latter conditioning is 
qualified as myeloablative and is mostly effectuated with high dose 
chemotherapy, often combined with total-body irradiation (TBI). Such 
aggressive conditioning regimens will have their impact on the integrity of many 
other tissues as well. With an increasing number of long-term survivors, the 
late effects of HCT have become perceptible more distinctly, and ways to 
prevent them more imperative. 
As one of the first centres in the world to perform a successful allogeneic bone 
marrow transplantation 1, the Leiden University Medical Centre (LUMC) has a 
large experience in HCT in children. Unfortunately many of our patients from 
the early days of HCT were lost to follow-up after reaching adulthood. We 
therefore decided to trace and recall as many long-term survivors as possible 
and evaluate the late effects of HCT in these patients. 
Patients and Methods 
Patient selection 
We included all patients who received a HCT between 1974 and 1995 for 
either a haematological malignancy or severe aplastic anaemia (SAA) before 
the age of 18 years, who had a disease-free survival of at least 5 years and 
were at least 16 years of age at the time of the study. Patients living abroad 
were excluded, as well as one patient who would be unable to participate due 
to severe impairment caused by a massive intra-cranial haemorrhage in the 
period of HCT. A total of 33 of the 49 patients responded to our invitation, of 
whom 22 gave their informed consent. The main reasons for not participating 
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were: patients attending another hospital for their regular check-ups, the time-
consuming nature of the study, and the study being regarded as too physically 
and emotionally taxing. Patient characteristics are presented in table 1.  
 
 
Table 1. Patient Characteristics 
Patient nr. Sex 
(m/f) 
Indication for 
HCT 
TBI dose 
(Gy) 
Age HCT 
(years) 
Age study 
(years) 
Follow up 
(years) 
Remarks 
1 m SAA - 10.2 31.0 20.8  
2 m SAA - 12.4 31.6 19.2  
3 m SAA - 15.1 32.2 17.2  
4 f SAA PNH 4.0 17.9 27.8 10.0  
5 m ALL 1 6.0 x 2 13.9 21.1 7.2  
6 f ALL 1 6.0 x 2 15.7 21.8 6.0  
7 m ALL 2 7.5 4.1 18.4 14.4 Cranial irradiation before HCT 
8 m ALL 2 7.5 5.8 19.6 13.8 Cranial irradiation before HCT 
9 f ALL 2 6.0 x 2 11.9 18.1 6.1  
10 f ALL 2 8.0 14.3 29.3 15.1 Cranial irradiation before HCT 
11 f JMML 5.0 0.9 19.2 18.4  
12 f AML 7.5 7.0 25.8 18.8 Papillary thyroid carcinoma 
13 m AML 7.5 7.4 21.6 14.3  
14 f AML 8.0 10.7 24.8 14.1  
15 f AML 8.0 10.1 24.3 14.2  
16 f AML 8.0 14.3 30.3 16.0 2 x spontaneous abortion 
17 f AML 8.0 15.9 25.2 9.3  
18 f AML 8.0 15.2 31.3 16.1  
19 m AML 8.0 10.3 21.1 10.8 
HCT twice, progressive lung  
disease, avascular hip necrosis 
20 m MDS 7.5 9.6 23.5 13.9  
21 f CML (Ph+) 7.5 10.0 27.6 17.8 Avascular hip necrosis 
22 m NHL 2 6.0 x 2 14.1 20.7 6.6  
SAA Severe Aplastic Anaemia 
SAA PNH Severe Aplastic Anaemia Paroxysmal Nocturnal Haemoglobinuria 
ALL1 Acute Lymphoblastic Leukaemia in 1st remission 
ALL 2 Acute Lymphoblastic Leukaemia in 2nd remission 
JMML Juvenile MyeloMonocytic Leukaemia 
AML Acute Myelogenous Leukaemia in 1st remission 
CML (Ph+) Chronic Myelogenous Leukaemia (Philadelphia positive) 
NHL 2 Non-Hodgkin Lymphoma in 2nd remission 
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Conditioning for HCT 
Conditioning consisted of cyclophosphamide (Cy, 60 mg/kg/day i.v. for 2 
consecutive days) in all patients and was combined with TBI in children 
suffering from a haematological malignancy. In addition to this Cy-TBI regimen, 
cytarabine (1 g/m2/day for 2 consecutive days) was given to patients treated 
for myeloid leukaemia or myelodysplastic syndromes between 1988 and 1998 
(n=1). From 1990 onward, patients treated for lymphoblastic leukaemia or non-
Hodgkin lymphoma received etoposide (350 mg/m2/day for 2 consecutive 
days) (n=4) in addition to TBI-Cy.  TBI was administered unfractionated (i.e. as 
one or two single fractions > 4.0 Gy), delivered at a mean dose rate of 23 
cGy/min. To reduce radiation damage, lungs were compensated for their 
different radiation-density, and eyes were shielded during TBI from 1987 
onward. 
As age is an important determinant with respect to tolerability of irradiation 
dose in children, a TBI regimen with age-dependent total dose was applied, i.e. 
0-2 years: 5.0 Gy, 2-4 years: 7.0 Gy, 4-10 years: 7.5 Gy, >10 years 8.0 Gy. 
The latter dose was ‘increased’ in 1989 to 2 single fractions of 6.0 Gy, given on 
2 consecutive days, instead of the equivalent 9.0 Gy once, which had too much 
side effect in adults. Of the 4 patients treated for SAA, one who was 
transfusion-sensitised received 4 Gy TBI in addition to Cy, the other 3 received 
no TBI.  
Growth and endocrine functions 
Parameters used to evaluate growth and endocrine function were height, 
weight, serum levels of insulin-like growth factor 1 (IGF-1), free thyroxin (FT4), 
thyroid stimulating hormone (TSH), luteinising hormone (LH), follicle stimulating 
hormone (FSH), oestradiol, testosterone, 25-OH vitamin D, use of hormone 
preparations (e.g. thyroxine, oral contraception etc.) and bone mineral density 
(BMD). Height is measured with a stadiometer and expressed in standard 
deviation score (SDS) for age and sex based on Dutch references 2. Target 
height was calculated from parental height with corrections for secular trend 
(+4.5 cm) and sex differences (13 cm) 2. Final height (FH) SDS was compared 
to height SDS at the time of HCT and to target height SDS. BMD was 
measured with dual-emission x-ray absorption (DEXA) scan (Hologic QDR) in 
femoral necks and lumbar spine and results were expressed as gender specific 
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SD scores for young adults. Osteoporosis was defined as BMD <-2.5 SDS, 
Osteopenia as BMD < -1.0 SDS. 
Renal function 
Creatinine clearance was estimated using the formula of Cockcroft and Gault 3 
with correction for body surface area. Glomerular Filtration Rate (GFR) was 
estimated using the Modification of Diet in Renal Disease Study 1 (MDRD1) 
formula, which includes age, sex, serum creatinine, serum urea and serum 
albumin 4. GFR and creatinine clearance were considered normal if > 85 
ml/min/1.73m2. 
Lung function 
We used a standardised questionnaire to evaluate subjective pulmonary 
symptoms. Parameters for lung function were forced expiratory volume in one 
second (FEV1), functional residual capacity (FRC), vital capacity (VC), total 
lung capacity (TLC), residual volume (RV), and transfer factor for carbon 
monoxide (TLCO), corrected for haemoglobin content. Results are expressed as 
percentage of the predicted values, derived from Quanjer et al. for VC, FEV1 5, 
from Stocks et al. for TLC, FRC and RV 6, and from Stam et al. for TLCO 7. 
Other late effects 
An ophthalmologist and a dermatologist examined patients for dermal and 
ocular late effects. Secondary tumours were identified from the medical 
records. 
All laboratory evaluations were performed using standard in house, 
commercially available assays. 
Quality of life 
The sickness impact profile and the Medical Outcome Study 36-item Short 
Form Health Survey were used as generic questionnaires in the assessment of 
Quality of life (QOL). The Functional Assessment of Cancer Therapy-Bone 
Marrow Transplant Scale (FACT-BMT) was used as a disease-specific 
measure of QOL. Coping was assessed by means of the Utrecht coping list. 
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Results 
Table 2 summarises the results of individual patients. 
Growth and endocrine function 
All patients had reached FH. In seven patients, pubertal growth spurt was 
almost completed at time of HCT (including one 12 year old boy with SAA who 
had received high doses of androgens for several years; his height at HCT was 
186.5 cm). Of the remaining 15 patients, two had received cranial irradiation 
prior to TBI. Their FH’s were –4.0 and –3.3 SDS.  One other patient (no TBI) 
had received high doses of corticosteroids for several years, first for his SAA, 
later for severe chronic graft-versus-host-disease (GVHD). His FH was –3.5 
SDS. In the remaining 12 patients, only one patient (not treated with TBI) had 
an increase in height SDS (+1.4 SD) between HCT and FH. In the other 11 
patients (all had received TBI) median FH SDS was –2.1 (range -3.7 to 0), 
median difference between height SDS at HCT and FH SDS was - 1.6 (range –
2.3 to –0.1), and median difference between target height SDS and FH SDS 
was –1.6 (range –2.6 to –0.5). None of the patients had been treated with 
growth hormone (GH).  
Hypergonadotrophic hypogonadism was diagnosed in 10 of the 12 girls, with 
recovery of gonadal function in two of them. Six girls received sex hormone 
replacement therapy and two used oral contraception. One patient who had 
recovered from hypogonadism had 2 pregnancies, both resulting in 
spontaneous abortion. All 7 males treated with TBI and 1 of the 3 males who 
only received cyclophosphamide had elevated FSH levels, suggestive of 
severely decreased fertility. Three boys were using sex hormone replacement 
therapy. In one of the remaining 7 boys testosterone was decreased and LH 
elevated, suggestive of decreased Leydig cell function.  
One patient with pre-existing hyperthyroidism before HCT underwent 
thyroidectomy and received thyroxine suppletion. Of the remaining patients, 
two had developed primary hypothyroidism after TBI and were receiving 
thyroxine suppletion. Free T4 and TSH were normal in all patients. 
None of the patients had vitamin D deficiency. In two patients (one male), BMD 
measurement of the femoral neck was impossible due to hip replacement 
surgery after avascular hip necrosis as a result of extensive use of 
glucocorticosteroids for GVHD. One female patient had osteoporosis of the 
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lumbar spine BMD (BMD –2.6 SDS), with osteopenia of both femoral necks (-
1.8 and –2.0 SDS). Another female patient had osteoporosis of her right 
femoral neck (BMD –2.6 SDS), with osteopenia of the other hip and lumbar 
spine (BMD –2.4 and –1.9 SDS respectively). Of the remaining patients, 9/18 
had osteopenia of one or both hips, and 6/20 had osteopenia of the lumbar 
spine. 
Renal function 
Median estimated creatinine clearance was 100 ml/min/1.73m2 (range 83-124). 
Median estimated GFR using the MDRD1 formula was 99 ml/min/1.73m2 
(range 76-131). One patient had a decreased estimated creatinine clearance 
(83 ml/min/1.73m2) but normal estimated GFR (88 ml/min/1.73m2). Another 
patient had a decreased estimated GFR (76 ml/min/1.73m2) but normal 
estimated creatinine clearance (89 ml/min/1.73m2). In both patients actual 
creatinine clearance (measured using 24-hr urine samples) was normal (101 
and 141 ml/min/1.73m2 respectively).  
Lung function 
Apart from the patient with severe pulmonary fibrosis after a re-transplantation, 
3 patients reported mild shortness of breath during exercise. The remaining 18 
patients were free of pulmonary symptoms. Lung function tests were missing in 
one female patient due to a technical error. One patient had severe pulmonary 
fibrosis due to radiation damage and pulmonary GVHD, which resulted in 
oxygen dependency and a VC of only 20% of predicted. This patient was 
excluded from the analyses. Median VC was 80% (54-115), median TLC was 
83% (56-125), median RV was 70% (42-222) median RV/TLC was 92% (56-
158), median FEV1/VC was 106% (88-124) and median TLCO was 60% (40-
104). TLC, VC and TLCO were significantly decreased in our population (one-
sample Student t-test, p<0.001), whereas FEV1/VC was significantly increased 
(p=0.015). All patients with pulmonary symptoms had abnormal pulmonary 
function tests. 
Other late effects 
Of the 19 TBI treated patients, 12 received TBI before 1987, which means that 
they did not have their eyes shielded to reduce the radiation dose to the 
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lenses. Two of these patients had a history of lens extraction for severe 
cataract after HCT. In the other 10 patients, mild cataract was found. The one 
patient who received a relatively low dose of 4 Gy TBI also had mild cataract. 
She had also received high doses of corticosteroids during the initial treatment 
of her SAA. Of the 7 patients receiving TBI after 1987 (i.e. with eye shielding), 
only one had very mild cataract. Of the 3 patients who did not receive TBI, one 
patient, treated with corticosteroids for GVHD for a long time, had mild 
cataract. Two patients with chronic GvHD had keratoconjunctivitis sicca.  
Physical examination by a dermatologist revealed no dysplastic naevi in any of 
the patients. One patient was treated for basal cell carcinoma in the past, and 
in one patient a basal cell carcinoma was diagnosed and excised. Four 
patients had sclerotic skin lesions as a result of chronic GVHD. 
Three patients (all treated with TBI) had developed a secondary tumour (one 
thyroid carcinoma and 2 basal cell carcinoma, as described above).  
Quality of life 
Results of the QOL measurements are published elsewhere 8. Of the generic 
QOL measures, most results fell within the normal range of functioning, 
although some illness-related impairment was reported on subscales for 
general and work-related functioning. Compared to a reference sample of 
patients who had received BMT as adults, patients involved in this study 
scored significantly higher on the ‘emotional well-being’ subscale of the FACT-
BMT, indicating significantly better emotional functioning. The age at BMT and 
total body irradiation (TBI) were not related to patients’ QOL. 
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 Discussion 
Impaired growth is an important late complication of HCT, with TBI as the most 
important etiological factor. TBI may have a direct effect on growth (by inducing 
growth plate damage) as well as an indirect effect (by causing GH deficiency, 
hypogonadism or hypothyroidism). The indirect effects can be overcome by 
hormone replacement therapy. Other factors that may contribute to impaired 
growth are chronic GVHD, its treatment with glucocorticosteroids, and cranial 
irradiation prior to HCT, resulting in GH deficiency.  
In our evaluation, median adult height after TBI was 1.6 SDS (±11 cm) lower 
compared to both target height and height at HCT. In patients who also had 
received cranial irradiation, adult height was even more compromised. These 
results are comparable to final heights reported in the literature  9-12.  
Except for the two girls who were the youngest at the time of HCT, all women 
who had received TBI developed hypergonadotrophic hypogonadism after TBI. 
In two of these women gonadal function recovered, and one of them became 
pregnant twice. These results are in line with the literature, reporting a positive 
correlation between age at HCT and incidence of ovarian failure 13-15.  As could 
be expected from earlier reports 16, TBI resulted in decreased fertility in men. In 
addition, with increasing age, signs of Leydig cell failure became more evident, 
with elevated serum levels of LH in 4 of 7 men. 
Hypothyroidism after HCT is related to radiation damage to the thyroid gland. 
The incidence of hypothyroidism after TBI in this study was 2/18 (11%) which is 
relatively low compared to incidences reported in the literature (45% after sf-
TBI and 15% after fractionated TBI) 16.  An explanation for this lower incidence 
could be the relatively low total TBI dose in our study (most patients received 
7.5-8.0 Gy, compared to 10 Gy in most studies with sf-TBI). 
Osteopenia was present in 64% of the patients, two of whom also had 
osteoporosis. As most patients had a relatively low adult height, BMD SDS is 
probably slightly higher if corrected for height. Unfortunately, these data were 
not available. The percentage of patients with reduced BMD in our study is 
comparable to that reported in adults by Kauppila et al. (68%) 17. The most 
important factor contributing to the decreased BMD is the use of 
glucocorticosteroids in patients with chronic GVHD. In addition, hypogonadism 
(especially in girls with ovarian failure), non-compliance in patients with sex 
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hormone replacement therapy, and TBI also contribute to the decreased BMD 
16. The small population size prevented further analyses of these influencing 
factors. 
Renal function was normal in all 22 patients. Decreased renal function is 
related to the use of nephrotoxic agents (e.g. cisplatin, cyclosporine, 
amphoterecin B) and total TBI dose. The reported incidence of renal 
dysfunction in adults receiving fractionated TBI at total doses of less than 12 
Gy is approximately 5% 18;19. Recently, results of a prospective study into 
chronic renal failure after HCT were reported by our transplant centre 20. In that 
study, TBI was not a risk factor for either acute or chronic renal failure in the 
first 2 years after HCT. Frisk et al., however, report repeated measurements of 
GFR and describe a gradual decrease in GFR with time after HCT 21. They 
report renal insufficiency (GFR < 70 ml/min/1.73m2) in as much as 27% of 26 
patients after paediatric HCT and 7.5 Gy single-fraction TBI (median follow-up 
of 10 years), compared to 0% of the 14 patients receiving radiation-free 
conditioning for HCT. We do not have an explanation for the low incidence of 
renal insufficiency after TBI in our patients, but differences in the use of 
nephrotoxic agents during treatment of initial disease and during the 
transplantation period may play a role.  
There was a decrease in lung function parameters compatible with restrictive 
pulmonary disease in 66% of our population (i.e. decreased TLC and RV, 
increased FEV1/VC). In addition, diffusion capacity, measured by TLCO was 
also significantly decreased (<80% of predicted) in 10/20 (50%) patients. None 
of the patients had obstructive lung disease. The majority of the patients (82%) 
were free of symptoms. Restrictive lung disease and decreased diffusion 
capacity is associated with TBI, and in longitudinal studies lung function 
stabilises after initial decrease 11;22-25. In contrast to the high incidence of 
restrictive lung disease in our population, Frisk et al. reported an incidence of 
only 21% 10 years after 7.5 Gy sf-TBI 11 , and Cerveri et al. reported 26% two 
years after 6x2.0 Gy fractionated TBI 24. These differences can be explained by 
the absence of GVHD in the first study (autologous transplants only) and the 
shorter follow-up and possibly the use of fractionated TBI in the latter study. 
The incidence of cataract, a well known late effect of ocular irradiation, 
depends on total dose, dose rate and fractionation. Our results are comparable 
to those reported in the literature 26;27. The study of Kempen-Harteveld et al. 27 
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was a national study on paediatric HCT recipients and included all patients 
receiving TBI in our centre until 2001. Before eye shielding was applied, the 
incidence of cataract after sf-TBI was >90%, whereas with eye shielding it was 
approximately 30%. 
Three patients had developed a secondary malignancy. Based on both animal 
data and the experience with radiation induced tumours in humans, more 
secondary tumours can be expected in the future. 28;29 
Our cross-sectional evaluation revealed a substantial number late of effects in 
a wide variety of organ systems, and all patients in our study suffered from 
more than one such late complication. Therefore life-long follow-up of all 
patients treated with HCT is indicated. Shielding of radiosensitive organs may 
reduce the incidence of late effects (e.g. eye-shielding to prevent cataract), but 
is not feasible for many organs (e.g. gonads) in children treated for 
malignancies. Growth hormone therapy is a promising option for the treatment 
of radiation induced growth impairment (own unpublished data), but multi-
centre studies are needed to determine its benefits and risks in this category of 
patients. 
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Abstract 
Few data are available on the long-term effect of bone marrow transplantation 
(BMT) on growth. This study examines those factors that play a role in the final 
height outcome of patients who underwent BMT during childhood. Data on 181 
of 230 patients with aplastic anaemia, leukaemia, and lymphomas who had 
BMT before puberty (mean age 9.8 ± 2.6 years) and who had reached their 
final height were analysed. An overall decrease in final height standard 
deviation score (SDS) value was found compared with the height at BMT (P < 
107) and with the genetic height (P < 107). Girls did better than boys, and the 
younger in age the person was at time of BMT, the greater the loss in height. 
Previous cranial irradiation + single-dose total body irradiation (TBI) caused the 
greatest negative effect on final height achievement (P < 104). Fractionation of 
TBI reduces this effect significantly and conditioning with busulphan and 
cyclophosphamide seems to eliminate it. The type of transplantation, graft-
versus-host disease, growth hormone, or steroid treatment did not influence 
final height. Irradiation, male gender and young age at BMT were found to be 
major factors for long-term height loss. Nevertheless, the majority of patients 
(140/181) have reached adult height within the normal range of the general 
population.  
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Introduction 
 The success of bone marrow transplantation (BMT) in treating malignant and 
non-malignant haematological disorders and the improvement of the 
sophisticated techniques involved in this procedure have extended the 
indications for transplantation and have increased the number of patients who 
survive BMT 1;2. Nevertheless, one of the many negative effects that these 
successfully treated children have to face is the endocrine dysfunction 
associated with the chemotherapy, radiotherapy, and immunosuppressive 
treatment they receive before and after marrow transfusion, which could 
eventually induce growth delay. To our knowledge, only two single-centre 
studies have dealt with the final height achievement of patients who had BMT 
during childhood 3;4. Because the BMT procedure is relatively recent, making it 
difficult to include large numbers of patients who have reached their final adult 
height, the statistical power of these two studies was frail. The European BMT 
Working Party for Late-Effects conducted this multi-centre study with the aim of 
evaluating the final height achieved by children who underwent BMT for 
haematological disorders and identifying those factors that influence the long-
term growth in these patients.  
Patients and methods  
Study design  
The study is based on a retrospective survey using a two-step-questionnaire 
approach, involving centres that are part of the European-BMT group.  
A first questionnaire was sent to 284 BMT centres asking for the number of 
patients with severe aplastic anaemia (SAA), leukaemia, and lymphomas who 
underwent BMT before onset of puberty (breast stage 1 in girls and testicular 
volume less than 4 mL in boys) and who had reached their final adult height. 
Final height was defined either on a documented closure of the hand, wrist, or 
iliac crest epiphyses or growth velocity less than 1 cm/yr 5.  
One hundred of the 284 centres (35%) completed and sent back the first 
questionnaire form. Sixty-two centres (22%) confirmed that they did not have 
cases that met the inclusion criteria. A second questionnaire was sent to the 
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remaining 38 centres that claimed to have patients eligible for the study. 
Twenty-two of the 38 centres answered the second questionnaire, providing 
data on a total of 230 patients.  
The questionnaire included queries regarding the primary haematological 
disorder, irradiation therapy used during first-line treatment (between diagnosis 
and pre-BMT conditioning treatment), BMT-related data (age and type of BMT, 
conditioning regimen, grading of acute and chronic graft-versus-host disease 
[GVHD], and type and duration of immunosuppression therapy), and 
endocrine-related data that included parental height, patient’s height and 
weight at BMT, final adult height achieved, age at latest measurement, growth 
hormone treatment, and sex hormone replacement therapy performed.  
Patients’ characteristics  
Of the 230 forms received, 49 patients were excluded from the study either 
because the onset of puberty was before BMT or because of insufficient key 
data necessary for a correct and comprehensive statistical analysis. BMT was 
performed between October 1973 and October 1993. The characteristics of the 
181 patients who met the inclusion criteria are summarised in table 1.  
 
Table 1. Patients’ characteristics at diagnosis and at transplantation 
Patients studied  181 (112 M; 69 F)    
Mean age at diagnosis (yrs) 8.1 ± 3.3 (range 0.9-14.4) 
Diagnosis and disease status at BMT  
- ALL 73 (15-1st CR: 45-2nd CR: 11-≥2nd CR; 2 relapse) 
- AML 1st CR 46  
- CML chronic phase 10  
- Myelodysplastic syndrome 2  
- NHL 2  
- SAA 48  
Mean age at BMT (yrs)  9.8 ± 2.6 (range, 1.5-14.9) 
Type of BMT  
- Allogeneic  153 (149 identical, 2 unrelated, 2 mismatched related) 
- Syngeneic 3 
- Autologous 25 
GVHD  
- Acute-grade 3-4 16 
- Chronic-limited  37 
- Chronic-extended 18 
Mean follow-up period (yrs)    9.2 ± 3.1 (range 2.9-19.7) 
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The type of irradiation applied to the patients in relation to the primary disorder 
is shown in table 2. Fifty patients received cranial radiation therapy (CRT) as 
prophylaxis or treatment of central nervous system involvement (<18 Gy in 4 
patients, 18 Gy in 29 patients, 24 Gy in 16 patients, and 36 Gy in 1 patient). 
Irradiation during conditioning regimen included single-dose total body 
irradiation (sTBI) in 52 patients at a median dose of 8 Gy (range, 3 to 10 Gy; 3 
SAA patients received 3 to 4 Gy, whereas the remaining patients received 7 to 
10 Gy); fractionated TBI (fTBI) in 73 patients (6 to 13.2 Gy) administered in 2 to 
8 fractions; thoraco-abdominal irradiation (TAI) in 17 patients (5 to 11 Gy); and 
total lymphoid irradiation (TLI) in 2 patients (7.5 Gy). Seventeen children with 
acute lymphoblastic leukaemia (ALL) received a booster dose of 4 to 10 Gy to 
the testicles. 
 
Table 2. Irradiation applied to the patients in relation to the primary disease. 
 First line irradiation therapy Irradiation during conditioning 
Diagnosis 
No. of 
patients
Non-
Irradiated  CRT 
Cranio- 
spinal Testes Ocular sTBI fTBI TAI TLI Boost 
ALL 73 0  42 4 10 3  25 47 1 - 17 
AML 46 7  3 - - -  20 17 1 - - 
CML 10 2  1 - - -  1 7 - - - 
MDS 2 0  - - - -  2 - - - - 
NHL 2 0  - - - -  1 1 - - - 
SAA 48 27  - - - -  3 1 15 2 - 
TOTAL 181 36  46 4 10 3  52 73 17 2 17 
 
 
Patients subjected to irradiation as part of the pre-BMT conditioning regimen 
also received cyclophosphamide (Cy) alone or in combination with other 
cytotoxic drugs (cytarabine, etoposide, and vincristine). Of the 36 patients who 
did not receive irradiation, 10 children (7 acute myeloid leukaemia [AML], 2 
chronic myeloid leukaemia [CML], and 1 SAA) were conditioned with 
busulphan and cyclophosphamide only (Bu/Cy). Steroid therapy for acute 
and/or chronic GVHD was administered in 87 patients for a median period of 4 
months (range, 0.5 to 168 months); 62 of them stopped treatment within 12 
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months, whereas 14 patients had treatment for periods longer than 24 months. 
Cyclosporin-A was administered in 90 patients for a median period of 6.5 
months (range 2 to 84 months); 67 of them stopped treatment within 12 
months, whereas 11 patients had treatment for periods longer than 24 months.  
Sex hormone replacement therapy was administered to 55 patients (24 male 
and 31 female), starting at 14.0 ± 3.3 years of age (range, 12 to 18 years of 
age) in males and at 14.4 ± 1.8 years of age (range 11 to 18.8 years of age) in 
females. Growth hormone (GH) treatment was administered in 28 patients for a 
median period of 3.5 years (range 0.3 to 7 years), starting at 13.2 ± 2.1 years 
of age (range 9.8 to 17.9 years of age), 3.8 ± 2.0 years from BMT (range, 0.9 
to 8.3 years).  
Statistical analyses 
Height measurements of each patient both at the time of BMT and final height 
were expressed as the standard deviation score (SDS) from the mean of the 
normal population 5. The genetic height of each patient was calculated as the 
mean of the mother’s and the father’s height-SDS (genetic height = [mother’s 
SDS + father’s SDS]/2). 
The difference between the height-SDS value at BMT and that of the final 
height was calculated for each patient and was regarded as the delta-SDS 
value, expressing the gain (zero or positive values) or the loss of height 
(negative values) after transplantation in terms of SDS.  
Statistical analyses for the comparisons of delta-SDS values were performed 
according to the type and age at BMT, gender, pre-transplant conditioning 
regimens, complications, and therapies applied. The relationships between 
dependent and explanatory covariates were investigated by using the analysis 
of variance and the χ2 statistics for continuous and categorical covariates, 
respectively.  
The association between delta-SDS, as dependent variable, with the type of 
BMT, age at transplant, gender, radiotherapy, chronic GVHD severity, and GH 
treatment were also investigated using the multiple logistic regression analysis 
6. This multivariable technique permits identification of covariates that are 
associated with the probability of the studied outcome and expresses each 
covariate association, adjusted for the effect of the other covariates included in 
the regression model, in terms of relative risk point estimates (RR) and its 
confidence intervals.  
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To this aim, the dependent variable delta-SDS was dichotomized to distinguish 
between subjects who had normal growth after transplant (i.e., delta-SDS value 
≥0) and those who had growth failure (delta-SDS <0). Patients were also 
divided into three groups to identify subjects who received CRT (with or without 
TBI), subjects who received radiation therapy that did not include CRT, and 
patients who have never received any irradiation therapy (reference group, RR 
= 1). The age at transplant (continuous covariate) was categorised into three 
levels according to the 33rd (1.5 to 8.8 years) and the 66th percentile values of 
its frequency distribution (8.8 to 11 years). Patients with age greater than 11 
years at transplantation were used as a reference (i.e., RR = 1). The statistical 
analyses were performed using the SPSS statistical software, version 8.0 
(SPSS Inc, Chicago, IL) 7.  
Results  
Final height achievement was documented by closure of hand, wrist, or iliac 
crest epiphyses in 9 patients who were 18.5 ± 2.4 years of age at latest 
evaluation and by growth velocity less than 1 cm/yr in the remaining patients, 
who were 19.1 ± 2.8 years of age. Final height-SDS values of 140 of 181 were 
within normality for the general healthy population (between -2.0 and +2.0 
SDS). Three patients achieved height values greater than +2.0 SDS, whereas 
the remaining 38 are to be considered as short stature (below -2.0 SDS).  
Considering the entire cohort of patients (Fig 1), the height-SDS value at BMT 
(-0.15 ± 1.16) was significantly higher (paired Student’s t-test; P < 107) than the 
final height-SDS value (-1.09 ± 1.45), resulting in a mean decrease of 0.94 ± 
1.30 SDS from transplant to adulthood.  
Whereas the height-SDS value at BMT was comparable to that of the genetic 
height (-0.22 ± 1.02 SDS), the final height-SDS value was significantly lower (P 
< 107). The mean delta-SDS value of the whole cohort was -0.94 ± 1.30 (range 
-6.9 to +2.6). The 112 boys did worse than the 69 girls, having a mean delta-
SDS value of -1.17 ± 1.34 compared with -0.56 ± 1.13, respectively (t-test; P < 
0.002). Girls were younger at BMT compared with boys (8.9 ± 2.7 and 10.3 ± 
2.4 years, respectively; P<0.0005). Age was found as an additional factor that 
influences growth, because the younger the age at BMT the higher the delta-
SDS value (linear regression analysis; regression coefficient = 0.218; P < 107) 
and the lower the final height-SDS (regression coefficient = 1.104; P = 0.01). 
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Figure 1. Correlation between the genetic height, height-SDS at BMT, and final height-
SDS. Numerals indicate the number of cases studied in each group. The dotted area 
indicates the height-SDS distribution for the normal general population. Box plot: The 
lower line of the box indicates the 25th percentile, the upper line indicates the 75th 
percentile, and the horizontal lines above and below the boxes represent the 3rd and 
the 97th percentile, respectively. Statistical analyses: paired Student’s t-test. 
 
 
 
The type of BMT was found to have no effect on the delta-SDS value (analysis 
of variance, one-way ANOVA); in fact, the 28 patients who underwent 
autologous-syngeneic BMT (for statistical purposes, the 3 children who 
received a transplantation from a monozygotic twin were considered as part of 
the autologous group) had a delta-SDS value of -0.95 ± 1.25 compared with 
that of -0.94 ± 1.31 in the 153 cases who had allogeneic BMT.  
Seven different groups were identified according to the type of irradiation and 
chemotherapy applied (table 3); the age at BMT was similarly distributed in 
these groups (analysis of variance).  
As shown in Fig 2, the most severe growth failure was found in patients who 
received CRT+sTBI (mean delta-SDS value, -2.07 ± 0.91) followed, 
respectively, in decreasing degree of severity by sTBI (-1.37 ± 1.06), CRT+fTBI 
(-1.11 ± 1.61), fTBI (-0.88  ± 1.25), and TAI/TLI (-0.71 ± 0.72). The non-
irradiated group had virtually no growth deficit after BMT (-0.07 ± 1.08). 
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Table 3. Characteristics of patients divided according to the irradiation protocol applied. 
Type of irradiation 
No. of  
Patients 
Age at BMT (yr) 
(mean ± SD) 
Delta-SDS 
(mean ± SD) 
Final height-SDS 
(mean ± SD) 
CRT 3 11.2 ± 0.4 -0.93 ± 1.10 -1.20 ± 2.16 
CRT+sTBI 13 8.4 ± 2.2 -2.07 ± 0.91 -2.42 ± 1.22 
CRT+fTBI 34 10.2 ± 2.3 -1.11 ± 1.61 -1.69 ± 1.68 
sTBI 39 9.5 ± 2.5 -1.37 ± 1.06 -1.15 ± 1.06 
fTBI 39 10.0 ± 2.9 -0.88 ± 1.25 -0.98 ± 1.21 
TAI/TLI 17 8.7 ± 2.2 -0.71 ± 0.72 -0.85 ± 0.93 
No irradiation 36 10.3 ± 2.9 -0.07 ± 1.08 -0.21 ± 1.54 
 - Cy only (SAA) 26 9.8 ± 2.8 -0.12 ± 1.08 -0.15 ± 1.68 
 - Bu/Cy 10 11.7 ± 2.7 +0.05 ± 1.13 -0.36 ± 1.16 
 
 
 
 
 
Figure 2. Delta-SDS (final height SDS minus SDS at BMT) in the different irradiation 
groups. Numerals indicate the number of cases studied in each group. (Box plot) The 
lower line of the box indicates the 25th percentile, the upper line indicates the 75th 
percentile, and the horizontal lines above and below the boxes represent the 3rd and 
the 97th percentile, respectively. 
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A similar pattern was found when final height-SDS values were considered (Fig 
3). The delta-SDS value of the 10 non-irradiated patients conditioned with 
Bu/Cy (+0.05 ± 1.13) was not statistically different from the 26 non-irradiated 
SAA patients (-0.12 ± 1.08). 
 
 
 
Figure 3. Final height-SDS achievement in the different irradiation groups. Numerals 
indicate the number of cases studied in each group. The dotted area indicates the 
height-SDS distribution for the normal general population. Box plot: The lower line of 
the box indicates the 25th percentile, the upper line indicates the 75th percentile, and 
the horizontal lines above and below the boxes represent the 3rd and the 97th 
percentile, respectively. 
 
 
Comparing the delta-SDS value among the patients divided into groups 
according to diagnosis, no significant difference was found between the ALL 
(73 cases; -1.26 ± 1.35), AML (46 cases; -0.96 ± 1.06), and CML groups (10 
cases; -0.74 ± 1.98). The delta-SDS found in the SAA group (48 cases; -0.43 ± 
1.09) was significantly better than that of the ALL and AML groups. Dividing the 
SAA group into non-irradiated (27 cases; -0.12 ± 1.06 delta-SDS) and 
irradiated (21 cases; -0.82 ± 1.01), a significant statistical difference was found 
(Wilcoxon rank-sum test; P < 0.03). 
 The severity of chronic GVHD (126 cases with no GVHD: -0.84  ± 1.20 delta-
SDS; 37 cases with limited GVHD: -1.08 ± 1.30; and 18 cases with extended 
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GVHD: -1.34 ± 1.85) did not significantly influence the delta-SDS mean value 
(analysis of variance: P = 0.22), even though an increasing severity of the 
chronic GVHD showed a tendency toward worsening of delta-SDS.  
On a long-term basis, cortisone treatment (87 treated patients [-1.03 ± 1.48 
delta-SDS] v 84 not treated [-0.79 ± 1.07]) and cyclosporin-A treatment for 
GVHD (91 treated [-0.84 ± 1.22] v 80 not treated [-0.99 ± 1.38]) were found to 
have no effect on delta-SDS values.  
The 55 patients who received sex hormone replacement therapy reached a 
similar final height-SDS (-1.05 ± 1.53) compared with the group of patients who 
started and completed pubertal development spontaneously (-1.05 ± 1.35).  
The mean delta-SDS found in the 28 patients treated with exogenous GH (-
1.14 ± 1.24) was not statistically different from that of the remaining 153 
patients (-0.90 ± 1.31) not treated with exogenous GH. Because irradiation was 
the major factor in altering the delta-SDS value in our cohort, this analysis was 
performed within the same conditioning group. Twelve of 34 patients who 
received CRT+fTBI and who were treated with GH (delta-SDS -0.75 ± 1.32) 
were compared with the remaining 22 patients who did not receive GH 
treatment (delta-SDS -1.31  ± 1.75); 8 of 13 patients who received CRT+sTBI 
and who were treated with GH (delta-SDS   -1.83 ± 0.71) were compared with 
the remaining 5 patients who did not receive GH treatment (delta-SDS -2.46 ± 
1.13); and 7 of 39 patients who received sTBI and who were treated with GH 
(delta-SDS -1.24 ± 1.38) were compared with the remaining 32 patients who 
did not receive GH treatment (delta-SDS -1.40 ± 1.0). None of the comparisons 
was found to be statistically significant, but there seems to be a trend towards 
better growth in the GH-treated group. We also failed to show differences 
within the same gender, both between GH-treated (20; -1.21 ± 1.34 delta-SDS) 
and untreated boys (92; -1.77 ± 1.35) and between GH-treated (8; -0.99 ± 
1.01) and untreated girls (61; -0.50 ± 1.14 delta-SDS).  
Multiple-logistic regression was used to model the relationship between the 
dependent variable delta-SDS and the explanatory covariates (gender, age at 
transplant, type of BMT, irradiation applied, chronic GVHD severity, and GH 
therapy). Stepwise multiple logistic regression identified irradiation, age at 
transplant, and gender as statistically relevant explanatory covariates that 
significantly contributed to the model that was fitted to the data (table 4).  
The role of each covariate in determining a relevant growth deficiency (delta-
SDS <0) while accounting for the effect of the other covariates included in the 
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logistic regression model and the estimated effect size is reported as relative 
risk point estimates with their 95% confidence intervals (table 4). 
 
Table 4. Stepwise regression logistic analysis identifying the role of each covariate 
in determining a relevant growth deficiency (delta-SDS less than 0) while 
accounting for the effect of the other covariates.  The estimated effect magnitude is 
reported as relative risk point estimates (RR) with their 95% confidence intervals 
(CI).  
 
Covariate 
Relative Risk 
for growth failure 
 
95% CI 
 
P value 
Irradiation 
 No irradiation (36) 
 CRT ± TBI*    (50) 
 TBI/TAI/TLI§   (95) 
 
1.0 
6.96 
6.89 
 
Reference level 
2.11-22.95 
2.55-18.57 
 
0.0002 
 
Gender 
 Female   (69) 
 Male  (112)  
 
1.0 
4.52 
 
Reference level 
1.75-11.66 
 
0.0069 
 
Age (years) 
 >11   (60) 
 8.8-11  (61) 
 <8.8  (60) 
 
1.0 
2.61 
5.29 
 
Reference level 
1.73-16.23 
0.95-7.19 
 
0.01 
*  Patients who received CRT during first line therapy. 
§  Patients who did not receive CRT but who had either single or fractionated TBI, TAI 
or TLI during pre-BMT conditioning. 
 
Discussion 
The normal growth process during childhood reflects the child’s general well-
being, and it is regulated by and depends on the interaction between genetic, 
nutritional, metabolic, and hormonal factors. Nevertheless, growth is not always 
linear, especially in children who have periods of chronic illnesses and/or 
undergo toxic treatment procedures. The end result of growth is the final adult 
height, which is used in this study as the long-term marker for treatment-related 
toxicity in patients who underwent BMT during childhood.  
Growth impairment in the short term has been repeatedly reported after BMT 8-
12, but data on final height achievement are scarce, and the only two published 
reports dealt with a limited number of patients 3;4. This is the first multi-centre 
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study on final height with a large number of patients that takes into 
consideration the various potential risk factors that might affect growth after 
transplantation performed during childhood. Solid tumours and haematological 
disorders in which short stature is a trait of the disease itself (Fanconi’s 
anaemia, Thalassemia, inborn errors, etc) were excluded.  
Our data showed a similarity between the genetic height and the height at BMT 
on one hand and a decreased value of final height-SDS compared both with 
the genetic height and the patient’s height-SDS at BMT on the other, 
suggesting that the growth impairment in transplanted patients occurred mostly 
during the period after transplantation (Fig 1).  
The outcome of final height in this study did not change significantly between 
the different types of haematological malignancies (ALL, AML, and CML), 
suggesting that, in this cohort of patients, the primary disease itself does not 
affect growth. This study confirms that irradiation is the major contributor for 
long-term growth impairment (final height achievement). Patients who were not 
irradiated had virtually no decrease in final height-SDS compared both with the 
height at BMT and the genetic height, underlining what was reported in smaller 
series of patients 3;4. Among the different irradiation settings, leukaemia 
patients who received CRT during first-line treatment and sTBI during pre-BMT 
conditioning had the most severe long-term impairment of growth (Figs 2 and 
3). Moreover, patients with an identical primary disorder (SAA) who were 
treated with two different conditioning regimens (Cy+irradiation v Cy only) 
presented two completely different patterns of growth, with the most favourable 
being the non-irradiated group. 
Because the Bu/Cy conditioning regimen has been more recently introduced to 
reduce the detrimental effects of irradiation 13, the number of the Bu/Cy 
patients in this study is too small to draw unequivocal conclusions regarding 
the effect of this regimen on the long-term growth. Nevertheless, and 
notwithstanding these limitations, final height achieved by these patients was 
similar to their predicted final height, suggesting that, despite the known radio-
mimetic effect of busulphan 14, Bu/Cy pre-BMT conditioning regimen has less 
interference on the growth process than does irradiation. Published data 
available on the effect of Bu/Cy regimen on growth are discordant, and report 
experience on the short-term growth, but not on final height achievement. 
Whereas Wingard et al. 15 reported on the similarity between the effect of 
Bu/Cy and TBI, 2 years after transplant, 8 of 24 patients in that study who were 
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conditioned with Bu/Cy also received CRT during first line treatment. Other 
studies 16-18 found no harmful effect of Bu/Cy on growth. However, these three 
studies were based on a short-term follow-up (3 to 6 years), whereas the 
present study reports the final height outcome of Bu/Cy conditioning, albeit on 
a limited number of patients. Unfortunately, although Bu/Cy conditioning should 
be encouraged, at least in paediatric patients, the attempt to substitute a TBI-
based conditioning regimen with Bu/Cy was not found to be advantageous 
when applied to patients with ALL 19.  
The type of BMT (autologous or allogeneic) did not influence final height 
achievement. In this context, because chronic GVHD is a relatively common 
complication in patients who receive allogeneic BMT 20 and is not encountered 
after autologous BMT, the severity of chronic GVHD and its treatment (steroids 
and cyclosporin-A) were also found to have no significant effect on growth, 
even though a tendency toward worsening delta-SDS with increasing severity 
of chronic GVHD was documented. Although steroids and severe chronic 
systemic illness (i.e., chronic GVHD) are known to induce growth impairment in 
children, our study, however, despite being limited by a relatively small sample 
size, suggests that children surviving after transplantation have an adequate, 
although partial, capacity to catch-up with growth in the long term.  
Being younger at BMT, the female group was theoretically supposed to 
experience greater growth impairment than males. Nevertheless, the loss in 
height-SDS was more profound in boys than in girls, although the two groups 
were comparable for differences in genetic heights and height at BMT, sex 
hormone replacement therapy, and age of commencement of sex hormone 
treatment. This phenomenon therefore remains open for further specific 
studies.  
The loss in growth velocity in patients after BMT seems to be the result of a 
complex interaction of different factors related to the effect of irradiation and 
chemotherapy, such as lesions of bone, cartilage, and the epiphyseal growth 
plate; gonadal damage; delayed or precocious puberty; and hypothyroidism. 
Growth delay has also been attributed to GH deficiency 8-12;18;21. Data on GH 
secretion were not included in the questionnaire, and GH therapy was 
prescribed by some of the BMT centres. Despite the relatively small number of 
patients who received GH treatment in our cohort, the effect on the final height 
outcome was less enthusiastic than that reported by others. Thomas et al 22 
showed that growth impairment after BMT in a homogeneous group of 49 
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children with leukaemia who received CRT and TBI resulted prevalently from 
severe spinal growth suppression (reduced spinal height) that was 
unresponsive to GH treatment; also, there was an inappropriate response with 
absent catch-up growth in their legs. Even in children surviving brain tumours 
(a group with florid radiation-induced GH deficiency), GH treatment increased 
the short-term growth velocity but did not significantly improve the final height 
23. Furthermore, in our cohort, a reduced final height was also observed in 
patients with SAA irradiated with TAI/TLI only, i.e., with irradiation fields not 
involving the skull and its neuro-endocrine structures. This observation is 
further emphasised by the finding that patients who received CRT with or 
without TBI (high cumulative irradiation dose to the hypothalamic-pituitary 
region) had an equal relative risk for developing growth failure, as those 
patients who had irradiation that did not include CRT (stepwise multiple logistic 
regression analysis). GH deficiency, therefore, does not seem to play a major 
role in growth impairment after BMT. Because patients are already at high risk 
for secondary tumours after BMT 24;25, and although available data on the 
safety of GH-treatment in patients with a history of malignancies are reassuring 
26, we recommend caution in selecting patients as candidates for GH treatment 
after BMT, especially because a positive long-term effect of GH treatment on 
growth is not yet ascertained in such patients. Furthermore, because we found 
that, in the long term, 140 of 181 patients who attained their final height 
reached normal heights (within ±2 SDS for the general population), we also 
suggest that growth should be clinically followed-up once every 6 months and 
that only a few selected cases of severe and persistent growth deficiency, 
observed after the interruption of the post-transplant medication, be considered 
for GH treatment.  
This study gathered data on patients who were transplanted during a period 
when CRT was frequently used as prophylaxis treatment in the majority of ALL 
patients and single-dose administration of irradiation was widely used. At 
present, CRT is used in a small and selected group of children, and irradiation 
schedules encourage fractionated TBI. Because irradiation was found to have 
a significant role in long-term growth impairment, especially in patients who 
received cranial irradiation before transplant and received sTBI during pre-BMT 
conditioning, we expect an improvement in the height prognosis in children 
transplanted during the 1990’s.  
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Abstract 
Pubertal development after total-body irradiation (TBI) was investigated in 40 
children (21 boys) treated with allogeneic bone marrow transplantation (BMT) 
for haematological malignancies at a mean age of 11.3 years. The mean age 
at the last visit was 19.0 years. Twenty-five patients (15 boys) were prepubertal 
at the time of BMT. Data on secondary sexual characteristics, the pituitary-
gonadal axis and longitudinal growth were retrospectively collected from the 
medical records. In boys not receiving additional testicular irradiation (n = 19), 
penile growth and pubic hair development was normal and all had serum 
testosterone levels within the adult range. The majority of them, however, had 
incidental elevations of LH, suggesting minor Leydig cell damage. Testicular 
volume at last measurement was small (mean: 10.5 ml) and serum FSH levels 
were elevated in all boys, with normalisation in only one, suggesting severe 
impairment of reproductive gonadal function. Of the ten girls who received BMT 
before puberty, six had a spontaneous onset of puberty and menarche; the four 
other girls needed hormonal substitution therapy. Recovery of gonadal function 
after cessation of substitution was seen in one girl, who became pregnant but 
had a spontaneous abortion. Decrease in height SDS was seen in the majority 
of patients and was positively correlated with male gender and lower age at the 
time of BMT. 
 
Conclusion: Careful monitoring of both gonadal function and growth after bone 
marrow transplantation and total body irradiation is warranted in order to detect 
disturbances early and ensure normal pubertal development in children treated 
for haematological malignancies.  
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Introduction 
Over the last two decades bone marrow transplantation (BMT) has become an 
important treatment modality for haematological malignancies, and a 
combination of total-body irradiation (TBI) and high-dose chemotherapy is 
frequently used in preparative regimens for BMT. The main aims of these 
preparative regimens are: (a) myeloablation in order to enable grafting of donor 
marrow and (b) the eradication of malignant cells that might have survived 
previous treatment. Unfortunately, TBI and high-dose chemotherapy have 
important negative effects on several organs including those of the endocrine 
system, which may lead to disturbances in both growth and pubertal 
development after BMT for childhood malignancies 1-3. As the number of 
patients with long-term disease-free survival increases, more patients who 
received BMT during childhood reach adulthood and the final outcome of 
growth and pubertal development after BMT can be assessed. We previously 
reported that final height was decreased in patients who underwent BMT for 
haematological malignancies 4. In the present study we investigated the effects 
of TBI and BMT on pubertal development and gonadal function in patients 
grafted for haematological malignancies during childhood. 
Patients and methods 
Between 1970 and 1995 148 patients suffering from haematological 
malignancies received an allogeneic BMT before the age of 16 years at the 
Department of Paediatrics, Leiden University Medical Centre. Of those 
patients, 79 were still alive in July 1997, 40 of whom (21 boys, 19 girls) were 
older than 16 years of age at the time of their last visit. These 40 patients were 
included in the present study, 16 of whom (10 boys) were also included in the 
previous study on final height  4. Patient characteristics are given in table 1.  
At the time of BMT, 25 patients were pre-pubertal. The mean age at the time of 
BMT was 11.3 years (range 0.9-15.9) and at the time of the last examination 
19.0 years (range 16.1-25.4).  
TBI was delivered by linear accelerator with energies of either 5.0 or 6.0 MV 
and at a midline instantaneous dose-rate of approximately 23 cGy/min. 
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Table 1. Patient characteristics  
 Prepubertal at BMT  In Puberty at BMT* 
 Boys (n=15) Girls (n=10)  Boys (n=6) Girls (n=9) 
Age at BMT in years: 
 mean; median 
 (range) 
 
9.9; 10.2 
(4.0 - 14.1) 
 
8.7; 9.1 
(0.9 – 14.4) 
 
 
13.8; 13.5 
(12.6 - 15.3) 
 
14.9; 14.4 
(14.2 - 15.9) 
Age at last visit: in years: 
 mean; median  
 (range) 
 
18.5; 18.2 
(16.1 – 21.7) 
 
19.1; 19.0 
(16.5 – 23.9) 
 
 
18.9; 18.0 
(16.9 - 23.3) 
 
19.8; 18.9 
(16.8 – 25.4) 
Indication: 
 AML 
 
7 
 
7 
 
 
4 
 
6 
 ALL 4 1  2 2 
 CML - 2  - 1 
 MD 2 -  - - 
 NHL 2 -  - - 
TBI-dose: 
 5.0 Gy 
 
- 
 
1 
 
 
- 
 
- 
 7.5 Gy 7 5  - - 
 8.0 Gy 4 4  1 4 
 2 x 6.0 Gy 4 -  5 5 
Additional Irradiation: 
 Testes 
 
2 
 
- 
 
 
- 
 
- 
 Cranium 1 1  1 1 
* The three male patients with uncertain pubertal status at the time of BMT are included in this
category.  ALL acute lymphoblastic leukaemia, AML acute myeloid leukaemia, CML chronic myeloid
leukaemia, MD myelodysplasia 
 
 
One girl, who underwent BMT in the 1st year of life, received a single fraction 
TBI of 5.0 Gy. All other patients undergoing BMT before the age of 10 years 
received a single fraction TBI of 7.5 Gy. Patients older than 10 years received 
TBI either as a single fraction of 8.0 Gy (until 1990) or as two fractions of 6.0 
Gy each, on 2 consecutive days (from 1990 onwards). 
Conditioning regimens included cyclophosphamide (60 mg/kg per day for 2 
consecutive days) in all patients. From 1989 onwards, the patients undergoing 
BMT for myeloid leukaemia (n = 11) also received cytarabine (2 x 1.0 g/m2 day 
for 2 consecutive days) and patients with BMT for lymphoblastic leukaemia (n = 
4) or non-Hodgkin lymphoma (NHL)(n = 1) received etoposide (350 mg/m2 day 
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for 2 consecutive days). Two boys (both treated before puberty) received an 
additional testicular irradiation with 10 Gy in four fractions prior to BMT; four 
other patients had previously received cranial irradiation with a total dose of 18 
Gy in 12 fractions (n = 3) or 24 Gy in 18 fractions (n = 1).  
Information about pubertal development was obtained from the medical 
records and consisted of the following data: Tanner stages of breast or genital 
development and pubic hair 5, testicular volume measured with orchidometer, 
age at menarche, height measurements, serum levels of LH and FSH and 
oestradiol in girls and testosterone in boys, data on substitution therapy with 
sex steroids and on the use of oral contraceptives. The onset of puberty was 
defined as the age at which breast development was first recorded in girls 
(Tanner breast stage ≥ B2) or a testicular volume ≥ 4 ml was reached in boys. 
If clear signs of pubertal development (e.g. penile growth and pubic hair 
development) had occurred in boys while testicular volume had not reached 4 
ml, onset of puberty was determined on the basis of the combination of 
progression of Tanner stages and increasing serum levels of testosterone. 
When puberty was induced, the onset of puberty was defined as the start of 
treatment with sex steroids. In three boys puberty started approximately at the 
time of transplantation, but unfortunately Tanner stages and testicular volumes 
at the time of BMT were not recorded.  
In girls puberty was induced using increasing doses of ethinyloestradiol 
(starting dose: 0.05 μg/kg/day). After a period of at least 1 year 
medroxyprogesterone was added (5 mg/kg/per day for 12 days every 4 
weeks). In boys intra-muscular injections of testosterone were used (starting 
dose 50 mg every 3 weeks, increasing the dosages over a period of 2 years 
until the adult dose of 250 mg every 3 weeks was reached).  
Height data were analysed for patients treated before the onset of puberty who 
had not received any additional irradiation (12 boys and 9 girls). Height 
standard deviation scores (SDS) were calculated using Dutch references 6. 
Height velocity was calculated as the height increment within a time interval of 
0.5-1.5 years and expressed as cm/year. Target height SDS was calculated 
using the formula: (maternal height + paternal height ±12 cm)/2 + 3 cm 7. 
Standard laboratory methods were used for the measurement of serum levels 
of oestradiol, testosterone, LH and FSH (detection limits: 40 pmol/l, 0.2 nmol/l, 
0.1 U/l and 0.1 U/l, respectively).  
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Differences in continuous variables between groups of patients were analysed 
with Wilcoxon rank sum tests. The Wilcoxon signed rank test was used to 
analyse the changes in height SDS. Associations between continuous 
variables were tested by Spearman correlation analyses and multiple 
regression analyses were used to determine the independence of the effects 
noted in bivariate analyses. The significance level was set at 5% in all 
analyses.  
Results  
Onset of puberty after BMT  
In all boys who had not received additional testicular irradiation, puberty started 
spontaneously at a mean age of 13.0 years (range 10.0-15.2 years). One of 
these boys, treated for relapsing NHL at the age of 14.1 years, had a late onset 
of puberty (age 15.2 years). Hypergonadotrophic hypogonadism developed in 
the two boys who had received testicular irradiation and puberty was induced 
at the age of 14.2 and 15.3 years, respectively.  
Of the ten girls treated before puberty, six (including the girl who had received 
cranial irradiation) had a spontaneous onset of puberty at a mean age of 11.0 
years (range 9.7-12.7 years). In the remaining 4 girls puberty was induced after 
hypergonadotrophic hypogonadism had developed. The mean age at start of 
the induction therapy was 14.1 years (range 13.5-14.7 years). At the time of 
induction of puberty, bone age (calculated according to Greulich and Pyle) was 
delayed in all four girls: mean delay 2.2 years (range 1.1-3.0 years).  
Progression of puberty and menarche 
Puberty, as measured by progression of Tanner stages, developed normally in 
the 19 boys who did not receive additional testicular irradiation. At the last 
examination they had all reached Tanner stages G4 or more and P4 or more. 
Testicular volume increased above 4 ml in all boys with a spontaneous onset of 
puberty after BMT (range 6-14 ml), but only 7 of those 13 boys reached a 
testicular volume of ≥ 10 ml. The last recorded testicular volumes in the three 
boys with uncertain pubertal status at BMT were 12, 12 and 14 ml at the ages 
of 18.2, 19.7 and 16.9 years, respectively. The last recorded testicular volumes 
in the boys transplanted during puberty, were 8, 14 and 18 ml at the ages of 
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17.1, 16.8 and 16.3 years, respectively. Figure 1 represents development of 
testicular volumes in time after BMT. The mean testicular volume at the last 
measurement in all boys who had not received additional testicular irradiation 
was 10.5 ml (mean age 17.4 years).  
 
 
 
 
 
 
Figure 1. Testicular volume after TBI in boys who did not receive additional testicular 
irradiation. 
 
 
 
The six girls with a spontaneous onset of puberty after BMT had their 
menarche at a mean age of 12.7 years (range 11.1-14.2 years). Of those six 
girls, five had a normal progression of puberty and reached Tanner stages B5 
and P5 without exogenous oestrogens. The other girl had several transient 
Chapter 6 
80 
episodes of hypergonadotrophic hypogonadism, both before and after 
menarche. Her pubertal development was delayed and she started using oral 
contraceptives at the age of 16.5 years, 5 years after menarche (breast 
development had not progressed beyond Tanner stage B3).  
All nine girls treated during puberty developed gonadal insufficiency and 
required hormonal substitution therapy, making it impossible to assess further 
spontaneous pubertal development. Before receiving exogenous oestrogens, 
however, one girl had regression of breast development (substitution started 3 
years after BMT), and in another girl breast development had stagnated at the 
time substitution was started (1 year after BMT). In two of the remaining girls 
there were insufficient data on breast development and in the other girls 
substitution therapy was given within several months after BMT. 
Endocrine gonadal function and fertility  
In the 19 boys who had not received additional testicular irradiation, adult 
levels of serum testosterone (>15 nmol/l) were reached at any time after BMT 
(figure 2, upper panel). Episodic elevations of LH (8.1-11.5 U/l), however, were 
seen in 10 of them (figures 2, middle panel), and in five patients these 
elevations were accompanied by decreased testosterone levels (9.4-14.8 
nmol/l). Elevation of FSH was found in all boys (figure 2, lower panel). In only 
one patient FSH levels returned to normal (<10 U/l). This patient was pre-
pubertal at the time of BMT. Unfortunately, we have no data on 
spermatogenesis in our patients; to our knowledge none of the male patients 
has fathered a child.  
Disturbances in the pituitary-gonadal axis were seen in all girls, even though 
six girls had a spontaneous onset of puberty and five of them went through 
puberty normally. One of these five girls (the only patient that had received a 
low TBI dose of 5.0 Gy) did not develop hypergonadotrophic hypogonadism, 
but  she  did  show  an  abnormal  response  to  a  gonadotrophin  releasing 
hormone (GnRH) test. The remaining four girls with a normal progression of 
puberty developed hypergonadotrophic hypogonadism, defined as elevated 
levels of serum gonadotrophins without detectable oestradiol. In three of them 
endocrine gonadal function recovered quickly without oestrogen substitution; 
the other girl required substitution therapy but she had already reached breast 
stage B5 at the time gonadal insufficiency was diagnosed (age 14.6 years). All 
four  girls  who did  not  require oestrogen substitution  reported having  regular  
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Figure 2. Serum levels of testosterone, LH and FSH after TBI in boys who did not 
receive additional testicular irradiation. 
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menses (without the use of exogenous oestrogens) during the last years of 
their follow up. 
The remaining girls (all nine girls undergoing BMT during puberty and the four 
girls who did not enter puberty spontaneously) developed hypergonadotrophic 
hypogonadism and received substitution therapy with ethinyloestradiol and 
progesterone. Recovery of gonadal function after cessation of hormonal 
substitution was seen in one girl, who received BMT during puberty, but before 
menarche. This patient later became pregnant twice, both of which resulted in 
spontaneous abortions. 
Growth  
At the last examination final height (height velocity <1 cm/year) was reached by 
18 of the 21 patients (12 boys and 9 girls) who were treated before puberty and 
had not received (additional) cranial or testicular irradiation. The other three 
patients had height velocities of 1.3, 1.5 and 2.1 cm/year. None of the patients 
were diagnosed with growth impairment due to growth hormone insufficiency or 
hypothyroidism. Data on (changes in) height SDS at different times after BMT 
are summarised in table 2.  
At the last examination height SDS was significantly lower compared to target 
height SDS (P < 0.001) and compared to height SDS at BMT (P < 0.001); the 
magnitude of these differences in SDS was similar in both sexes. Height SDS 
also decreased between BMT and the onset of puberty (P = 0.003) as well as 
between onset of puberty and last examination (P = 0.001). 
When analysed for boys and girls separately, the decrease in height SDS 
between BMT and onset of puberty was significant in girls only (P = 0.008), 
whereas the mean decrease in height SDS between onset of puberty and last 
visit was significant in boys only (P = 0.002). The total decrease in height SDS 
was less in the four girls who needed induction of puberty (range 0.1-1.0) than 
in the five girls with a spontaneous onset of puberty (range 0.9-2.1; P = 0.05). 
These two groups did not differ significantly in age at time of BMT, but the age 
at onset of puberty was higher in the girls who needed substitution: median 
14.0 years (13.5-14.7 years) versus 11.0 years (10.6-12.7 years; P = 0.014).
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Table 2. Height SDS and changes in height SDS in patients treated before puberty who 
did not receive additional irradiation 
 
 All patients (n=21)  Boys (n=12)  Girls (n=9) 
 Mean Median (range)  Mean Median (range)  Mean Median (range) 
Age at onset of puberty    13.1 13.7 (10.0 to 15.2)  12.5 12.7 (10.5 to14.7) 
Height SD Scores         
Target SDS -0.1 0.3 (-1.8 to 1.1)  -0.2 0.0 (-1.8 to 0.7)  0.2 0.3 (-0.8 to 1.1) 
SDS at BMT -0.2 -0.2 (-1.8 to 1.8)  -0.4 -0.3 (-1.8 to 1.3)  0.1 0.0 (-1.0 to 1.8) 
SDS at onset puberty -0.7 -0.9 (-2.7 to 1.3)  -0.6 -0.7 (-2.0 to 1.0)  -0.7 -1.2 (-2.7 to 1.3) 
SDS at last visit -1.5 -1.7 (-3.6 to 0.9)  -1.9 -2.0 (-3.6 to -0.5)  -1.0 -1.0 (-2.2 to 0.9) 
Changes in SD Scores         
from BMT until onset of puberty -0.5 -0.5 (-1.8 to 0.4)  -0.2 -0.2 (-0.9 to 0.4)  -0.8 -0.9 (-1.8 to -0.1) 
from onset puberty until last 
visit -0.9 -0.9 (-3.8 to 0.9)  -1.3 -1.0 (-3.8 to -0.1)  -0.2 -0.4 (-1.2 to 0.9) 
from BMT until last visit -1.3 -1.1 (-3.6 to 0.1)  -1.5 -1.6 (-3.6 to -0.3)  -1.1 -1.0 (-2.1 to 0.1) 
Difference Target SDS and 
SDS at last visit -1.5 -1.6 (-3.0 to 0.3)  -1.7 -1.9 (-3.0 to 0.2)  -1.1 -1.1 (-2.5 to 0.3) 
 
 
As in our previous analyses, the total loss of height SDS was more severe in 
patients treated at an earlier age (r = 0.76). A correlation existed, however, 
between the age at the time of BMT and other factors that could possibly 
influence final height or loss of height SDS, such as the age at onset of puberty 
(r = 0.76) or the TBI dose (r = 0.88). A multiple regression analysis of the 
factors TBI dose, age at BMT, age at onset puberty, gender and need for 
induction of puberty, revealed that male gender and a younger age at the time 
of BMT were the only factors with an independent (negative) effect on 
longitudinal growth.  
Discussion  
To evaluate the effects of TBI and BMT on pubertal development properly, 
patients should have completed puberty. As the BMT procedure in patients 
with haematological malignancies is relatively young, only recently children 
who have received a BMT before the onset of puberty completed their pubertal 
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development and reached their final height. As the prognosis for normal 
pubertal development and gonadal function in survivors of childhood leukaemia 
treated with chemotherapy alone (i.e. without BMT) is excellent 8;9, 
disturbances in pubertal development in survivors of BMT and TBI are likely to 
be the result of irradiation (e.g. total-body, testicular or cranial irradiation) or of 
(the additive effect of) high-dose chemotherapy used in preparative regimens. 
Of the hypothalamus-pituitary-gonadal axis the gonads are most vulnerable to 
damage caused by chemotherapy and/or irradiation; dysfunction of the 
hypothalamus or the pituitary gland is less common and is almost always 
associated with cranial irradiation, which can lead to a premature 10-12 as well 
as a delayed 13 onset of puberty. Our two patients who had received cranial 
irradiation before the onset of puberty, however, both had a normal timing of 
puberty. 
The spontaneous onset of puberty and the subsequent normal pubertal 
development in all boys not receiving additional testicular irradiation is in line 
with the findings of other investigators 1;14;15. The Leydig cells, responsible for 
the production of testosterone, are more resistant to irradiation than are 
spermatogonia, and recovery of Leydig cell function can be seen after absolute 
radiation doses as high as 24 Gy 14. The normal pubertal development and the 
fact that all patients had reached adult serum levels of testosterone at some 
time after BMT, however, do not necessarily mean that Leydig cells are 
unaffected. The elevated LH and decreased testosterone levels, incidentally 
found in the serum of some patients, suggest that TBI can cause subtle 
changes in Leydig cell function. Other investigators have found decreased 
responses to HCG stimulation after TBI 3, which further supports this 
suggestion. 
The elevated levels of FSH in all boys and the relatively small testicular 
volumes indicate that the germinal epithelium of the testis is damaged by the 
preparative regimens used. In contrast to others 2;16 we did not find a trend 
towards normalisation of FSH levels in our male patients, even though most 
patients received single fraction irradiation which is believed to be less 
detrimental to the testicular germinal epithelium than is fractionated irradiation. 
This can be explained by the lower total radiation dose used in single-fraction 
TBI, but there is also evidence that fractionation of one dose may lead to 
longer sterile periods in man 17. Variations in the exposure to alkylating agents 
prior to BMT could be responsible for this absence of testicular recovery, as the 
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cumulative dosage rather than the daily dosage is the most important factor 
determining gonadotoxicity of cyclophosphamide, also used in the preparative 
regimens 16;18;19. In view of the known vulnerability of germinal epithelium to 
irradiation and the elevated FSH levels, we expect most of the male patients to 
be infertile. We have no data on semen analysis in our patients, however, and 
recovery of spermatogenesis has been described 7 to 8 years after a single 
fraction of 10 Gy TBI 2. Moreover, in a group of 463 male TBI patients, Sanders 
et al. 2 found evidence of testicular recovery in 17% (defined as normal serum 
levels of LH, FSH and testosterone with evidence of sperm production), and 5 
of these patients had fathered one or more children. There was no evidence for 
increased risk of congenital malformations or complications during pregnancy 
or delivery. Ovarian damage can be caused by alkylating agents as well as by 
irradiation. As a total dose of at least 20.0 g of cyclophosphamide is required to 
produce amenorrhoea in women younger than 30 years of age 2, it is likely that 
most of the disturbances found in our patients can be attributed to the 
irradiation and not to the cyclophosphamide used in the conditioning (120 
mg/kg). 
Gonadal function was less often affected in girls treated before the onset of 
puberty compared to those treated during puberty. The percentage of girls 
treated before puberty with a spontaneous onset of puberty and menarche 
(60%) is comparable with that reported by Sarafoglou et al. (56%) 15, even 
though their patients had received hyperfractionated TBI. Others have reported 
slightly lower incidences of spontaneous onset of puberty after TBI between 
31% and 45% 15;20. The finding that all girls treated after the onset of puberty 
developed gonadal failure is also in line with reports of other investigators 21-23 
and suggests that the pre-pubertal ovary is more resistant to irradiation. 
Attempts to limit radiation-induced damage to the (post-) pubertal ovary using 
GnRH analogues have been successful in rats 24, but not in rhesus monkeys 
25. As radiation doses used in these animal studies (1 x 30 Gy in rodents and 
20 x 2 Gy in monkeys) are higher than those used in TBI, it would be 
worthwhile to investigate whether the use of GnRH analogues can reduce 
ovarian damage in patients receiving TBI after the onset of puberty. Recovery 
of ovarian function occurred in one girl, transplanted for acute myeloid 
leukaemia (AML) during puberty. She became pregnant twice, but 
unfortunately both pregnancies resulted in spontaneous abortions. Women 
receiving high-dose alkylating agents and TBI are at risk for spontaneous 
Chapter 6 
86 
abortions, pre-term delivery and low birth weight infants, as described by 
Sanders et al. 26. In this large survey, female TBI patients had a spontaneous 
abortion rate of almost 40% and the incidence of pre-term labour and delivery 
was >60%. This is probably caused by radiation-induced changes in the 
myometrium or uterine vasculature 26;27. If gonadal function is preserved or 
recovers, however, patients are still at risk for early menopause 28, as is shown 
by the girl who had a spontaneous onset of puberty and menarche but later 
developed secondary amenorrhoea and hypogonadism. As recovery of ovarian 
function after hypergonadotrophic hypogonadism is possible, hormonal 
substitution should be stopped at regular intervals in order to re-evaluate 
gonadal function. 
It should be emphasised that patients should be well-informed about the risk of 
infertility as well as the possibility of (recovery of) fertility and the increased 
abortion rate in order to allow them to make appropriate decisions about 
procreation and contraception. In children treated during puberty the possibility 
of germ cell preservation should be discussed with patients and/or parents. 
The use of TBI in preparative regimens for BMT has an adverse effect on 
growth and final height 4;29;30. Potential mechanisms include radiation-induced 
hypothyroidism, growth hormone deficiency and damage to the epiphyseal 
growth plate 3. The results of the present height analyses are comparable to 
the results we reported previously 4. In this previous study, pre-pubertal linear 
growth velocity SDS was not statistically different from zero in the first 3 years 
after BMT. In the present analyses we compared height SDS at the time of 
BMT to height SDS at the onset of puberty. In all girls and most boys, height 
SDS at the onset of puberty was lower than at the time of BMT suggesting that 
loss of height SDS already occurred before the onset of puberty, even when 
puberty was not delayed. The fact that decrease in height SDS was greater 
when patients were treated at a younger age, (a result which was found in a 
European study on final height after BMT as well 31) further supports the 
suggestion that height SDS already decreases before the onset of puberty in 
these patients. 
Although there was no significant difference between boys and girls in the 
decrease in height SDS, in a multiple regression analysis, male gender (but not 
oestrogen substitution) proved to be an independent factor determining this 
decrease. Interestingly there was a difference in total loss of height SDS since 
transplantation between girls who had a spontaneous onset of puberty and 
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girls who needed induction of puberty. The most likely explanation for this is 
that, in the case of induction of puberty, the relatively late introduction of 
relatively low doses of oestrogens had resulted in a prolonged period of growth 
by delaying progression of bone age, thereby increasing final height. All four 
girls in whom puberty was induced did indeed have a delay in bone age at the 
onset of puberty.  
We previously suggested that a lack of compensatory increase in peak linear 
growth velocity, an increase that is present in normal early-developing children, 
could be responsible for a correlation between age at onset of puberty and 
decrease in height SDS 4. Although this is a plausible explanation, we cannot 
exclude that the correlation between height loss and timing of puberty is 
caused by selection bias, as only those patients who were not in puberty at the 
time of BMT were included in the previous (and present) analyses of growth. 
This way a correlation was created between the age at onset of puberty and 
the age at BMT, as patients who entered puberty early could only be included if 
they were treated at a younger age, whereas patients treated at a relatively 
later age could only be included if they entered puberty late. In the multiple 
regression analysis the age at onset of puberty did not prove to be an 
independent factor determining the decrease in height. Therefore, more data 
are necessary in order to establish the influence, if any, of the timing of puberty 
on the final height of patients receiving BMT and TBI. 
After TBI and BMT for haematological malignancies, pubertal development is 
normal in most boys, although subtle changes in Leydig cell function can be 
expected and spermatogenesis is likely to be severely affected. In 
approximately 50% of girls treated before puberty, pubertal development (and 
gonadal function) is normal, whereas gonadal insufficiency can be expected in 
the vast majority of those girls treated after the onset of puberty. As changes in 
gonadal function are possible and data on long-term prognosis for fertility and 
endocrine gonadal function are limited, careful follow up remains necessary. 
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Abstract 
Patterns of growth and body proportions were studied in 75 children receiving 
total-body irradiation (TBI) and haematopoietic stem cell transplantation (SCT) 
before onset of puberty. Of the 19 patients receiving growth hormone (GH), 
only data obtained before onset of GH were included.  
Thirty-two patients reached final height (FH). Median change in height SD 
score (SDS) between SCT and FH was -1.7 in boys and -1.1 in girls. 
Peak height velocity (PHV) was decreased in the majority of the patients 
(median PHV 5.7 cm/yr in boys and 5.3 cm/yr in girls), even though it occurred 
at appropriate ages. 
Changes in body proportions were analysed by linear mixed-effects models. 
Decrease in sitting height SDS did not differ between boys and girls (0.15 
SD/yr). In boys, decrease in leg length SDS was of comparable magnitude 
(0.12 SD/yr), whereas in girls decrease in leg length was less pronounced 
(0.02 SD/yr), leading to a significant decrease in SDS for sitting height/height 
ratio in girls only. 
The sex-specific effects of several variables (e.g. age at SCT, time since SCT, 
onset of puberty) on height SDS were analysed by linear mixed-effects 
modelling, showing a slightly faster decrease in younger children, and a more 
pronounced decrease during puberty in boys compared with girls. 
We conclude that 1) younger children are more susceptible to growth 
retardation after TBI and SCT, 2) pubertal growth is more compromised in 
boys, and 3) leg growth is relatively less affected in girls, possibly due to a high 
incidence of gonadal failure in girls. 
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Introduction 
Haematopoietic stem cell transplantation (SCT) has become a standard 
treatment option for many children with congenital or malignant disorders of the 
haematological system. The intensive conditioning regimens required in most 
cases, often result in impaired growth and reduced final height, especially if 
unfractionated total-body irradiation (TBI) is part of the conditioning regimen 1. 
TBI can impair growth both directly, by damaging the epiphyseal growth plates, 
and indirectly, by decreasing growth hormone (GH) secretion or by causing 
hypogonadism or hypothyroidism 2. Other factors that may contribute to growth 
delay are chronic graft-versus-host disease in recipients of allogeneic 
transplants, use of corticosteroids, psychosocial dysfunction, and insufficient 
nutritional intake. 
In contrast to the extensively documented negative effect of TBI and SCT on 
height, more recently completed with data on final height 1;3-8, the effect of TBI 
and SCT on other aspects of growth are less intensively studied. To our 
knowledge, for example, height development after TBI and SCT (including 
influences of sex and puberty) has not yet been modelled, and the effect on 
body proportions has been subject of only few studies 5;9-12. Moreover, most of 
these studies included patients who had received cranial irradiation prior to 
TBI, patients who had already entered puberty at the time of SCT or patients 
who had been treated with GH. In addition, none of these studies considered 
sex differences. 
In an attempt to clarify these aspects of growth after SCT, we investigated sex-
specific development of height, body proportions and final height in children 
receiving TBI and SCT for haematological malignancies before the onset of 
puberty. Patients who had received cranial irradiation were excluded, as well 
as height measurements taken after onset of GH therapy. In addition, we 
constructed sex-specific models of growth after TBI and SCT. 
Patients and methods 
Between 1980 and 2001, 193 prepubertal children with a haematological 
malignancy received TBI-based conditioning for SCT at the Leiden University 
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Medical Centre. All children without a relapse after SCT, who had more than 2 
years of follow-up after TBI-based conditioning for SCT for a haematological 
malignancy before the onset of puberty were selected for this study (n= 89). 
We excluded patients who had received cranial irradiation (n= 6) or had 
developed chronic graft-versus-host disease (n=7) or had Down syndrome 
(n=1). A total of 75 patients were included; their characteristics are summarised 
in table 1. Puberty onset had occurred in 61 patients (40 males). 
 
 
Table 1. Population characteristics. 
  Male  Female 
Number of patients  53  22 
Age SCT  8.2 (2.3 to 13.9)  7.2 (0.8 to 12.3) 
Age puberty (40 m / 21 f)  12.3 (9.8 to 14.5)  10.9 (9.0 to 14.1) 
Follow-up (in years)  8.4 (2.0 to 15.5)  11.0 (3.5 to 20.2) 
Gonadal failure < age 15 yr  8  11  
SCT Type       
 Autologous  4  2 
 Identical Related  37  16 
 Matched unrelated  8  3 
 Haplo-identical  4  1 
Diagnosis:     
 ALL  26  7 
 AML  18  12 
 MDS  5  2 
 NHL  2  1 
 CML (Ph+)  2  - 
TBI dose     
 5.0 Gy  -  2 
 7.0 Gy  8  3 
 7.5 Gy  26  12 
 8.0 Gy  7  2 
 2x6.0 Gy  12  3 
Testicular booster 4x2.5 Gy  8  n.a. 
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Serum level of Insulin-like Growth Factor 1 and Insulin-like Growth Factor 
binding protein 3 were measured annually in all patients, and patients were 
tested for GH deficiency if growth was impaired. GH therapy was given to 19 
patients (13 males). Indications for GH therapy were GH deficiency (n=1), GH 
neurosecretory dysfunction (n=2) and growth impairment (n=16). Only data 
obtained before start of GH therapy were included.  
The study was approved by the by the Institutional Review Board (Leiden 
University Scientific Review Board) and the Review Board of the Netherlands’ 
Organization for Scientific Research (NWO). 
Conditioning for SCT 
Conditioning for SCT consisted of TBI and cyclophosphamide in all patients. In 
addition to cyclophosphamide (60 mg/kg/day i.v. for 2 consecutive days), 
cytarabine (1 g/m2/day for 2 consecutive days) was given to patients treated for 
myeloid leukaemia or MDS between 1988 and 1998 (n=20). From 1990 
onward, patients treated for lymphoblastic leukaemia or non-Hodgkin 
lymphoma (n=32) received etoposide (350 mg/m2/day for 2 consecutive days) 
in addition to cyclophosphamide. All patients received unfractionated TBI, 
delivered at a mean dose rate of 25 cGy/min. As age is an important 
determinant of the tolerable total irradiation dose in children, a TBI regimen 
with age-dependent total dose was applied (0-2 years: 5.0 Gy, 2-4 years: 7.0 
Gy, 4-10 years: 7.5 Gy, >10 years 8.0 Gy). The latter dose was ‘increased’ in 
1989 to two single fractions of 6.0 Gy, given on 2 consecutive days (instead of 
the equivalent 9.0 Gy once, which had too many side effects in adults). Eight 
boys received additional prophylactic testicular irradiation (10 Gy in four 
fractions prior to TBI). 
Auxological parameters 
Data on height, sitting height, Tanner stages of breast or genital development 
13 and testicular volume (measured with an orchidometer) were collected from 
the clinical records. Sub-ischial leg length was defined as height minus sitting 
height. The ratio between sitting height and height was used as parameter for 
body proportions. Auxological parameters were expressed as standard 
deviation scores (SDS) for sex and age, all based on the same reference 
population (n=14.500) from the1997 Dutch Growth Study 14;15. Patients were 
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considered to have reached final height if height velocity was less than 1 
cm/year in pubertal subjects.  
Puberty and gonadal function 
The onset of puberty was defined as the age at which breast development was 
first recorded in girls (Tanner breast stage ≥ B2) or a testicular volume ≥ 4 mL 
was reached in boys. If signs of pubertal development (e.g. penile growth and 
pubic hair development) had occurred in boys while testicular volume had not 
reached 4mL, onset of puberty was determined on the basis of the combination 
of progression of Tanner stages and increasing serum levels of testosterone. If 
puberty was induced, onset of puberty was defined as the onset of sex 
hormone replacement therapy. In girls, hypergonadotrophic hypogonadism was 
used as a parameter of ovarian failure. In boys, elevated serum levels of 
luteinising hormone (LH) with or without decreased serum levels of 
testosterone were used as a parameter for Leydig cell failure, and elevated 
levels of follicle stimulating hormone (FSH) were used as an indicator of Sertoli 
cell failure (as a result of germ cell loss and/or Sertoli cell loss).  
Statistical analyses 
S-PLUS 6 Professional (Insightful Corp., Seattle WA, USA) was used for all 
statistical analyses, with significance level set at 5%.  
A height velocity curve was fitted by monotone smoothing procedure as 
described by Ramsay et al. 16;17 for each individual who had at least five height 
measurements between 8 and 16 years of age for girls (n=16) or 10 and 18 
years of age for boys (n=29), and peak height velocity (PHV) and age at PHV 
were calculated. We used penalized least squares with a penalty that 
depended on the number of measurements (penalty 250/N2, with N = the 
number of individual measurements). 
Changes in SDS for the different auxological measurements with time since 
transplantation were fitted by mixed-effects models with data grouped by 
individual patients, SDS as dependent variable and time since SCT as major 
independent variable (see next paragraph for background information on 
mixed-effects models). We used the function ‘lme’ (linear mixed-effects) in S-
PLUS.   
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Choice of analysing methods 
The analysis of growth after SCT is a typical example of a repeated 
measurements analysis, in which both the number of observations and the 
interval between the observations may vary between the patients (i.e. both time 
between visits and duration of follow-up may vary). A traditional standard linear 
regression analysis assumes all measurements to be independent and may 
yield biased results, especially if the data are unbalanced. An alternative is to 
fit a growth curve separately for each individual and average the patterns. This 
has been done for the height velocity analyses, but has the disadvantage that 
estimated patterns are very uncertain for individuals with few measurements. 
Therefore, we only used data of patients with at least five measurements in the 
pubertal age for the construction of the pubertal height velocity curves.  
Mixed-effects models also fit a growth curve for each individual, after which the 
parameters for the growth curves are averaged to obtain a population effect. 
However, for persons with relatively little information, information is used from 
the other individuals to obtain their growth curve parameters. This is obtained 
by assuming that the growth curve parameters are a random sample from 
some distribution (usually a normal distribution), and the parameters are 
included as ‘random effects’. Moreover, the effects of some covariates can be 
chosen to be equal for all individuals, and these covariates are only included as 
‘fixed effects’. The use of mixed-effects models (combining random and fixed 
effects) allows the inclusion of all available data in the analyses without the risk 
of considerable bias. As far as we know, mixed-effects models have not been 
used before in the analysis of growth after SCT. 
Identification of factors influencing height SDS after SCT in the mixed-
effects model 
We used time, sex, puberty, age at SCT and gonadal failure as independent 
variables and height SDS after SCT as dependent variable for our model. The 
basis of our model was a linear change (decrease) in height SDS with time 
since SCT. As patients were recovering from their illness, we allowed the slope 
to be different in the first two years after SCT compared with the following 
years.  The value of the intercept and the slopes in the first two years after SCT 
and in the years thereafter differed per individual, as was expressed by their 
random effects. The slope of the major time variable was allowed to depend on 
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age at SCT, sex and the presence of gonadal failure before the age of 15 
years. The effect of gonadal failure was allowed to depend on sex.  
The effect of puberty on height SDS was divided into two components. The first 
component is a reference population effect: when patients from the same sex 
reach the pubertal age (approximately 8.5 years in girls and 10.5 years in boys) 
height velocity of the reference population gradually increases as a result of the 
pubertal growth spurt and subsequently decreases. If the child itself has not yet 
reached puberty, this will cause its height SDS to decrease in a non-linear way. 
The second component of the effect of puberty is the individual pubertal growth 
spurt of our patients, which will result in a gradual increase in height SDS after 
onset of puberty, which stabilises after 3 to 5 years. In patients with an early 
onset of puberty height SDS may even decrease at the end of their growth 
spurt. As this second component of puberty is an individual effect, which may 
vary between patients, it was included as a random effect as well. We allowed 
both puberty effects to depend on sex. We used sigmoid curves (logit 
transformations) to model both puberty effects.  
 
Formula 1 represents the relation for the sigmoid curve of the population effect, 
with x1 being the time in years since reaching the pubertal age (8.5 in girls and 
10.5 in boys).  
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Formula 2 represents the relation for the sigmoid curve of the individual 
puberty effect, with x2 being the time since individual onset of puberty in years.  
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The second part of both formulas is a correction forcing the results to equal 
zero at x=0. The optimal scale parameter, which is included in the model in a 
non-linear way, was obtained by fitting the model for an array of values of 
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‘scale’. The combination with the best Bayesian Information Criterion (BIC) 
value was chosen. 
Results 
Height and height velocity 
A total of 974 height measurements from 75 individuals contributed to the 
results. Figure 1 represents the smoothened individual curves of height velocity 
of 29 males and 14 females.  
 
Figure 1. Smoothened individual curves for height velocity of males (n=29) and 
females (n=14). 
 
 
In 4 patients (3 girls) no pubertal growth spurt could be detected; all showed an 
attenuation of decrease in height velocity between 10.0 and 12.5 years of age. 
Of the patients with a detectable pubertal growth spurt, median pubertal PHV 
was 5.7 cm/year in boys (n=29, range 3.5 – 8.6 cm/year) and 5.3 cm/year in 
girls  (n=14, range 3.1 – 7.3 cm/year). Median age at PHV was 13.4 years 
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(10.1 – 15.4) in boys and 10.9 years (8.6 – 14.0) in girls. Final height (FH) was 
reached by 32 (21 males) of the 56 patients who had not received GH. Of the 
patients who had reached FH, age and height SDS at time of SCT, at onset of 
puberty and at final height are summarised in table 2.  
 
 
Table 2. Age and height SDS at different times between SCT and FH of the 32 patients 
who have reached final height. 
 Male (n=21)  Female (n=11) 
Age (years)      
 SCT † 10.9 (5.6 to 13.9)  8.2 (0.8 to 12.3)  
 puberty onset * 13.2 (10.0 to14.5)  11.2 (10.0 to 14.1)  
 final height * 18.0 (15.4 to 20.2)  17.4 (16.0 to 19.2)  
Time (years)      
 SCT to puberty onset 1.5 (0.3 to 5.6)  2.8 (1.2 to 9.7) 
 puberty onset to final height 5.6 (2.6 to 7.3)  5.1 (3.9 to 7.8) 
Height (SDS)       
 target height +0.4 (-1.7 to +1.3)  -0.2 (-0.5 to +0.9) 
 SCT -0.6 (-1.9 to +0.9)  -0.6 (-1.9 to +1.5)  
 puberty onset -0.8 (-2.3 to +0.9)  -1.4 (-2.4 to +1.1)  
 final height -1.8 (-3.7 to +0.1)  -1.6 (-3.1 to +0.5)  
Height (cm)       
 target height § 186.9 (171.7 to 193.0)  169.5 (167.1 to 176.3) 
 final height ** 171.0 (157.6 to 184.4)  159.9 (150.7 to 173.8) 
Height differences (SDS)      
 puberty onset - SCT * -0.1 (-1.1 to +0. 7)  -0.5 (-1.2 to +0.0)  
 final height - SCT -1.7 (-3.4 to -0.0)  -1.1 (-2.2 to -0.0) 
 final height - target height -2.1 (-4.5 to -0.0)  -1.4 (-2.8 to +0.1)  
Height differences (cm)      
 final height - target height -14.9 (-32.1 to -0.2)  -9.3 (-18.2 to +0.4) 
Data represented as median (range). Patients treated with GH are excluded from analyses.  
Significant differences between boys and girls (Wilcoxon rank sum test) are marked by symbols: 
†=p=0.051; *= p<0.05; **=p<0.01; §=p<0.001. 
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Body proportions 
Since 1991, sitting height was measured on a routine basis as part of the 
follow-up protocol. A total of 373 sitting height measurements from 69 patients 
(19 females) contributed to the results. The results of the linear mixed-effects 
models for changes in SDS with time since SCT for the different auxological 
measurements are summarised in table 3.  
 
Table 3.  
Results of linear mixed-effects models for changes in SDS with time since SCT. 
 Intercept ¶  Change in SDS per year since SCT 
   Males (n=50)  Females (n=19) 
Height - 0.482 *  - 0.136 **  - 0.112 ** 
Sitting height - 0.145 §  - 0.147 **  -0.149 ** 
Leg length - 0.609 **  - 0.117 **  - 0.021 § 
Sitting height : height -0.463 **  + 0.002 §  - 0.094** 
¶  The intercepts did not differ between males and females 
§ Not significant;     *  p<0.001;       **  p<0.0001 
 
 
In males, there was a significant decrease in both sitting height SDS and leg 
length SDS, and these changes were of comparable magnitude. Therefore, the 
SDS for the sitting height/height ratio did not change. In females, however, the 
significant reduction in sitting height SDS was not accompanied by a significant 
reduction in leg length SDS, resulting in a significant decrease in sitting 
height/height ratio SDS. The decrease in sitting height/height ratio SDS was 
more pronounced in the 10 girls with ovarian failure before the age of 15 years 
(estimate -0.117 SD/year; p<0.0001; standard error 0.017) compared with the 
9 girls without ovarian failure (-0.032 SD/year; p=0.49; standard error 0.046). In 
boys, no differences were detected between the 8 boys with Leydig cell failure 
(all had received additional testicular irradiation) and the 42 boys without 
Leydig cell failure.  
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Model for changes in height SDS after SCT 
The final model is summarised in table 4 and the resulting curves are 
represented in figure 2.  
 
 
Table 4. Summary of the model of change in height SDS after TBI (n=75). 
 Value 95% CI p-value 
Height SD at transplant  -0.49 -0.72 to -0.26 <0.0001 
Time since SCT male -0.13 -0.17 to -0.084 <0.0001 
         idem female to male* -0.031 -0.093 to 0.03 0.3211 
Slope deviation first 2 years after SCT 0.0000018 -0.056 to 0.056 0.9999 
Age at SCT (from 4 years onward) 0.009 0.0022 to 0.016 0.0100 
Change slope at onset of puberty in reference 
population male  
0.062 0.0089 to 0.11 0.0227 
         idem female to male* 0.014 -0.056 to 0.085 0.6887 
Time since onset puberty reference population 
(β1 in formula 1) male§ -1.9 -2.2 to -1.6 <0.0001 
         idem female to male* 0.67 0.22 to 1.1 0.0039 
Time since onset puberty individual  
patient (β2 in formula 2) male§ 0.72 0.23 to 1.2 0.0047 
         Idem female to male* 0.45 -0.34 to 1.2 0.2702 
All time parameters are expressed in years. Overall p-values for effects of time since 
transplant, onset of puberty in the reference population, onset of individual puberty and sex 
were all <0.0001. The overall effect of sex on population start puberty had p=0.0007. 
*:   Difference between females and males. 
§:   See figure 2 for visualisation of effects.  
 
 
 
The model describes a linear decrease in height SDS with time after SCT. This 
decrease did not differ significantly (p=0.32) between boys and girls (figure 2a 
and 2d). For boys receiving SCT at the age of four, the decrease per year was 
-0.13 SD/yr (p<0.0001), whereas for girls it was –0.16 SD/yr. For each year 
increase in age at SCT, this decrease in height SDS is 0.009 SD/yr less 
(p=0.01).  The effect of reaching the population pubertal age (i.e. 8.5 years in 
girls and 10.5 years in boys) was best described by a combination of a linear 
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increase in height SDS (0.062 SD/yr for males, 0.076 for females) and a 
logistic decrease in height SDS with β1 = -1.9 for males and –1.2 for females, 
and scale parameter 0.4 (see formula 1 and figure 2b and 2e). The decrease in 
height SDS caused by reaching the pubertal age was significantly greater in 
boys compared with girls (p=0.0007). A modest pubertal growth spurt could be 
detected in both boys and girls, with a logistic increase in height SDS after 
onset of puberty with β2 = 0.72 for males and 1.17 for females, and scale 
parameter 0.8 (see formula 2, figure 2c and 2f). The difference in growth spurt 
between boys and girls was not significant (p=0.27).  
 
 
Figure 2. Graphic representation of several components of the model for growth after 
TBI-based conditioning for SCT, based on all 75 patients (dotted lines represent the 
95% confidence intervals). The upper three panels (a,b,c) represent the males, the 
lower three panels (d,e,f) females. The panels on the left (a,d) represent change in 
height SDS with time since SCT. The panels in the middle (b,e) represent change in 
height SDS with time since onset of puberty in the reference population (10.5 years in 
boys and 8.5 years in girls). The panels on the right (c,f) represent changes in height 
SDS with time since the individual onset of puberty.     
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Total TBI dose was determined by age at SCT. The effect of age at SCT was 
opposite to and dominant over the effect of total TBI dose. Therefore, total TBI 
dose was not included in the final model. ‘Gonadal failure’ was not included in 
the final model, as it did not significantly improve the fit. 
Discussion 
The present study is one of the largest single-centre study to date on growth 
and final height after TBI-based conditioning for SCT. In addition, it is the first 
study to analyse the effects of unfractionated TBI on body proportions in boys 
and girls separately, thereby identifying sex-differences in development of body 
proportions after single dose TBI.  By using the mixed-effects model approach, 
we were able to identify several factors that influence growth after TBI-based 
conditioning for SCT. 
Pubertal growth spurt 
Reference data on height velocity in Dutch children are not available. Beunen 
and Malina 18 summarised the results of 20 studies on pubertal PHV, in which 
mean PHV ranged from 8.2 to 10.3 cm/year for males and from 7.0 to 9.1 
cm/year for females. The mean age at PHV in these studies ranged from 13.4 
to 14.4 in males and from 10.2 to 12.6 in females. Although our patients 
reached PHV at appropriate ages, PHV was lower in the vast majority of them. 
We therefore conclude that the pubertal growth spurt is blunted in our patients.  
In the patients who had reached final height, the age at PHV was only slightly 
higher than the age at onset of puberty. As patients visited the clinic only once 
or twice a year, there might have been a delay of up to 12 months in the 
appreciation of onset of puberty by clinical definition. In addition, testicular 
volume as indicator of onset of puberty may be less suitable in our patients, as 
testicular volume is compromised after TBI 6.  
Final height 
Of the 75 patients included in the present study, 32 had reached final height 
without receiving GH therapy. The decrease in height SDS between TBI and 
final height in these patients was 1.1 SD in girls and 1.7 SD in boys, which is 
comparable to that described in most studies on final height after SCT (i.e. 1.0 
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- 1.5 SD) 1;3;4;7;8. Sf-TBI is generally believed to have a much greater impact on 
growth than does fractionated TBI (f-TBI) 19. This belief is largely based on 
studies in patients receiving higher doses (9-10 Gy) sf-TBI, and these studies 
did not include final height. Recently, several single centre studies reported 
final height data after TBI in prepubertal patients who had not received 
additional cranial irradiation. Frisk et al. used 7.5 Gy sf-TBI and reported a 
median decrease in height SDS of 1.1 SD in 9 patients 7. Cohen et al. used 12 
Gy f-TBI and reported a mean decrease in height SDS of 0.9 SD in 14 patients 
4. Sanders et al. used 12 to15.75 Gy f-TBI and report a mean decrease in 
height SDS of approximately 1.5 SD in 21 patients receiving TBI before the age 
of 10 years 8. The only multi-centre study by Cohen et al. report similar final 
height SDS in 39 pre-pubertal children receiving sf-TBI (-1.2 ±1.1 SD) 
compared with 39 children receiving f-TBI (-1.0 ± 1.2 SD), although total 
decrease in height SDS was slightly greater in the patients receiving sf-TBI (1.4 
versus 0.9 SD) 1. Based on the results of the available final height data, we 
conclude that sf-TBI and f-TBI may have a similar effect on growth (i.e. mean 
decrease in height SDS after pre-pubertal TBI of approximately 1 to 1.5 SD). 
As in previous studies, decrease in final height was greater in boys (median 1.7 
SD versus 1.1 SD in girls). In addition, in boys most of the decrease in height 
SDS occurred during puberty, whereas in girls decrease in height SDS was 
slightly greater before puberty (not significant) and much less during puberty 
(all puberty-sex interactions, with boys as the reference category, were 
positive). There are several possible explanations for these differences 
between boys and girls. First, the time between SCT and onset of puberty was 
slightly greater in girls (median 2.8 years versus 1.5 years in boys). Second, it 
is possible that maximum height velocity is limited by radiation-induced 
structural damage to the growth plates (e.g. to 5-6 cm/year). As PHV is greater 
in healthy boys compared with girls, limiting the PHV may have had a greater 
effect on boys. Third, ovarian failure frequently occurred in girls, whereas 
Leydig cell failure only occurred in the 8 boys who received a testicular booster 
irradiation. Delayed introduction of sex hormone replacement therapy in girls 
may have resulted in a prolonged period of prepubertal growth.  
Body proportions 
Data on body proportions after TBI-based conditioning for SCT are limited. 
Three studies compared sitting height SDS to leg length SDS 9-11, two other 
studies compared sitting height SDS to standing height SDS 5;12.  All studies 
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describe a greater impairment of growth of the spine compared with that of the 
lower limbs, with differences between sitting height SDS and height (or leg 
length) SDS of 0 SD to -1.5 SD (on average). Most studies, however, included 
a relatively small number of patients, or patients who had received cranial or 
craniospinal irradiation, or were treated with growth hormone 5;9-11. In addition, 
none of the previous studies investigated the differences in body proportions 
between boys and girls.  
In our study, changes in SDS for height, sitting height, leg length and sitting 
height/height ratio were investigated in boys and girls separately. In boys, the 
decreases in SDS for sitting height and leg length were of comparable 
magnitude. Therefore, sitting height/height ratio SDS did not change. In girls, 
however, a decrease in sitting height SDS was not accompanied by a decrease 
in leg length SDS, resulting in a significant decrease in sitting height/height 
ratio SDS. As oestrogen deficiency causes a relative increase in leg length 
compared with sitting height, we hypothesise that lack of oestrogen is 
responsible for the decrease in sitting height/height ratio SDS in girls. Indeed, 
the decrease in sitting height/height ratio SDS was more pronounced in girls 
diagnosed with gonadal failure before the age of 15 years. Possible 
explanations for the differences between our results and those of previous 
studies are the separate analysis of boys and girls, the exclusion of patients 
with a history of CNS irradiation or GH treatment, and differences in TBI 
regimens (most of our patients received a lower total dose of TBI (7-8 Gy sf-
TBI) compared with the other studies (9-10 Gy sf-TBI or >10 Gy f-TBI).  
Modelling growth after SCT 
Modelling growth after SCT is complicated by the fact that there are several 
time variables to consider (i.e. chronological age, time since SCT and time 
since onset of puberty), all of which are closely correlated. As we were 
interested in the effects of TBI and SCT on growth, we chose the SCT as 
starting point, with time since SCT as our primary time variable. As changes in 
absolute height in normally growing children are influenced by chronological 
age, we chose changes in height SDS as our main outcome variable. The 
effect of puberty on changes in height SDS was separated into the effect of the 
pubertal growth spurt in the reference population and the effect of the patients’ 
individual pubertal growth spurt (as mentioned in the methods). On empirical 
basis, we have used non-linear effects to account for these different effects of 
puberty. The other parameters were added to the model as linear effects. The 
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parameters ‘time since SCT’ and ‘individual puberty’ were added to the model 
with both fixed and random effects. The final model shows that in our patient 
population, there is a constant decrease in height SDS with time after TBI-
based conditioning for SCT, with no significant sex difference. It also shows a 
slight attenuation of this constant decrease with increasing age at SCT, even 
though the TBI dose was lower in younger children. This suggests that younger 
children are more vulnerable to the growth limiting effects of radiation. During 
puberty, the increase in height SDS as a result of the individual pubertal growth 
spurt of our patients was slightly greater in girls compared with boys (figure 
2c,f), but the difference was not significant. In boys (but not in girls), the 
individual pubertal growth spurt could not compensate for the loss of height 
SDS caused by the pubertal growth spurt in the reference population, leading 
to an accelerated loss of height SDS during puberty. As the logistic component 
of the negative effect of the pubertal growth spurt in the reference population 
was greater in boys compared with girls, the greater loss of height SDS during 
puberty in boys was more likely to be the result of the greater pubertal growth 
spurt in the reference population than to a lower individual growth spurt in the 
boys in our study. Indeed, median pubertal PHV after SCT was slightly higher 
in boys compared with girls after TBI, but the difference between the sexes (0.5 
cm/year) was less than observed between boys and girls in the normal 
population (>1 cm/year). 
 
This study shows that growth and body proportions after TBI and SCT are 
affected in a sex-specific way. It identifies several influencing factors that may 
help to clarify mechanisms behind growth delay after TBI and SCT. Moreover, 
this model of growth after TBI provides us with a powerful tool for future 
evaluations of the effect of growth hormone treatment on growth after TBI.  
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Abstract 
Growth is often impaired in children receiving total-body irradiation (TBI) as 
conditioning for haematopoietic stem cell transplantation (SCT). Radiation 
damage to the growth plates is an important cause, but decreased growth 
hormone (GH) secretion may also play a role. In January 1997 we introduced a 
protocol for the treatment with GH of children with impaired growth after single-
fraction TBI. This study is an evaluation of that protocol. The main outcome 
measure is the effect of GH therapy on height SDS after onset of GH therapy, 
estimated by random-effect modelling with corrections for sex, age at time of 
SCT and puberty (data analysed on intention-to-treat basis). Between January 
1997 and July 2005, 66 patients (48 male) treated for haematological 
malignancies had at least two years of disease-free survival after TBI-based 
conditioning for SCT. Stimulated and/or spontaneous GH secretion was 
decreased in 8 of the 29 patients tested because of impaired growth. 
Treatment with GH (daily dose 1.3 mg/m2 body surface area) was offered to all 
29 patients and initiated in 23 of them (17 male). At time of analysis, median 
duration of therapy was 3.2 years; median follow-up after start of GH therapy 
was 4.2 years. The estimated effect of GH therapy, modelled as non-linear 
(logit) curve, was +1.1 SD after 5 years. Response to GH therapy did not 
correlate to GH secretion status. 
We conclude that GH therapy has a positive effect on height SDS after TBI, 
irrespective of GH secretion status. 
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Introduction 
Growth impairment is a frequent complication in children receiving total-body 
irradiation (TBI)-based conditioning for haematopoietic stem cell 
transplantation (SCT), with a mean decrease in height SDS between pre-
pubertal SCT and final height of approximately 1.0 to 1.5 SDS in most studies 
1-5. Radiation-induced damage to the epiphyseal growth plate is a major cause, 
but other factors can also attribute to impaired growth, e.g. radiation-induced 
hypothyroidism, hypogonadism or growth hormone deficiency (GHD). Several 
studies have shown that decrease in height SDS is greater in boys, in younger 
children and in children with a history of cranial irradiation (CI) or craniospinal 
irradiation (CSI) 2-6. Studies on the effect of GH therapy on growth after TBI are 
limited and almost exclusively deal with children diagnosed as having GHD. 
We investigated the effect of GH therapy in children with impaired growth after 
TBI and SCT, irrespective of the diagnosis of GHD. 
Materials and methods 
In January 1997 we implemented a protocol for the diagnostic evaluation and 
subsequent treatment of children and adolescents (<16 years of age) with 
impaired growth after TBI-based conditioning for SCT. The treatment protocol 
was approved by the Patient Care Committee and Scientific Research 
Committee of the Department of Paediatrics of the Leiden University Medical 
Centre, and by the Review Board of the Netherlands’ Organisation for Scientific 
Research (NWO). Informed consent was obtained from all patients involved in 
this study. 
Inclusion criteria 
1) TBI-based conditioning and SCT for a haematological malignancy before the 
age of 14 years and 2) at least two years relapse-free survival after SCT and 3) 
impaired growth (decrease in height SDS > 0.5 SD since SCT or height SDS 
below patient’s target height range) and 4) absence of other causes of 
impaired growth (e.g. CI as part of initial treatment, chronic graft-versus-host 
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disease, pubertal delay, untreated hypothyroidism, prolonged use of 
corticosteroids).  
Diagnostic evaluation 
All patients eligible for inclusion were offered evaluation of GH secretion. 
Priming with sex steroids was used in prepubertal girls ≥ 8 years of age and 
prepubertal boys ≥ 9 years of age. The peak serum concentration of GH after 
stimulation with clonidine (0.15 mg/m2 orally) or arginine (0.5 g/kg i.v.) was 
used as a measure of stimulated GH secretion. Spontaneous GH secretion 
was measured by nocturnal GH concentration profiles, using 12 h continuous 
blood withdrawal (2 ml/h) from 2000 h until 0800 h with a sample interval of 20 
minutes. Results were analysed using the Cluster algorithm 7.  
Assays and reference values 
Serum GH was measured using a time-resolved immunofluorometric assay, 
specific for the 22-kD form of GH with detection limit 0.01 μg/l, (Delfia hGH 
IFMA; Wallac, Turku, Finland, calibrated against the international reference 
preparation 80/505 in which 2.6U=1mg). Plasma levels of IGF-I and IGFBP-3 
were determined at the endocrine laboratory of the Wilhelmina’s Children’s 
Hospital, Utrecht, the Netherlands. The assays were described previously 8. 
Results are expressed as age- and sex-specific SDS. 
According to national criteria, peak GH > 20 mU/l after pharmacological 
stimulation was considered sufficient. Based on nation-wide harmonisation of 
GH assays, 13.8 mU/l in our assay corresponds to 20 mU/l in the national 
reference assay. Therefore, GH response was considered insufficient if peak 
GH was < 13.8 mU/l (5.3 ng/ml).  
Criteria for normal spontaneous GH secretion were maximum GH > 5.3 μg/l 
and mean GH concentration > 1.2 μg/l, based on assay-specific references 9.  
Growth hormone deficiency (GHD) was defined as an insufficient peak GH 
(spontaneous or stimulated) on 2 separate occasions. GH neurosecretory 
dysfunction (NSD) was defined as sufficient peak GH after pharmacological 
stimulation but decreased maximum peak GH or mean GH concentration in a 
12 hour GH secretion profile. 
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Treatment and follow-up 
After diagnostic evaluation of GH secretion status, all patients were offered 
treatment with recombinant human GH at a daily dose of 1.33 mg/m2 body 
surface area. 
Height, Tanner stages of breast or genital development 10 and testicular 
volume (measured with an orchidometer) were monitored at 3 months’ intervals 
during treatment with GH. Height was measured with a Harpenden stadiometer 
and expressed as standard deviation scores (SDS) for sex and age 11. Target 
height (TH) was calculated according to the formula introduced by Tanner et al 
12 with corrections for sex (13 cm) and secular trend (4.5 cm), and TH range 
was defined as TH SDS +/- 1.3 SDS.  
The onset of puberty was defined as the age at which breast development was 
first recorded in girls (Tanner breast stage ≥ B2) or a testicular volume ≥ 4 mL 
was reached in boys. If signs of pubertal development (e.g. penile growth and 
pubic hair development) had occurred in boys while testicular volume had not 
reached 4mL, onset of puberty was determined on the basis of the combination 
of progression of Tanner stages and increasing serum levels of testosterone. If 
puberty was induced, onset of puberty was defined as the start of sex hormone 
replacement therapy. 
After completion of therapy, height was measured at 6 months’ intervals until 
final height (patients were considered to have reached final height if growth 
was less than 1.0 cm over a period of more than 12 months after the age of 15 
years). 
Patient population 
Between 1997 and 2005, 66 patients met the inclusion criteria (patient 
characteristics are summarised in table 1). Stimulated and spontaneous GH 
secretion were evaluated in 29 children, including one patient (nr. 29 in the 
tables, treated outside the protocol) who did not meet the inclusion criteria 
(SCT at age 14.3 years and <2 years survival). Twenty-three children started 
GH therapy (effective mean starting dose 34 μg/kg/day, range 27-39). For two 
of these patients (nr. 27 and 28), evaluation of GH secretion as well as follow-
up of GH therapy took place in another centre, with a different GH assay and a 
lower starting dose of GH in one (0.67 mg/m2; corresponding to 18 μg/kg/day). 
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Table 1. Patient characteristics.  
Figures represent either absolute numbers, or medians with ranges in parenthesis. 
 
 
All patients 
(n=66) 
GH tested 
(n=29) 
GH treated 
(n=23) 
Male : female 48 : 18 22 : 7 17 : 6 
Age HCT 7.7 (1.7-14.3)  7.7 (1.7-14.3)  7.7 (1.7-14.3) 
Age GH evaluation - 12.5 (7.2-15.9) 12.2 (7.2-15.9) 
Age last visit 16.6 (8.8-22.4) 16.8 (9.2-19.3) 17.3 (10.8-19.3) 
Follow-up since HCT 7.7 (2.0-17.0) 8.1 (2.1-17.0) 9.1 (2.1-17.0) 
Follow-up since GH evaluation - 4.4 (0.0-7.8) 5.1 (0.6-7.8) 
Follow-up since start GH - - 4.2 (0.5-7.7) 
Indication HCT    
 ALL 1st 10 6 4 
 ALL 2nd 27 13 12 
 AML 1st 11 6 6 
 AML 2nd 4 1 - 
 MDS 8 3 1 
 CML 4 - - 
 NHL 2nd 2 - - 
Type of graft    
 Allogeneic 60 28 22 
 Autologous 6 1 1 
TBI dose    
 5.0 Gy 1 - - 
 7.0 Gy 9 5 5 
 7.5 Gy 37 15 12 
 8.0 Gy 2 1 - 
 2 x 6.0 Gy  17 8 6 
Testicular Booster 6 4 3 
 
Conditioning for SCT 
Conditioning for SCT consisted of TBI and cyclophosphamide (60 mg/kg/day 
i.v. for 2 consecutive days) in all patients. In addition, 19 patients also received 
cytarabine (1 g/m2/day for 2 consecutive days) and 37 patients received 
etoposide (350 mg/m2/day for 2 consecutive days). All patients received 
unfractionated TBI, delivered at a mean instantaneous dose rate of 25 
cGy/min. As age is an important determinant of the tolerable total irradiation 
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dose in children, a TBI regimen with age-dependent total dose was applied (0-
2 years: 5.0 Gy, 2-4 years: 7.0 Gy, 4-10 years: 7.5 Gy, >10 years 8.0 Gy). The 
latter dose was ‘increased’ in 1989 to 2 single fractions of 6.0 Gy, given on 2 
consecutive days (instead of the equivalent 9.0 Gy once, which had too many 
side effects in adults). Six boys treated for ALL received additional prophylactic 
testicular irradiation (10 Gy in 4 fractions prior to TBI). 
Statistical Analyses 
S-PLUS 6 Professional (Insightful corp., Seattle WA, USA) was used for all 
statistical analyses, with significance level set at 5%. We recently developed 
sex-specific models that describe the changes in height SDS with time after 
TBI and SCT, with corrections for the effects of individual puberty and for the 
effect of puberty in the reference population, using the function ‘lme’ (linear 
mixed-effects) in S-PLUS 6. These models are based on 75 children who had 
at least 2 years of follow-up after pre-pubertal TBI-based conditioning for SCT 
for a haematological malignancy. Three of the 23 GH treated children from the 
present study were not included in this previous study (nrs. 5 and 14 were not 
pre-pubertal at time of SCT, nr. 29 due to relapse), the others contributed to 
the initial models until the start of their GH therapy. 
For the present analyses, we added the height measurements taken after start 
of GH therapy of these 20 patients to the dataset (total set 1236 post-TBI 
height measurements of 75 patients) and subtracted the individual growth 
profiles (obtained from the model) from the individual height SDS after start of 
GH therapy. The resulting values describe the difference between individually 
predicted growth (i.e. without GH therapy) and actual growth after start of GH 
therapy. This estimated effect of GH therapy was then analysed by adding a 
variable ‘time since start GH therapy’ to the model with a non-linear (logit) 
effect.  To prevent possible selection bias by exclusion of patients who 
discontinued therapy due to a poor response, analyses of the effect of 
treatment were done on an intention-to-treat basis. Therefore all data obtained 
after start of therapy was included in the analyses, even if GH therapy was 
discontinued by that time.  
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Results 
Growth hormone secretion 
Results of the analyses of GH secretion are represented in table 2. GH 
secretion was impaired in 7 of the 27 children tested in our clinic, including the 
patient treated outside the protocol. Two patients had classical GHD, five had 
NSD. Of the two patients tested in another centre (27 and 28), one had a 
decreased integrated mean spontaneous GH secretion using assay-specific 
reference values for that centre 13. 
Effect of GH therapy 
Table 3 summarises height SDS at different time points in the children 
receiving GH therapy. The median duration of GH therapy was 3.2 years 
(range 0.1-7.3 years). 
 
 
Table 3. Target height SDS and height SDS at different time-points in the 23 patients 
treated with GH.  * Adult height: Final height expressed as SDS for age 21 years. 
Patient 
 
Sex 
 
Duration 
GH Rx 
(years) 
follow up 
since start 
GH (years) 
Target 
height 
(SDS) 
Height at 
SCT 
(SDS) 
Height at 
start GH 
(SDS) 
Delta height 
after start GH 
(SDS) 
Adult 
height* 
 (SDS) 
1 m 1.5 1.5 -1.7 -2.3 -3.5 0.1  
2 m 1.9 4.0 1.1 1.2 0.1 0.0 -0.1 
4 m 3.3 4.1 1.6 -0.3 -0.9 0.5  
5 m 2.1 2.6 -2.2 -0.6 -2.6 0.0  
7 m 4.0 4.0 -0.3 -0.5 -1.6 -0.3  
8 m 7.2 7.2 0.0 0.4 -0.4 0.6  
10 m 6.4 6.4 -0.7 -2.7 -2.4 0.2  
11 f 3.6 5.4 0.6 -0.2 -1.0 1.0 -0.1 
12 m 2.6 4.7 -0.2 -1.0 -1.8 -0.6 -2.7 
14 f 0.1 2.5 -0.3 -1.5 -2.0 0.1 -2.0 
15 m 3.1 3.1 0.6 -1.2 -1.7 1.1  
16 f 5.7 6.3 1.0 -2.2 -2.0 0.4  
17 m 3.1 6.4 1.1 -0.9 -1.2 -0.8 -2.4 
18 f 1.6 3.6 0.0 -0.7 -1.5 0.2 -1.4 
19 m 3.0 5.8 1.6 1.2 0.2 0.4 0.4 
20 m 2.3 2.3 1.1 -1.1 -1.5 0.1  
21 m 3.3 3.3 -0.1 -1.5 -1.4 0.2  
22 f 0.7 4.2 0.7 -0.7 -1.7 0.2 -1.6 
23 f 4.9 7.7 0.2 -1.0 -3.4 0.4 -3.2 
24 m 4.3 5.3 1.2 -0.5 -0.3 -0.4 -1.7 
27 m 3.8 4.2 -1.4 -3.0 -3.5 -0.2 -4.0 
28 m 5.3 5.3 0.4 0.6 -0.8 0.3  
29 m 0.7 0.7 -0.8 -1.1 -1.6 0.3  
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Figure 1 represents the relative changes in height SDS in the 23 children 
treated with GH compared to height SDS at start of GH therapy. In the first 
year of therapy, there was a mean change in height of +0.35 SDS/year. Two 
patients discontinued therapy and one patient (nr 29, treated outside the 
protocol) died 27 months after SCT after relapse of his initial disease. In 17 of 
the remaining 20 children, there was an increase in height SDS in the first year 
of therapy, whereas in 3 there was a slight decrease (<0.05 SDS/year).  
 
 
Figure 1. Changes in height SDS after start of GH therapy in the 23 GH-treated 
children. The x-axis represents time since start of GH therapy in years, the y-axis height 
SDS compared with height SDS at start of GH therapy. Left panel: males, right panel 
females. 
 
 
The estimated net effect of GH therapy in the 20 patients who received SCT 
before the onset of puberty is represented in figure 2. The estimated net effect 
after 5 years of therapy is 1.14 (CI 0.88-1.41) SDS, with no significant 
difference between sexes (p=0.565). 
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Figure 2. Result of mixed-effect modelling: estimated net effect of GH therapy on 
development of height SDS in the 20 patients receiving HCT before onset of puberty. 
Dashed lines represent 95% CI. 
 
Predictive value of parameters of GH secretion 
To evaluate the role of GH secreting capacity in impaired growth after SCT, we 
added different parameters for GH secretion (integrated mean GH 
concentration, IGF-1 and IGFBP-3) to the mixed-effect model. None of the 
parameters had a significant effect on either loss of height SDS after SCT or on 
the increase in height SDS after initiation of GH therapy. 
Adverse effects, relapses and secondary tumours 
Within 2 weeks after start of therapy, patient nr. 14 repeatedly had urticaria and 
angioedema after injecting GH and decided to stop GH therapy. Due to 
increasing aversion of injections, patient nr. 22 decided to stop GH therapy 
after eight months.  
Chapter 8 
122 
In the 43 untreated patients compensated hypothyroidism was diagnosed in 12 
(28%) and autoimmune hypothyroidism in 1 (2%). In the 23 GH treated 
patients, compensated hypothyroidism was diagnosed in 8 (35%) before start 
of therapy, and in an additional 8 (35%) after start of therapy. Thyroxine 
suppletion was initiated in all patients with compensated hypothyroidism.  
Five boys and one girl developed exostoses during GH therapy, another boy 
experienced growth of pre-existing exostoses during GH therapy. In the 43 
untreated children, two boy developed exostoses. There was 1 relapse among 
the 23 GH treated patients (nr 29; treated outside the protocol relapsed 9 
month after start of GH therapy), compared to 6 relapses in the 43 untreated 
children. In the untreated group, one patient developed a schwannoma 7.3 
years after TBI. In the GH treated group 2 patients developed a secondary 
malignancy. Patient 28 developed an osteosarcoma 5.3 years after start of GH 
therapy (12.7 years after SCT). Patient nr. 22 (treated with GH for only 8 
months) developed papillary thyroid carcinoma 3.5 years after start of GH 
therapy (9.7 years after SCT).  
Discussion  
This study reports a positive effect of GH therapy on height SDS in children 
with impaired growth after TBI-based conditioning for SCT, even in the 
absence of GHD. The calculated net effect (1.1 SD after 5 years of GH 
therapy) did not correlate to GH secretion status. A potential limitation of our 
study is the use of single fraction TBI, as most SCT centres use fractionated 
TBI. As final height results from our centre are comparable to those reported by 
centres using fractionated TBI, we believe this to be a minor limitation. 
GHD was diagnosed in 8 of the 66 patients (12%) monitored since 1997. There 
is a wide variation in the reported incidence of GHD after TBI-based 
conditioning for SCT, with incidences from 0 to 84% 3-5;14-27. Factors 
contributing to these differences in incidence of GHD are: population size, 
duration of follow-up, TBI characteristics (dose, dose rate, fractionation), 
indications for GH testing and selection bias (e.g. exclusion of children with a 
history of CI or exclusion of children not tested for GHD). In addition, the 
criteria used for the diagnosis of GHD largely influence the incidence of GHD. If 
we had used ‘standard’ criteria for GHD (e.g. mean nocturnal GH concentration 
< 2.5 μg/l or peak  GH < 10 μg/l on two occasions, 23 of our 29 patients tested 
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(79%) would have been diagnosed as having GHD. The vast majority of the 
studies on GHD after TBI do not mention the GH assay used, nor do they 
mention the use of assay specific references. We believe that the relatively low 
incidence of GHD in the present study can be attributed to the absence of 
children with additional CI as well as to the use of assay-specific criteria for the 
diagnosis of GHD. 
Most patients included in the present study showed a decrease in height SDS 
between TBI and start of GH therapy (figure 1). A continuing decrease in height 
SDS could be expected based on previous reports in the literature as well as 
our model for growth after TBI. However, in most of the patients treated with 
GH, height SDS at last visit (mean follow-up of 4.4 years) was comparable to 
height SDS at start of therapy (table 3). 
Data on the effect of GH therapy on height after TBI-based conditioning for 
SCT are limited, with only 3 studies reporting final height 2;4;5. The first study by 
Cohen et al. is a questionnaire-based study on final height after pre-pubertal 
SCT in the European EBMT centres, showing no significant difference in final 
height between GH treated an non-GH treated patients 2. Due to the set-up of 
the study, no information was available on the indications for GH therapy, the 
GH doses used or the changes in height SDS after start of GH therapy. 
Therefore, no valid conclusions can be drawn from this study regarding effect 
of GH therapy. The second study by Frisk et al. reports final heights of 11 
patients treated with GH after TBI and autologous SCT for ALL (6 had received 
additional CI and one CSI). In that study, 6/11 GH treated patients were 
considered to have GHD based on maximum GH peak in 12- or 24-hour 
spontaneous GH secretion profiles. The GH assay (and probably also the 
reference standard) was the same as in the present study, but the cut-off for 
the diagnosis of GHD was much higher (maximum GH < 10 μg/l vs 5.3 μg/l in 
our study). According to multiple regression analyses, the effect of GH therapy 
on height SDS  was 0.18 SDS for each year of GH therapy. The third study by 
Sanders et al. reports the effect of GH therapy on ‘final height’ (height at the 
age of 16 years) of 90 TBI patients (32 CI) diagnosed with GHD, 42 of whom 
(21 CI) were treated with GH (20 - 30 μg/kg/day). According to multiple 
regression analysis, GH treatment resulted in 0.86 SD increase in final height 
in the 35 children with SCT before the age of 10 years, whereas no significant 
effect of GH therapy was found in the 7 children receiving SCT after the age of 
10 years. 
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The estimated net effect of GH therapy on height SDS in our study (1.1 SDS 
after 5 years) is comparable to that reported by Sanders et al. in children 
receiving SCT before the age of 10 years (0.9 SD), as well as to that reported 
by Frisk et al. (0.18 SD/year). Major differences with these previous studies are 
that the majority of the patients in the present study were not considered GH 
deficient (although diagnostic criteria differ between the studies 28), and that the 
estimation of the effect in the present study is based on mixed-effect modelling, 
a robust statistical method that allowed us to predict individual height SDS 
curves and compare those to actual height SDS after start of GH therapy 
without the risk of significant bias and without the need for final height in all 
patients. 
We also looked at the influence of GH secretion status on either decrease in 
height SDS until testing and on the effect of GH treatment. The results of GH 
secretion status did not correlate with decrease in height SDS before GH 
therapy or with response to GH therapy. This suggests that impaired growth 
after SCT is mainly caused by radiation damage to the epiphyseal growth plate 
(and thus end-organ sensitivity) and far less by decreased GH secretion.  
The incidence of (sub-clinical) hypothyroidism was more than twice as high in 
the GH treated patients compared to the non-treated patients. The reported 
incidence of radiation induced hypothyroidism after TBI in children is 15-50% 
and seems to be higher after unfractionated TBI 29. In GH deficient children, 
GH replacement therapy does not induce primary hypothyroidism. It either 
reveals previously unrecognised cases of central hypothyroidism or induces 
hypothyroxinaemia by increased conversion of thyroxine to tri-iodothyronine 30-
32. None of our patients had central hypothyroidism, however, and the majority 
of cases were not GH deficient. The higher incidence of compensated 
hypothyroidism in GH treated survivors of TBI is in line with the results of 
Sanders et al. 5. A possible explanation for this higher incidence of 
hypothyroidism in GH treated children could be that in GH treated patients 
thyroid function was monitored more closely, or that increased growth 
increased the demand for thyroxine. 
The risk of secondary cancers is increased in all survivors of TBI-based 
conditioning for SCT during childhood and cumulative incidence increases with 
time after SCT and in case of younger age at SCT 33. Although surveillance 
studies do not suggest an increased risk of disease recurrence in survivors of 
childhood cancer by GH therapy, potential oncogenic effects of GH remain a 
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concern 34;35. In supra-physiological doses both GH and IGF-I stimulate 
proliferation and differentiation of both normal and leukaemic cultured human 
lymphocytes 36;37, more physiological concentrations of GH (i.e. less than 50 
ng/mL), however, do not have an effect on colony formation, nor on the number 
of colonies or DNA-synthesis in cultured leukaemic cells. In the present study, 
two of the 23 GH treated patients developed a secondary tumour (one thyroid 
carcinoma and one osteosarcoma), compared to 1 out of the 43 untreated 
patients.  
Relapse of leukaemia occurred less frequently in the GH treated patients (1/23) 
compared to untreated patients (6/43; including one patient who considered 
starting GH therapy when his leukaemia relapsed almost 5 years after SCT).  
Nine of our 66 patients (13.6%, only one female) developed exostoses 
(believed to be osteochondromas). Exostoses were more frequent in the GH 
treated group (7/23, 30%) compared to the non-treated group (2/43, 4.7%). 
Osteochondromas develop in 9-23% of children with TBI-based conditioning for 
SCT 38-40. A role for GH therapy in promoting their development is suggested, 
but malignant degeneration is believed to be rare  5;38-40. 
In conclusion, our study shows that recombinant human GH (± 33 μg/kg/day) 
has a positive effect on height SDS after SCT, even in the absence of GHD. 
We could not establish a relation between decrease in GH secretion and either 
impaired growth after SCT or response to GH therapy (probably due to 
interference of growth plate damage). We therefore believe that evaluation of 
GH secretion has limited value in predicting the response to GH therapy, and 
treatment could be considered in every patient with severe growth impairment 
after TBI, even in the absence of GHD. Patients should be informed about the 
increased risk of secondary tumours after SCT and the concerns of oncogenic 
potential of GH therapy, as well as about the possibility of increased risk of 
osteochondromas. 
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Abstract 
It is generally assumed that busulphan/cyclophosphamide (Bu/Cy)-based 
conditioning regimens for haematopoietic stem cell transplantation (SCT) do 
not affect growth. We evaluated growth and endocrine function after Bu/Cy 
based conditioning in 64 children without a history of irradiation. Mean height 
standard deviation scores remained stable, but unexplained disturbances of 
growth after SCT were found in 17/48 (35%) of the children without growth-
limiting disorders (10/23 in patients treated for haematological malignancies). 
In 10 patients, growth hormone (GH) secretion status was evaluated, and 
insufficient GH secretion was diagnosed in four patients. Thyroid function was 
evaluable in 52 patients. Two developed antibody-mediated thyroid disorders 
and 10 (19%) compensated primary hypothyroidism. Gonadal function was 
evaluable in 21 patients and was normal in all seven patients treated with low-
dose Bu (8 mg/kg), whereas seven of the 14 children receiving high-dose Bu 
(16–20 mg/kg) developed gonadal failure; the majority of these patients had 
not been exposed to gonadotoxic therapy prior to Bu/Cy. Of the 49 evaluable 
patients, 16 developed subclinical hyperparathyroidism. We conclude that, 
besides gonadal and thyroid dysfunction, impaired growth and 
hyperparathyroidism often occur after Bu/Cy conditioning for SCT and that 
growth impairment may be the result of insufficient GH secretion. 
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Introduction 
Disturbances of growth and endocrine function are important side effects of 
total-body irradiation (TBI)-based conditioning regimens in children undergoing 
haematopoietic stem cell transplantation (SCT). In an attempt to reduce these 
side effects, radiation-free, myeloablative regimens containing high doses of 
busulphan (Bu) and cyclophosphamide (Cy) have gained increasing popularity 
in children under 3 years of age, but also in older children undergoing SCT for 
malignant as well as non-malignant disorders. In the majority of studies on 
growth after radiation-free conditioning for SCT, it was concluded that Bu/Cy 
does not affect longitudinal growth 1-5. Confronted with several children 
exhibiting unexplained growth impairment and decreased growth hormone 
(GH) secretion, we decided to evaluate growth and endocrine function in our 
paediatric Bu/Cy population. 
Patients and methods 
Patient selection  
We studied all patients with at least 2 years of follow-up after Bu/Cy-based 
conditioning regimens for SCT, who did not have a history of irradiation (n=84). 
Before further analysis, we excluded patients with conditions related to multiple 
endocrine problems, that is, iron overload in patients treated for thalassaemia 
(n=14) and Blackfan–Diamond anaemia (n=4), as well as patients with Down 
syndrome (n=2). Characteristics of the remaining 64 patients are summarised 
in table 1. Patients were divided into three groups based on the indication for 
SCT: group I consisted of patients with a haematological malignancy (n=26), 
group II of patients with an immunodeficiency syndrome (n=22) and group III of 
patients with other inborn errors or aplastic anaemia (n=16).  
The median age at the time of SCT was 2.3 years (range 0.1–14.7 years), the 
median time since SCT was 6.0 years (range 2.4–16.7 years). SCT was of 
allogeneic origin in all but one patient, who received an autologous SCT for 
acute myeloid leukaemia (AML). 
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Table 1. Patient characteristics 
Indication SCT 
Nr. of 
patients 
Sex 
m:f 
Age SCT (years) 
median (range) 
Follow-up (years) 
median (range) 
Group I: haematological malignancies 26 14:12 2.4 (0.5 – 12.4) 5.0 (2.4 – 11.3) 
 myelodysplastic syndrome (MDS) 13    
 acute myeloid leukaemia (AML) 5    
 acute lymphoblastic leukaemia (ALL) 5    
 acute undifferentiated leukaemia (AUL) 1    
 chronic myeloid leukaemia (CML) 1    
 non-Hodgkin Lymphoma (NHL) 1    
Group II: Immunodeficiency syndromes 22 12:10 0.8 (0.1 – 11.3) 10.0 (3.8 – 16.7) 
 severe combined immunodeficiency (SCID) 13    
 combined immunodeficiency (CID) 7    
 Wiskott-Aldrich syndrome (WAS) 2    
Group III: inborn errors and aplastic anaemia 16 10:6 5.1 (0.7 – 14.7) 4.7 (3.0 – 9.9) 
 severe aplastic anaemia (SAA) 2    
 X-linked adrenoleukodystrophy (X-ALD) 4    
 haemophagocytic lymphohistiocytosis (HLH) 4    
 metachromatic leukodystrophy (MLD) 2    
 autosomal recessive osteopetrosis (OP) 2    
 mucopolysaccharidosis type I/VI (MPS) 2    
 
Conditioning for SCT 
Bu was given in 16 doses divided over 4 consecutive days in all patients, either 
orally (until 2000) or intravenously (i.v.) (from 2000 onward). The cumulative Bu 
dose was 8 mg/kg in 10 severe combined immunodeficiency (SCID) patients, 
12–14 mg/kg in three myelodysplastic syndrome (MDS) patients and 16–20 
mg/kg in the remaining 51 patients. The standard dose of cyclophosphamide 
was 50 mg/kg, once daily i.v. for 4 consecutive days (total dose 200 mg/kg). In 
three patients, receiving an SCT from a matched unrelated donor for storage 
diseases, a higher dose (60 mg/kg) was given (total dose 240 mg/kg). In all, 13 
patients (12 MDS and one severe aplastic anaemia (SAA)) received a lower 
total dose of Cy (120 mg/kg, given as 60 mg/kg once daily for 2 consecutive 
days) in combination with a single gift of melphalan 140 mg/m2 i.v. 
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Data collection  
Data on height, pubertal development and endocrine function were collected 
from the clinical records. Height was expressed as standard deviation scores 
(SDS) for sex and age based on Dutch references 6. Target height (TH) was 
calculated from parental height with correction for sex differences (13 cm) and 
secular trend (+4.5cm) 6. TH range was defined as TH SDS ± 1.3 SD.   
Peak stimulated GH secretion was measured after stimulation with clonidine 
(150 mg/m2 p.o.) and, in case of an inadequate GH response to clonidine, also 
after stimulation with L-arginine (0.5g/kg i.v). To prevent false-negative GH 
responses to these stimulation tests, peri-pubertal children (girls >8.0 years of 
age and boys >10.0 years of age) were primed with sex steroids. Spontaneous 
GH secretion was measured in 36 samples, obtained by continuous blood 
withdrawal sampled at 20-min intervals between 20:00 and 18:00. Serum 
samples were analysed (in duplicate) with a time-resolved Immunofluorometric 
assay (Wallac, Turku, Finland; specific for the 22-kDa GH isoform, minimal 
detection limit 0.01 mg/l). Nocturnal spontaneous GH secretion was analysed 
with the Cluster pulse detection algorithm. Assay-specific reference values for 
12-h nocturnal GH profiles (see table 3) were constructed from raw data 
obtained from 76 healthy prepubertal children 7 (median age 10.7, median 
height –1.1 s.d.) after correction for differences in GH assays 8 (courtesy of 
Professor K Albertsson-Wikland and Dr C Löfqvist, Sweden). Insulin-like 
growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) were analysed with 
specific radio immunoassays in the Wilhelmina Children’s Hospital, Utrecht, the 
Netherlands, and expressed as SDS for age and gender 9. 
Serum levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), 
free thyroxine (free T4), thyroid-stimulating hormone (TSH), parathyroid 
hormone (PTH), alkaline phosphatase (AP) and 25(OH) vitamin D3 were 
analysed with commercially available assays and interpreted using assay-
specific references.  
Data analysis and statistics  
S-PLUS 6 Professional release 2 (Insightful Corp, Seattle, WA, USA) was used 
for statistical analysis, with the significance level (α) set at 5%. Changes in 
height SDS after SCT were analysed using a linear mixed-effect model with 
data grouped by individual patients, height SDS as dependent variable and 
time since SCT as independent variable with both fixed and random effects. 
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Possible effects of the variables ‘age at SCT’, ‘gender’ and ‘indication group’ on 
height SDS (intercept) and change in height SDS with time since SCT (slope) 
were analysed. Height measurements  obtained  after  the  onset  of  GH  
therapy  were  excluded  from  the analysis. In addition to the group analysis, 
the growth of individual patients was analysed. Growth was considered normal 
in patients with height SDS above -2 SD and height within TH range and no or 
only limited (<0.5 SD) decrease in height SDS. As an exception to these three 
criteria, a decrease in height SDS >0.5 SD towards TH SDS during the first 3 
years of life was considered normal. Also, growth was considered normal if 
height SDS increased after SCT (catch-up growth), even if height SDS was 
below –2 SD or below TH range. Gonadal dysfunction was defined as elevated 
serum levels of FSH and/or LH. In boys, elevation of LH (with or without 
decreased levels of testosterone) was used as an indicator of Leydig cell 
failure, whereas elevation of FSH was used as an indicator of Sertoli cell failure 
(i.e. inability to produce enough inhibin B to suppress FSH secretion as a result 
of either Sertoli cell loss or loss of germ cells). 
 
Results  
Growth  
Data on height development were missing in two patients from group II: a girl 
with combined immunodeficiency (CID) and kyphomelic dysplasia and a boy 
with Wiskott–Aldrich syndrome (WAS) living abroad (the referring centre stated 
that he was ‘growing well’). Of the remaining 62 patients, 571 height 
measurements were available. Height SDS at SCT and height SDS at the last 
visit are represented for the three subgroups in figure 1a.  
A linear mixed-effect model did not show any change in height SDS with time 
since SCT: the estimated change in height SDS for the complete study 
population was 0.0001 SD/year. We then added the covariates ‘group’ (I, II or 
III), ‘age at SCT’ and ‘gender’ to the model (as single covariate and in different 
combinations). Of the covariates, only the factor ‘group’ had a significant effect: 
group II had a lower intercept (estimated height SDS at SCT) and a positive 
slope (estimated increase in height SDS with time since SCT 0.049 SD/year, 
P=0.038). 
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Figure 1. Changes in height SDS after SCT. The mean height SDS in the three 
subgroups at SCT and last visit. (a) Represents all patients (n=62). (b) Represents 
patients without growth-limiting disorders (n=48). Error bars represent standard error of 
the mean. 
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Separate analysis of the three subgroups yielded similar results, but the 
estimated increase in height SDS after SCT in group II (0.059 SD/year) was no 
longer significant (P=0.057). The fitted models (no covariates used) are 
summarised in table 2. 
 
 
Table 2. Results of the linear mixed-effect models for changes in height SDS with time 
since SCT (SD/yr) in different groups of patients. 
 Group n HSDS at SCT (95% CI) Change after SCT (95% CI) 
All patients  62 -1.15   (-1.55 to –0.75) 0.000   (-0.042 to +0.042) 
 I 26 -0.61   (-1.08 to –0.13) -0.044   (-0.131 to +0.043) 
 II 20 -2.14   (-2.84 to –1.44) +0.059   (-0.002 to +0.121) 
 III 16 -0.76   (-1.58 to +0.06) -0.035   (-0.114 to + 0.044) 
     
No growth-limiting disorders  48 -0.77    (-1.19 to –0.35) +0.002   (-0.045 to +0.049) 
 I 23 -0.50    (-0.97 to –0.04) 0.000    (-0.073 to +0.073) 
 II 14 -1.81    (-2.73 to –0.88) +0.059   (-0.027 to +0.146) 
 II 11 +0.01   (-0.69 to +0.71) -0.074    (-0.156 to +0.008) 
Data represent estimations and 95% confidence intervals (95% CI) of intercept (height 
SDS at SCT) and slope (change in height SDS with time). Data of all patients and of 
the patients without known growth-limiting disorders are presented. 
 
 
 
Eight patients had a genetic disorder associated with impaired growth and/or 
skeletal abnormalities: two mucopolysaccharidosis (MPS), two osteopetrosis 
(OP), two Nezelof syndrome, one Noonan syndrome and one deletion of the 
adenosine deaminase gene. In addition, six patients had acquired growth-
limiting disorders (three chronic graft-versus-host disease (GVHD), one 
chemotherapy-induced renal Fanconi syndrome, one treatment with high-dose 
steroids for immune-mediated pancytopenia and one malabsorption 
syndrome). None of the patients had a decrease in height SDS (>0.5 SD) due 
to a delayed onset of puberty.  
Growth and endocrine function after Bu/Cy 
 137 
 
Exclusion of the 14 patients with growth-limiting disorders from the analysis 
resulted in a higher intercept of the linear model (i.e. higher HSDS at SCT), but 
it had no effect on changes in height SDS after SCT (in group III exclusion 
even caused a tendency towards a decrease in height SDS in time, an effect 
caused by catch-up growth after SCT in the excluded patients with MPS and 
OP). Height SDS at SCT and height SDS at the last visit for the 48 patients 
without growth-limiting disorders are represented in figure 1b for the three 
subgroups. 
Finally, we evaluated the growth pattern of individual patients and found 
unexplained abnormal growth in 17/48 patients (35%) without growth-limiting 
disorders (10/23 in group I, 3/14 in group II and 4/11 in group III). Of these 17 
patients, 11 had a decrease in height SDS >0.5 SD (in six height SDS was also 
outside their TH range and/or below – 2 SD). Of the remaining six patients 
without decrease in height SDS >0.5 SD, height SDS was below TH range as 
well as below –2 SD. In the other three patients impaired growth was only 
based on height SDS below the TH range (one from each group, only the one 
from group II had a height <1 SDS). Total dose of Bu was 16–20 mg/kg in all 
17 patients.  
GH secretion status  
GH secretion status was evaluated in 10 of the 17 patients with unexplained 
growth delay. The other seven patients either declined analysis of GH 
secretion or had a bone age that was too high to expect a significant effect of 
GH therapy on height (severe GH deficiency (GHD), warranting GH 
replacement in adult life was not suspected in any of these patients). Results of 
the evaluation of GH secretion are represented in table 3.  
GH secretion was normal in 6/10 patients. In one patient, GHD was diagnosed, 
as both spontaneous and stimulated GH secretion were impaired. In two other 
patients spontaneous GH secretion was decreased (integrated mean GH and 
maximum GH below the 5th percentile for pre-pubertal children), but the GH 
response to pharmacological provocation was preserved, consistent with GH 
neurosecretory dysfunction (GHNSD) 10. In addition, one patient who had 
already entered puberty by the time GH secretion was evaluated (no. 351, 
table 3) was also considered to have GHNSD, as all parameters of 
spontaneous GH secretion were near the lower limit of the reference interval 
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for pre-pubertal children (whereas spontaneous GH secretion is expected to 
increase after the onset of puberty). In addition, his serum levels of IGF-1 and 
IGFBP-3 were below –4 SDS. 
 
 
Table 3. Evaluation of GH secretion in 10 patients with unexplained growth delay 
after SCT. 
Patient  Spontaneous  
GH secretion 
Stimulated 
GH secretion
IGF-1 BP-3 
UPN Disease Bu 
(mg/kg) 
Age 
(year) 
Height 
(SD) 
 Mean GH 
(mU/L) 
Nr of 
peaks 
Max. GH 
(mU/L) 
 Test 1 
(mU/L)
Test 2 
(mU/L) 
SDS SDS 
222 AML 20 6.6 -2.7  1.52* 4 9.2*  37.0 n.a. -2.7* -1.4 
351 CID 16 14.3 -3.8  3.84 3 19.7  19.2* 28.7 -5.5* -4.6* 
Auto12 AML 20 9.2 -3.0  0.59* 1* 5.0*  6.5* 31.7 -1.1 1.2 
318 ALL 20 8.8 -0.4  0.78* 4 5.3*  6.9* 5.6* 0.0 2.5 
457 MDS 14 7.1 -1.1  5.40 5 20.7  26.1 n.a. -2.7* -0.1 
364 AML 20 8.0 0.0  4.03 5 15.4  14.9* 13.7* 0.3 -1.4 
414 FHL 20 9.3 -1.6  4.90 4 20.7  27.8 n.a. -1.3 0.6 
379 AML 20 6.6 -0.7  7.8 5 44.0  43.9 n.a. 0.8 -0.1 
241 CID 20 12.0 -3.9  n.a. n.a. n.a.  27.9 45.0 n.a. n.a. 
228 SCID 18 9.0 -1.4  n.a. n.a. n.a.  59.3 n.a. n.a. n.a. 
Reference:                Median 
            (p5 – p95) 
 
5.8 
(3.2 - 20.6)
5 
(3 - 7) 
27.2 
(13.1 – 94.9) 
     
UPN=unique patient number; *=decreased;  n.a. = not available. References for 
spontaneous GH secretion are for prepubertal children (see methods). 
 
 
All children with insufficient GH secretion were offered treatment with 
recombinant human GH (0.33 mg/kg/week once daily subcutaneous). One 
patient has refused treatment, another recently started therapy and two (nos. 
351 and 222, see table 3) have received GH for the last 2 and 4 years, 
respectively. GH treatment resulted in a progressive increase in height SDS. At 
the last visit height had increased 1.3 SD since the onset of GH therapy in both 
patients 
Growth and endocrine function after Bu/Cy 
 139 
Thyroid function 
TSH and free T4 were measured at regular intervals in 52 of the 64 patients. In 
40 of these patients (77%) thyroid function was normal at all times. Two 
patients developed an antibody-mediated thyroiditis: hyperthyroidism in one 
boy, 4.5 years after SCT for X-linked adrenoleucodystrophy (X-ALD), and 
hypothyroidism in a girl, one year after SCT for acute lymphoblastic leukaemia 
(ALL) (this girl also developed an immune-mediated pancytopenia and was 
treated for 6 months with high doses of corticosteroids). Neither patient 
suffered from chronic GVHD. The remaining 10 children (six boys and four 
girls, mean age at the time of SCT 3.6 years; seven from group I, one from 
group II and two from group III) had one or more episodes of compensated 
hypothyroidism (i.e. mildly elevated serum TSH with normal serum free T4). 
None of the 10 children had chronic GVHD, and only one was diagnosed with 
acute GVHD. All patients with thyroid dysfunction had received 16–20 mg/kg 
busulphan; three patients had received melphalan as well. In three of the 
patients compensated hypothyroidism persisted. A TRH test showed primary 
hypothyroidism and all three are receiving thyroxin substitution. 
Pubertal development and gonadal function 
Owing to the young age of our population, the evaluation of puberty and 
gonadal function was only possible for 26 of the 64 patients. Data on pubertal 
development and gonadal function were incomplete in five patients (one in 
group I, four in group II). Seven patients (all SCID, three girls, age at last visit 
11.7–16.5 years) had received a low cumulative busulphan dose of 8 mg/kg. 
Their gonadal function remained normal throughout follow-up. The other 14 
patients had received 16–20 mg/kg busulphan. Data on their gonadal function 
are summarised in table 4. 
Pubertal development was normal in all boys, and none developed Leydig cell 
failure. Sertoli cell failure developed in all three boys treated during puberty, 
none of them had received gonadotoxic chemotherapy prior to conditioning. Of 
the boys receiving SCT before the onset of puberty, none developed Sertoli 
cell failure, but 4/5 have only recently entered puberty. Both girls receiving SCT 
during puberty developed gonadal failure, none of them had received 
gonadotoxic chemotherapy prior to SCT. In addition, two of the four girls 
receiving SCT before the onset of puberty did not have a spontaneous onset of 
puberty and developed gonadal failure. One of them had been exposed to 
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gonadotoxic chemotherapy prior to conditioning. Until now, gonadal function 
seems to be preserved in the other two girls. 
 
Table 4. Gonadal function after high-dose Bu/Cy in 14 patients 
UPN Gender 
Age at 
SCT 
Age at onset 
puberty 
Age at 
last visit 
Indicatio
n SCT 
Gonadotoxic 
treatment prior 
to conditioning 
Bu/Cy 
(mg/kg) 
Gonad
al 
failure 
227 m 0.6 10.0 10.5 OP no 20 / 200 no ? 
290 m 5.2 12.1 12.6 FHL no 16 / 200 no ? 
241 m 5.9 12.9 14.8 CID no 20 / 200 no ? 
317 m 6.1 10.9 11.5 X-ALD no 20 / 200 no ? 
245 m 10.7 unknown 19.8 WAS no 16 / 200 no 
358 m 12.4 pre SCT 17.2 MDS no 16/120/mel yes 
357 m 13.2 pre SCT 17.5 SAA no 16/120/mel yes 
432 m 14.0 pre SCT 16.2 X-ALD no 16 / 240 yes 
222 f 2.1 10.9 12.2 AML yes 20 / 200 no ? 
313 f 4.9 not yet induced 11.5 MLD no 16 / 200 yes 
105 f 7.9 11.0 16.1 CID no 16 / 200 no 
411 f 10.2 12.1 (induced) 14.2 MDS yes 16/120/mel yes 
386 f 11.2 pre SCT 15.5 SAA no 16 / 200 yes 
406 f 14.6 pre SCT 18.3 MLD no 16 / 200 yes 
m=male; f=female; pre SCT=in puberty at time of SCT; mel=melphalan 140 mg/m2; ?=less 
than 2 years in puberty; ages are in years; abbreviations of the indication for SCT are 
explained in table 1. 
 
Calcium metabolism 
Calcium metabolism was monitored in 49 patients using serum levels of PTH, 
AP and 25-OH-Vitamin D. Disturbances in calcium metabolism were 
encountered in 17 patients (35%). One patient, treated for autosomal recessive 
SCID (Bu/Cy 8/200 mg/kg), had developed renal Fanconi syndrome during the 
transplantation procedure. In another patient, vitamin D deficiency was 
identified as a probable cause of hyperparathyroidism, and treatment with 
vitamin D resulted in normalization of PTH. One patient had hypocalcaemia 
(serum calcium 2.15 mmol/l) as a possible cause of hyperparathyroidism, but 
although treatment with calcium and vitamin D resulted in normalization of 
serum calcium, PTH remained mildly elevated (6.0–7.5pmol/l). The remaining 
14 patients with sub-clinical hyperparathyroidism (PTH 6.0–21.1 pmol/l) had 
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normal levels of both calcium (median 2.33 mmol/l; range 2.22– 2.55) and 
vitamin D (median 25-OH-Vitamin D 60 nmol/l; range 33–83; reference 30–
120). In five patients, PTH was elevated despite a relatively high serum Ca 
>2.45mmol/l. Six of the 14 patients with hyperparathyroidism were treated with 
calcium tablets and vitamin D3, the others were advised to increase the dietary 
intake of calcium. In two patients treated with D3 and calcium (including the 
patient who initially had hypocalcaemia), PTH levels remained elevated despite 
therapy. 
Other endocrine functions 
Six patients had non transplant-related disturbances of adrenal function (four 
patients with X-ALD and two patients treated with high doses of 
corticosteroids). In the other patients adrenal function was normal. 
Overall, disturbances of growth and/or endocrine functions were encountered 
in as many as 46 patients (72%), with more than one function disturbed in 17 
(26%), even though the follow-up was not always complete for all endocrine 
organs, and gonadal function could not be evaluated in the majority of the 
patients due to the pre-pubertal age. 
Discussion  
The majority of studies have failed to show a negative effect of radiation-free, 
Bu/Cy-based conditioning on growth 1-5, and it is suggested that inadequate 
growth after SCT cannot be attributed to the Bu/Cy conditioning 5. In our study, 
we did not find significant changes in height SDS either, but we did encounter 
unexplained impaired growth or GH secretion in as many as 35% of the 
patients who did not suffer from growth-limiting disorders (malnutrition, chronic 
GVHD, use of steroids, disorders of puberty, hypothyroidism, renal failure and 
gastrointestinal diseases were excluded). We believe that differences in patient 
population (i.e. inclusion of groups II and III) do not explain the differences in 
results between previous studies and the present one, as we found 
unexplained abnormal growth in 39% of the patients treated for a 
haematological malignancy (group I). A more likely explanation for the 
discrepancy is that in the other studies changes in height SDS were 
investigated in groups of patients only, whereas we also considered absolute 
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height SDS and evaluated individual growth patterns. In group analysis, 
impaired growth of one individual can be compensated by catch-up growth in 
another individual. In addition, results can be biased by differences in duration 
and intensity of follow-up, which we avoided by using mixed-effect model 
analysis with grouping of data from individual patients. 
The ultimate end point of studies on growth is final height, but data on final 
height after Bu/Cy-based conditioning are very limited. In a multi-centre study 
from the EBMT on final height after SCT 4 no effect of Bu/Cy on final height 
could be detected. This study, however, included only 10 patients who had 
received Bu/Cy conditioning at a relatively high mean age of 11.7 years, and 
the authors concluded that the number of patients was too small to draw 
unequivocal conclusions. Compared to this EBMT study, the children included 
in the present study were much younger at the time of SCT, which may have 
contributed the differences in the effect of Bu/Cy on growth. Unfortunately, the 
young age at the time of SCT also resulted in the lack of data on final height in 
the present study. 
In 10 of our patients, the impaired growth prompted us to evaluate GH 
secretion status, revealing decreased GH secretion in four of them (one GHD, 
three GHNSD). To our knowledge, GHNSD has never been described in Bu/ 
Cy-conditioned patients without a history of irradiation, whereas GHD has only 
been described once in two such patients 1. From studies in children treated 
with cranial irradiation, it is known that physiological tests of GH secretion are 
more sensitive than pharmacological tests in diagnosing disturbances in GH 
secretion 11;12. The continuing increase in height SDS in both patients treated 
with recombinant GH suggests that impaired growth resulted from GHNSD and 
emphasizes the relevance of physiological tests for GH secretion.  
We found disturbances in thyroid function in 23% of Bu/ Cy-conditioned 
patients. Thyroid dysfunction is a well-known complication in survivors of SCT, 
and is found after TBI as well as radiation-free conditioning 13. The most 
common disorders after radiation-free conditioning are euthyroid sick syndrome 
(ETS, diagnosed in up to 48% of patients) 14 and (compensated) 
hypothyroidism. ETS is most often detected in the first 3–12 months after SCT 
and is often related to complications, including GVHD 15. In our clinic, thyroid 
function is not routinely screened until 12 months after SCT, and tri-
iodothyronine (T3) is only measured on indication (e.g. hypothyroidism). 
Therefore, we have no information on the incidence of ETS in our population. 
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The incidence of (compensated) hypothyroidism in our population (19%) is 
slightly higher than the 10–15% reported in most studies of patients receiving 
radiation-free conditioning for SCT 5;14-17. Of these studies, only Afify et al. 5 
dealt exclusively with children (SCT for AML at a median age of 10.9 years) 
who had received Bu/ Cy-based conditioning, of whom 3/21 (14%) developed 
hypothyroidism. It is possible that the young age at the time of SCT is 
responsible for the slightly higher incidence in the present study, as the thyroid 
gland is believed to be more vulnerable in young children. 
Several mechanisms for the development of hypothyroidism have been 
suggested. One possibility is that it is a direct (toxic) effect of chemotherapy on 
the thyroid gland. If so, the conditioning alone is capable of causing damage, 
as three of the 10 patients with hypothyroidism were not exposed to 
chemotherapy prior to SCT. Another possibility is that it is part of a GVHD-like 
phenomenon, or that chemotherapy induces mild thyroid damage that allows 
immune mechanisms to intervene, resulting in antibody-mediated thyroid 
disease 16. Indeed, Kami et al. 15 found a correlation between acute GVHD and 
hypothyroidism after SCT, and they noticed antibody-mediated hyperthyroidism 
in eight patients (14%), seven of whom later developed compensated 
hypothyroidism. In our population, two patients (4%) developed an antibody-
mediated disorder of the thyroid gland, but neither had manifestations of 
chronic GVHD. Thyroid-specific antibodies were absent in the other 10 
patients, making an antibody-mediated thyroid disorder less likely as the cause 
of compensated hypothyroidism.  
Gonadal damage is a well-known side effect of alkylating agents, such as 
busulphan, cyclophosphamide and melphalan 5. The risk of gonadal failure 
increases with the cumulative doses of gonadotoxic therapies (e.g. radiation 
and/or alkylating agents), as well as with age at the time of therapy in females 
18;19 (probably due to decreased number of primordial follicles). As far as we 
know, the only other data on gonadal function after high-dose busulphan (16–
20 mg/kg) and Cy (200 mg/kg) in children who have not been exposed to 
gonadotoxic therapy prior to conditioning are reported by Couto-Silva et al. 20, 
who described gonadal failure in 2/3 girls who had not received gonadotoxic 
chemotherapy prior to conditioning. Several other reports concern patients with 
thalassaemia, who are at risk of gonadal failure due to iron overload as well 
21;22. Sanders et al. 22 reported that conditioning with Cy (200 mg/kg) did not 
result in gonadal failure in 24 girls and 27 boys receiving SCT for SAA before 
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puberty. Accordingly, in the present study, gonadal failure did not occur with 
the addition of a relatively low dose of busulphan (8 mg/kg) to such 
conditioning in patients with SCID (none of these patients had received 
gonadotoxic therapy prior to conditioning). In contrast, gonadal damage 
occurred in 3/8 boys and 3/4 girls who received 16–20 mg/kg busulphan and 
high-dose Cy without prior exposure to gonadotoxic agents. We therefore 
conclude that high-dose Bu/Cy itself is a major cause of gonadal damage, even 
in the absence of gonadotoxic therapy prior to conditioning. In addition, four of 
the patients who did not develop gonadal failure only recently entered puberty, 
warranting caution with the conclusion of normal gonadal function in these 
children. In girls with preservation of gonadal function, the risk of premature 
ovarian failure is likely to be increased 23. Recovery of gonadal function, 
although rare, has been documented in both sexes 22. Patients should be 
aware of the possibility of premature ovarian failure as well as recovery of 
gonadal function, in view of contraceptive measures and family planning. 
Hyperparathyroidism was found in 35% of our evaluable patients. Probable 
causes were renal Fanconi syndrome in one patient and vitamin D deficiency in 
another. In the remaining 15 patients, hyperparathyroidism occurred despite 
adequate serum levels of calcium and vitamin D. Insufficient intake of calcium 
is a likely explanation for the elevated levels of PTH, but primary (i.e. calcium-
independent) hyperparathyroidism cannot be excluded, especially since 
hyperparathyroidism was present in five patients despite a relatively high 
serum level of calcium and, in addition, suppletion of vitamin D and calcium did 
not result in normalization of PTH in two of the seven patients. Damage to the 
parathyroid glands can result in primary hyperparathyroidism, as is shown in 
patients who have received neck irradiation 24. We speculate that high-dose 
alkylating agents may have similar effects on parathyroid glands, but more 
studies are needed to clarify both the origin and relevance of sub-clinical 
hyperparathyroidism in these patients. In view of the high incidence of sub-
clinical hyperparathyroidism in our population, we suggest that the evaluation 
of calcium metabolism should be incorporated into follow-up protocols after 
SCT, and if necessary, suppletion of calcium and vitamin D should be started. 
In conclusion, our data show that disturbances of both growth and endocrine 
functions are common after radiation- free Bu/Cy-based conditioning for SCT, 
even in the absence of chemotherapy prior to conditioning. We also show that 
impaired growth can be the result of insufficient GH secretion in these patients. 
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In addition, these data show that conditioning with high-dose Bu/Cy can result 
in gonadal failure in children without prior exposure to gonadotoxic 
chemotherapy, and that both hypothyroidism ad hyperparathyroidism 
frequently occur after radiation-free Bu/Cy-based conditioning for SCT. 
Therefore, both growth and endocrine function should be closely monitored in 
these patients. If growth is impaired without apparent explanation, GH 
secretion should be investigated, preferably by physiological testing.  
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Abstract 
To Quality of life (QOL) was assessed in 22 young adults, 14 years -on 
average- after having received bone marrow transplantation (BMT) during 
childhood at the Leiden University Medical Centre. All were disease-free and 
>16 years when interviewed. The sickness impact profile and the Medical 
Outcome Study 36-item Short Form Health Survey were used as generic 
questionnaires in the assessment of QOL. The Functional Assessment of 
Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT) was used as a 
disease-specific measure of QOL. Coping was assessed by means of the 
Utrecht coping list. BMT-related variables were obtained from medical files. Of 
the generic QOL measures, most results fell within the normal range of 
functioning, although some illness-related impairment was reported on 
subscales for general and work-related functioning. Compared to a reference 
sample of patients who had received BMT as adults, patients involved in this 
study scored significantly higher on the ‘emotional well-being’ subscale of the 
FACT-BMT, indicating significantly better emotional functioning. The age at 
BMT and total body irradiation (TBI) were not related to patients’ QOL. We can 
conclude that at long term, having received BMT during childhood does not 
negatively affect the QOL of patients. 
Quality of life after BMT 
 151 
Introduction 
Bone marrow transplantation (BMT) has become a standard treatment option 
for many children with congenital or malignant disorders of the haematological 
system 1. It is an intensive procedure associated with lengthy hospitalisation 
(for some time in protective isolation), and risk of severe pre-treatment and 
treatment-related morbidity 2;3. As the number of survivors of BMT increases, 
the long-term effects of this treatment procedure on the quality of life (QOL) of 
patients and their family members are becoming more important. 
QOL has been defined as ‘the functional effect of an illness and its consequent 
therapy upon a patient, as perceived by the patient’. 4 QOL research has long 
been plagued by a lack of consensus on the definition of the core concepts and 
by a lack of standardisation of assessment tools 5;6. QOL measures include 
generic and disease-specific ones. While generic measures of QOL can be 
used across different patient populations, the disease-specific ones include 
aspects of health (symptoms, impairments, and disabilities) that are relevant to 
patients with a particular disease. The choice of measure to use in an 
investigation into QOL is a difficult one to make 7. Inherent to the assessment 
of QOL are also a number of methodological considerations, including the 
phenomenon of ‘response shift’ (a change in the meaning of an individual’s 
self-reported QOL), that can affect the validity of the measures used 8-11. 
However, despite the ongoing debate on the meaning of QOL, its assessment, 
and its usefulness in health care 5-16, most would argue that assessing the QOL 
when investigating the impact of a clinical intervention provides valuable 
information on patient outcome 17. 
Studies conducted on the QOL of adult BMT recipients have yielded 
contradictory results. While some studies indicate that the QOL of adult 
recipients is relatively unaffected, at long term, others report a wide variety of 
problems, including low energy levels and sleep difficulties, low self-esteem, 
sexual difficulties, psychological distress, and impaired social relationships 18-
25. Two recent reviews highlight these contrasting findings and attribute them, 
in part, to differences in methodology 26;27. 
Notwithstanding the differences in methodology, the reviews point to some 
interesting research findings. Firstly, age at BMT seems to play an important 
role in the QOL of adult BMT recipients, younger BMT recipients doing better 
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following BMT 26. Secondly, TBI dose seems to be related to poorer sexual, 
cognitive, and physical functioning 26. Thirdly, the time post BMT has been 
found to be unrelated to psychosocial status, functional QOL, and affective 
status 26. Fourthly, fatigue, psychological distress, and sexual dysfunction are 
frequently reported following BMT 27. 
The long-term effects of having received BMT during childhood or adolescence 
have hardly been studied. A recent prospective longitudinal study on children 
who received haematopoietic stem cell transplantation (HSCT) indicated that 
both at 1 year and 2 years post HSCT, there was a low prevalence of 
behavioural and social problems in children 28. These findings support the 
results of a recent cross-sectional retrospective study on paediatric patients 
who received a BMT 1–13 years earlier. Most patients (75%) reported no 
physical or psychological impairment 29. Another cross-sectional study revealed 
that young adults who underwent BMT during childhood reported fewer 
problems when compared with their healthy peers with respect to interpersonal 
relationships, sleep, depression, and leisure possibilities, 3-9 years after BMT 
30. On the other hand, they reported more problems with regard to their 
physical appearance, and their studies and work possibilities 30. A fourth cross-
sectional retrospective study revealed that patients who underwent stem cell 
transplantation (SCT) between the ages of 5 and 18 years were at a risk of 
developing long-term emotional or social problems, 2-13 years later 31. In turn, 
a fifth study assessing the behavioural adjustment, QOL, and adaptive 
functioning of children and adolescents, pre- and 6 months post BMT, revealed 
an improvement in overall QOL at 6 months post BMT, and no symptoms of 
serious psychological maladjustment at either pre- or 6 months post BMT (as 
rated by their mothers) 32. 
The aim of this study is to assess the long-term effects of having undergone 
BMT in childhood on QOL in young adulthood. In addition to assessing the 
health-related QOL of young BMT recipients, we included demographic and 
BMT-related variables (e.g. age, gender, age at BMT, intelligence quotient 
(IQ)) into our investigations. Recent studies have indicated that these variables 
may be associated with the QOL of BMT recipients 26;33;34. For example, 
younger BMT recipients have been found to overcome BMT-related toxicities 
more readily than adult BMT recipients, females have been found to be at a 
greater risk of developing sexual problems post BMT, TBI dose has been 
reported to be associated with BMT patients’ cognitive functioning, and higher 
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intellectual ability has been linked to better coping with childhood cancer and 
its treatment 26;33;34. Furthermore, research has indicated that patients’ QOL is 
not determined exclusively by disease-related factors. Psychological 
concomitants of an illness, such as the way in which patients cope with it, have 
been found to play a crucial role 35-39. Thus, in addition to demographic and 
BMT-related variables, we aimed at investigating the role of coping in the QOL 
of young adults who underwent BMT during childhood.  
Patients and methods  
Patients and procedure  
The assessment of QOL was part of a larger investigation into the long-term 
consequences of BMT during childhood. The study was approved by the 
Medical Ethics Committee of the Leiden University Medical Centre (LUMC). 
Individuals who were invited to participate in these investigations were 
recruited from the total number of patients who had received allogeneic BMT at 
the department of Paediatrics of the LUMC between 1968 and January 1993. 
They were selected on the basis of five criteria: 1. having received a (first) BMT 
at least 5 years prior to the study; 2. having been below the age of 18 years 
when receiving BMT; 3. having received BMT on the basis of the indication of 
haematological malignancy or severe aplastic anaemia; 4. being 16 years or 
older when participating in the current study; and 5. the disease being in 
complete remission when participating. 
A total of 61 patients met the selection criteria. In all, 12 patients could not be 
contacted, because they had moved house without leaving a forwarding 
address, or because they had moved to another country. Thus, a total of 49 
patients were invited to participate, of whom 22 participated. Signed informed 
consent was obtained from all participants. The characteristics of both 
participants and non-participants are summarised in table 1. 
The health status of participants was compared to non-participants’ by chart 
review. Health status did not differ between the two groups: 7/22 participants 
suffered from severe transplant-related morbidity (e.g. severe chronic graft-
versus-host disease or secondary neoplasms) compared to 5/27 non-
participants. The reasons for not participating were: the time-consuming nature 
of the study (n=8, 30%), patients attending another hospital for their regular 
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check-ups (n=7, 26%), reasons not given (n=5, 19%), patients not considering 
themselves as being ill (n=4, 15%), and the study being regarded as too 
physically and emotionally taxing (n=3, 11%).  
 
 
 
Table 1 Sample characteristics 
  Participants  Non-participants 
  
N (%) Mean 
(s.d.; median; range) 
 N (%) Mean 
(s.d.; median; range) 
Sex       
- Female  12 (54.5%)   12 (44.4%)  
- Male  10 (45.5%)   15 (55.6%)  
Age (years)   25 (5; 24; 18–32)   22 (5; 21; 18–36) 
Age at BMT (years)   11 (4; 11; 1–16)   11 (3; 12; 5–17) 
Time since BMT (years)   14 (4; 14; 6–21)   11 (4; 11; 6–26) 
Indication of BMT       
- Severe aplastic anaemia   4 (18.2%)   6 (22.2%)  
- Acute myeloid leukaemia  9 (40.9%)   11 (40.7%)  
- Acute lymphoblastic leukaemia  5 (22.7%)   7 (25.9%)  
- Chronic myeloid leukaemia  1 (4.5%)   0 (0%)  
- Myelodysplastic syndrome  2 (9.1%)   2 (7.4%)  
- Non-Hodgkin’s lymphoma  1 (4.5%)   1 (3.7%)  
TBI dose       
- No TBI  3 (13.6%)   2 (7.4%)  
- 4–5 Gy   2 (9.1%)   4 (14.8%)  
- 7–8 Gy  13 (59.1%)   13 (48.1%)  
- 2 x 6Gy  4 (18.2%)   8 (29.6%)  
IQ   110 (16; 81–131)    
 
 
Patients who agreed to participate were invited to attend the LUMC to undergo 
a series of tests and complete a number of questionnaires. Pulmonary function, 
endocrinological variables, ophthalmological variables, and QOL were 
assessed. In this paper, we will report the findings on the patients’ QOL. 
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Results of other investigations (e.g. lung function and renal function) will be 
reported elsewhere. 
Measures Demographic and BMT-related variables 
Patients were asked to report their age and sex and, as a part of the larger 
study, patients’ IQ was assessed by means of the Wechsler adult intelligence 
scale-revised (WAIS-R) 40. Information on patients’ disease characteristics (e.g. 
indication for BMT, age at BMT, use of TBI) was obtained from their medical 
files.  
QOL measures  
As mentioned earlier, choosing the appropriate measure to investigate the 
QOL of a given patient sample is difficult 7. For the purpose of the study 
described here, we chose to assess BMT patients’ QOL by means of two 
widely known generic measures of QOL, with proven reliability and validity, in 
addition to using a recently developed disease-specific measure of QOL, which 
has not yet been used in a paediatric sample. By this means, we intended to 
benefit from advantages offered by both generic measures (e.g. availability of 
data for comparison across different patient populations and from large 
community samples) and disease-specific ones (greater sensitivity to changes 
in QOL caused by factors associated with a specific health problem) 41. 
Thus, we used two generic QOL measures: the sickness impact profile (SIP) 
and the Medical Outcome Study 36- item Short Form Health Survey (MOS SF-
36) 42;43. The SIP and the SF-36 have proven to be reliable and valid 
instruments, and have been used in a wide variety of patient populations, 
including patients with cancer 44-48. The SIP focuses on the impact of an illness 
as reported by the patient, and contains 136 items in 12 categories, from which 
three additional aggregate scores can be calculated (‘physical dimension’, 
‘psychosocial dimension’, and ‘total score’). SIP scores are presented as 
percentages of maximal dysfunction ranging from 0 to 100, higher scores 
indicating higher level of dysfunction 42. SIP scores lower than 6 indicate no 
impairment, scores between 6 and 10 are indicative of mild impairment, scores 
between 15 and 20 indicate moderate to severe impairment, and scores above 
20 are indicative of severe illness-related impairment 49. The MOS SF-36 
comprises 36 items in eight functional dimensions: ‘physical functioning’, ‘role 
functioning - physical’, ‘bodily pain’, ‘general health’, ‘vitality’, ‘social 
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functioning’, ‘role functioning - emotional’, and ‘mental health’. The raw scores 
are transformed in order to obtain a 0–100 scale, higher scores indicating 
better functioning 43. 
To assess the disease-specific QOL of BMT patients, we used the 4th version 
of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant 
Scale (FACTBMT) 50. It is a valid and reliable measure of QOL in BMT patients 
50;51. The FACT-BMT consists of the 35-item Functional Assessment of Cancer 
Therapy (FACT-G) and a 12-item Bone Marrow Transplantation Subscale 
(BMTS). The latter assesses specific BMT-related issues. The FACT-BMT 
assesses the effects of cancer therapy on patients in four areas: physical well-
being, social/family well-being, emotional well-being, and functional well-being. 
A higher score indicates better QOL. 
In addition, we assessed the strategies patients used to cope with problems in 
daily life by means of the Utrecht Coping List (UCL) 52;53. The UCL is a reliable 
and valid Dutch questionnaire consisting of 49 items that are categorised into 
seven scales: ‘seeking distraction’, ‘expressing emotions’, ‘seeking social 
support’, ‘avoiding’, ‘fostering reassuring thoughts’, ‘passive coping’, and 
‘active coping’. Patients were asked to rate how often they adopted certain 
coping behaviours on a four-point scale, ranging from ‘seldom/never’ to ‘very 
often’. Higher scores indicate a more frequent use of a given coping strategy.  
Statistical analyses  
Firstly, to investigate the impact of having received BMT in the past on patients’ 
QOL, we compared patients’ scores on the SIP, MOS SF-36, FACTBMT, and 
UCL, to the scores of reference samples, by means of t-tests. Secondly, we 
conducted simple Pearson correlation analyses between patients’ demographic 
and BMT-related variables, and patients’ scores on the SIP, MOS SF-36, 
FACT-BMT, and UCL.  
Results 
Sample characteristics  
Table 1 describes the characteristics of the sample involved in the current 
study. The sample consisted of 12 females (54.5%) and 10 males (45.5%) with 
a mean age of 25 years (s.d.=5; range=18–31 years) and a mean IQ score at 
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the time of assessment of QOL of 110 (s.d.=16). The mean age at which the 
patients had received BMT was 11 years (s.d.=4). All patients received 
allogeneic transplants. Conditioning for BMT consisted of cyclophosphamide 
(60 mg/kg once daily for 2 consecutive days), in most patients combined with 
TBI. TBI was delivered by a linear accelerator with energies of either 5.0 or 
6.0MV, and at a midline instantaneous dose rate of approximately 23 cGy/min. 
Patients receiving BMT for SAA received either no TBI or 4 Gy single-fraction 
TBI. One patient, receiving BMT for MDS in the first year of life, received 5 Gy 
single-fraction TBI. The remaining patients received either a single fraction of 
7.5-8.0 or 12 Gy in two fractions. 
Generic QOL  
Compared to reference data from randomly selected Dutch individuals (n=192), 
between the ages of 18 and 30 years, who were interviewed as part of a 
validation study (n=594) of the Dutch version of the SIP 54, the scores of BMT 
patients did not differ significantly from those of reference individuals, except 
on the aggregate ‘total score’ of the SIP, with BMT patients functioning worse 
than reference individuals. Furthermore, the scores of BMT patients on the 
‘work’ subscale of the SIP fell into the ‘severe illness-related impairment’ range 
of SIP scores (7/22 BMT patients scored 30 or higher on the ‘work’ subscale; 
table 2). Of the BMT patients involved in this study, three were unemployed, of 
whom one was unable to work because of a physical handicap. The remaining 
participants were either employed or were fulltime students. 
When compared to healthy reference Dutch individuals, ages 25-34 years 
(n=221), who were involved in a study on the validation of the Dutch version of 
the MOS SF-36 55, the scores of BMT patients again did not differ significantly 
from those of reference individuals, except where general health was 
concerned. BMT patients scored significantly lower on the ‘general health’ 
subscale (18/22 BMT patients scored 75 or lower on this subscale), indicating 
significantly worse functioning (table 3). 
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Table 2. Mean scores (and standard deviations) of BMT patients (n=22) compared to 
the scores of a reference sample of randomly selected Dutch individuals (n=192) 54 on 
the sickness impact profile. 
SIP BMT patients 
Mean (s.d.) 
Reference individuals 
Mean (s.d.) 
  t 
Sleep and rest 4.4(7.2) 2.8 (5.5) 1.0 
Eating 0.9(2.1) 0.9 (2.8) — 
Work 20.4(29.7) 6.7 (19.4) 2.1 
Home management 5.6(10.3) 1.2 (5.5) 2.0 
Recreation and pastimes 5.4(8.9) 4.2 (9.7) 0.6 
Ambulation 2.3(5.9) 0.5 (2.8) 1.4 
Mobility 1.2(3.3) 0.5 (2.8) 1.0 
Body care and movement 1.7(2.5) 0.5 (1.4) 2.2 
Social interaction 4.2(5.1) 2.1 (5.5) 1.8 
Alertness behaviour 4.8(10) 2.7 (6.9) 1.0 
Emotional behaviour 5.6(7.9) 3.0 (6.9) 1.5 
Communication 0.4(1.9) 0.6 (2.8) -0.4 
Physical dimension 1.6(2.6) 0.5 (1.4) 2.0 
Psychosocial dimension 3.8(4.4) 2.1 (4.2) 1.7 
Total score 3.9(3.9) 1.7 (2.8) 2.6** 
** P<0.01. 
 
 
Table 3 Mean scores of BMT patients (n=21) and of a reference sample of randomly 
selected Dutch individuals (n=221) 55 on the Medical Outcome Study Short Form Health 
Survey 
MOS SF-36 BMT patients 
Mean (s.d.) 
Reference individuals 
Mean (s.d.) 
  t 
Physical functioning 80.4(24.4) 89.5 (17.8) -1.7 
Role functioning-physical 73.8(33.0) 82.5 (32.4) -1.2 
Bodily pain 83.4(19.0) 84.1 (23.9) -0.2 
General health 62.9(16.1) 77.5 (19.7) -3.9*** 
Vitality 61.4(17.4) 69.1 (19.0) -1.9 
Social functioning 79.2(22.5) 90.7 (16.5) -2.3 
Role functioning-emotional 90.0(21.9) 86.8 (29.6) 0.6 
Mental health 75.6(13.3) 78.8 (17.5) -1.0 
*** P<0.001. 
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Disease-specific QOL  
Compared to a sample of 56 adults who received a BMT in adulthood 
participating in a prior study by Kopp et al. (mean age=34.01, s.d.=9.73; mean 
time from BMT until study (in months)=44.82, s.d.=38.56) 51, patients involved 
in the current study scored significantly higher on the ‘emotional well-being’ 
subscale, indicating significantly better emotional functioning (table 4).  
We were unable to compare our results on the FACT Total (Fact-G) and the 
BMTS to the findings of Kopp et al. 51, because we used the fourth version of 
the FACT-BMT, as opposed to Kopp and colleagues who used the third 
version of this assessment scale. The fourth version of the FACT-BMT includes 
an additional subscale (relation with doctor), and incorporates 12 items in the 
calculation of the BMTS, whereas in the third version only 10 items are scored. 
 
 
Table 4 Scores of BMT patients (n=21) on the Functional Assessment of Cancer 
Therapy-Bone Marrow Transplant Scale (FACT-BMT) compared to those of a reference 
sample of adult BMT recipients (n=56) 51 by means of t-tests. 
FACT-BMT 
BMT patientsa 
Mean (s.d.) 
Reference individualsb 
Mean (s.d.) 
  t 
Physical well-being (0–28) 23.9 (3.8) 21.1(7.0) 2.2 
Social/family well-being (0–28) 22.4 (3.6) 20.1(5.3) 2.2 
Emotional well-being (0–24) 22.0 (3.5) 15.6(4.3) 6.7*** 
Functional well-being (0–28) 21.1 (2.6) 20.5(5.7) 0.6 
FACT total (FACT-G) (0–108) 89.4 (10.7) — — 
BMTS (0–40) 31.3 (6.0) — — 
*** P<0.001. 
a One patient did not complete the FACT-BMT. 
b Kopp et al. 51  used the third version of the FACT-BMT, which included an additional subscale 
(‘relationship with doctor’), relative to the fourth version that we used in the study described here. 
Furthermore, in the third version of the FACT-BMT, 12 items are scored in the calculation of the 
BMTS, whereas in the fourth version, only 10 items are scored. Therefore, it was not possible to 
compare our results on the FACT-G and the BMTS with those of Kopp et al. 51 
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Coping 
We compared the scores of BMT patients on the UCL to healthy Dutch 
students (n=55, ages 20–30 years) involved in a validation study of this 
questionnaire 53, and found that BMT patients scored significantly lower on the 
‘passive coping’ and ‘fostering reassuring thoughts’ subscales of the UCL, 
indicating a less frequent use of these coping strategies compared to reference 
individuals (table 5).  
 
 
Table 5. The scores of BMT patients (n=21) a on the Utrecht Coping List (UCL) 
compared to those of healthy reference individuals (n=55) 53 by means of t-tests 
UCL subscales 
BMT patients 
Mean (s.d.) 
Reference individuals 
Mean (s.d.) 
    t 
Active coping 17.5(3.3) 19.2 (3.7) -1.9 
Seeking distraction 16.0(3.7) 18.3 (3.1) -2.5 
Avoiding 15.3(2.1) 15.8 (3.5) -0.8 
Seeking social support 12.7(3.2) 14.9 (4.2) -2.4 
Passive coping 9.2(2.4) 12.5 (2.7) -5.2*** 
Expressing emotions 6.1(1.7) 7.0 (1.8) -2.0 
Fostering reassuring thoughts 10.7(1.9) 13.2 (2.7) -4.5*** 
*** P<0.001. 
a One patient did not fill in the UCL. 
 
 
 
Correlations 
Patients’ scores on the QOL measures (FACT-BMT, SIP, and MOS-36) were 
significantly correlated with each other in a comprehensible and predictable 
manner (table 6).  
Demographic and BMT-related variables (age, sex, age at BMT, time since 
BMT, indication BMT, TBI dose, IQ) were not significantly correlated with 
patients’ QOL or with their coping behaviour as assessed by the UCL, except 
where age at BMT was concerned. The younger the patients were at receiving 
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BMT, the more they are inclined at expressing their emotions as a coping 
strategy (r= -0.63, P<0.01). Finally, seeking social support as a means of 
coping with stress was significantly positively related to the emotional 
component of BMT patients’ role functioning (r=0.63, P<0.01), whereas passive 
coping was significantly negatively related to patients’ mental health (r= -0.67, 
P<0.01). 
 
 
Table 6. Correlations between the measures of BMT patients’ quality of lifea 
 1 2 3 4 5 6 7 8 9 10 11 
SIP 
           
1. total score -           
MOS SF-36 
           
2. Physical functioning -0.75*** -          
3. Role functioning-physical -0.59** 0.72*** -         
4. Bodily pain  0.69***  -        
5. General health -0.68** 0.59**   -       
6. Vitality -0.78*** 0.68** 0.57**  0.64**- -      
7. Social functioning -0.75*** 0.60**   0.61** 0.55**- -     
8. Role functioning-emotional -0.59** 0.63** 0.58**   0.59** -     
9. Mental health     0.69***  0.69** -    
FACT 
           
10. FACT total (FACT-G) -0.70*** 0.66** 0.70***  0.66** 0.64** 0.64** 0.73*** 0.66**   
11. BMTS -0.88*** 0.65** 0.58**  0.64** 0.80**    0.75*** - 
*** P<0.001,  **  P<0.01,  
a Only significant correlations are depicted in this table. 
 
Discussion  
The aim of this study was to assess the long-term effects on QOL of young 
adults who had undergone BMT in childhood. When compared to healthy 
reference individuals, the scores of BMT patients on generic measures of QOL 
were not significantly different from those of healthy individuals. BMT patients 
reported functioning as well as healthy individuals on different aspects of 
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health-related QOL, except where general health and overall functioning were 
concerned, where patients reported worse functioning. These results are in line 
with previous studies on the long-term effects of having undergone BMT during 
childhood 28;29;32.  
Where work-related functioning was concerned, our patients reported suffering 
from some illness-related impairment (e.g. working fewer hours per week 
because of illness-related complaints; only being able to do easy/light chores 
due to illness-related impairment; only being able to work continuously for a 
short period of time or having to take regular breaks). In total, three participants 
were unemployed, of whom one was unable to work because of a physical 
handicap. The remaining participants were employed or fulltime students, and 
reported some problems in their work-related functioning, which they 
considered to be related to their having undergone BMT during childhood. 
These findings are in line with Barrera and colleagues 32, who reported that 
young adults, who underwent BMT during childhood, experienced more 
problems, compared to their peers, with regard to their studies and work 
possibilities.  
When compared to adults who underwent BMT during adulthood, BMT patients 
involved in the current study, scored significantly better on a disease-specific 
measure of emotional well-being, indicating better emotional functioning. 
Despite the problems involved in comparing adult BMT recipients to childhood 
BMT recipients, this finding could illustrate the role of age at receiving BMT on 
patients’ QOL. As previously reported by Schmidt and colleagues, and later by 
Andrykowski in the review paper, younger patients may overcome BMT-related 
difficulties more readily than older BMT recipients 26;56. However, when we 
investigated whether demographic and BMT-related variables (e.g. age, 
gender, age at BMT, TBI dose) were related to patients’ QOL, we found no 
relationships between these variables and measures of patients’ QOL. Further 
research on QOL following undergoing BMT in childhood could shed more light 
on this topic.  
We also investigated which strategies BMT patients adopted to cope with 
problems they encounter in everyday life. Patients reported coping with their 
problems in quite the same manner as their peers, with the exception that they 
reported adopting less passive coping strategies (e.g. isolating themselves 
from others) and fostering less reassuring thoughts (e.g. telling oneself 
everything will be all right). These findings could be interpreted as reflecting a 
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more positive and mature coping style in childhood BMT survivors relative to 
their peers. Similar findings have been reported in previous studies on 
survivors of childhood cancer 57;58. Furthermore, seeking social support as a 
means of coping with stress was related to better role functioning (emotional 
part), whereas passive coping was related to poorer mental health. These 
results are in line with coping literature 59;60.  
When interpreting the results, a number of limitations of this study should be 
kept in mind. Firstly, the cross-sectional nature of the study described here 
makes it impossible to draw conclusions about causality. Longitudinal studies 
on the long-term effects of receiving BMT are needed. Secondly, the reference 
groups we used in this study merit attention. We compared the scores of our 
BMT patient sample on the FACT-BMT to those of adult BMT recipients. This 
was the best reference published. Thirdly, the low response rate is another 
limitation of this study. As mentioned before, the main reasons for not 
participating were: patients attending another hospital for their regular check-
ups, the time-consuming nature of the study, and the study being regarded as 
too physically and emotionally taxing. We did not attempt to include patients in 
the QOL study, described here, without them participating in the physiological 
measures needed for the larger study. Participating in only one section of the 
large study on long-term consequences of undergoing BMT during childhood 
was not an option. Since information gathered on non-participants via chart 
review showed that they did not differ from participants on demographic and 
BMT-related variables (e.g. sex, age at BMT, time since BMT, TBI dose; table 
1), we believe that the low response rate did not affect the validity of our 
findings. However, participants and non-participants could have differed on 
other important variables such as on their way of coping with BMT. Finally, the 
relatively small number of participants, and the relatively large number of 
variables we investigated could be considered another limitation.  
Notwithstanding these limitations, an important finding of this study pertains to 
the apparently adequate adaptation of the patients to such an intensive 
medical procedure as receiving BMT. Future research should focus on 
identifying patients at risk for developing a maladaptive response to BMT. This 
would help refining psychosocial support offered to BMT recipients. Studies 
already conducted on adult BMT recipients could be used as a model for 
developing studies on children receiving BMT 21;61. 
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In this general discussion, the most important long-term endocrine effects of 
haematopoietic stem cell transplantation (HCT) will be discussed, combining 
the results presented in this thesis with other data from the literature. The first 3 
paragraphs discuss growth, growth hormone (GH) secretion and effects of GH 
therapy, followed by 3 paragraphs on ovarian, testicular and thyroid function 
respectively. In the last paragraph, conclusions and recommendations are 
presented. 
Longitudinal growth and final height in recipients of HCT 
Longitudinal growth is a complex process that is influenced by genetic, 
metabolic, hormonal, nutritional and emotional factors. Disturbances of any of 
these factors can lead to impaired growth. Impaired growth has long been 
recognised as an important side effect of HCT 1, and many factors may 
contribute to this delay, e.g. anorexia, graft-versus-host disease (GVHD) of the 
intestine, use of glucocorticosteroids, hypogonadism, hypothyroidism, growth 
hormone deficiency (GHD), growth hormone resistance caused by growth plate 
damage. When growth ceases and the epiphyseal growth plates close, final 
height, the end result of longitudinal growth, is reached. The influence of 
impaired growth on final height depends on the capacity for catch-up growth, 
which is determined by both the cause and the duration of impaired growth 2.  
Only recently data on final height after HCT were published (chapters 5 and 7 
included)  3-8. These data confirm that radiation is the major etiological factor in 
impaired growth after HCT, as patients who were not irradiated showed 
virtually no decrease in final height. In an attempt to reduce radiation-induced 
growth impairment, radiation-free conditioning regimens with high doses of 
busulphan and cyclophosphamide (Bu/Cy) have been used, especially in 
young children, but data on final height are limited. Most centres report no 
negative effect of Bu/Cy conditioning on growth several years after HCT 9-11. 
However, in a small number of children without a history of cranial irradiation 
growth is delayed after radiation free, Bu/Cy-Based conditioning 12-14 (see also 
chapter 9). Therefore, larger populations and a longer follow-up period are 
needed to assess the effect of radiation-free Bu/Cy-Based conditioning 
regimens on growth after HCT. 
Of the patients who do receive radiotherapy prior to HCT, the type of radiation 
most often used in conditioning for HCT is total body-irradiation (TBI). In 
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patients receiving TBI, final height standard deviation scores (SDS) are 
approximately 1 to 2 SD lower than the height SDS at the time of HCT 3;5-8 (see 
also chapters 5, 6 and 10) . In contrast to most of the earlier reports on growth 
after TBI 15, final height (FH) data do not support a major beneficial effect of 
fractionation on the reduction of adult height. Decrease in height SDS between 
HCT and FH reported by centres using single fraction TBI (7-8 Gy) 6;8 (see also 
chapter 7) are comparable to that reported by a large centre using fractionated 
TBI 7. In addition, a large multi-centre study found no significant difference in 
either FH or decrease in height SDS between HCT and FH, between 39 
patients receiving single fraction TBI and 39 patients receiving fractionated TBI 
(chapter 5) 5. 
Radiation-induced decrease in height SDS is more prominent in patients 
receiving HCT at a younger age. The influence of age can be explained by the 
higher growth potential at younger ages. By the time final height is reached, 
permanent impairment of growth will therefore lead to a greater decrease in 
height SDS in younger children. In addition, younger children appear to be 
more sensitive to radiation damage, resulting in a faster decrease in height 
SDS in younger children (chapter 7) 8.   
In most studies on final height, decrease in height SDS after TBI is more 
prominent in boys compared to girls 5;7;8;16 (see also chapter 7). The difference 
in loss of height SDS between boys and girls is attributed to blunting of the 
growth spurt. As the absolute height gain during the pubertal growth spurt is 
greater in boys than in girls, significant blunting of this growth spurt will lead to 
a more prominent decrease in final height SDS in boys. Another factor that 
could contribute to the difference in loss of height SDS between boys and girls 
is the timing of puberty after TBI. As hypergonadotrophic hypogonadism is 
much more frequent in girls than in boys 16;17, a great proportion of the girls will 
not enter puberty spontaneously (chapter 6). In these girls, puberty is 
frequently induced with relatively low doses of oestrogens and at a higher age 
compared to the mean age of spontaneous puberty in healthy girls. The late 
introduction of low doses of oestrogens may have a positive effect on final 
height.  
Aetiology of impaired growth after HCT 
As stated earlier, the most important contributor to growth impairment after 
HCT is radiation.  There are several ways in which radiation may lead to 
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impaired growth, some of which are easily detectable and reversible (e.g. 
radiation induced hypothyroidism and hypogonadism). Other ways in which 
radiation leads to impaired growth are by damaging the hypothalamic-pituitary 
axis, resulting in impaired growth hormone (GH) secretion, and, probably more 
importantly, by damaging the growth plate, resulting in GH resistant impaired 
growth.  Other factors contributing to impaired growth after HCT are 
chemotherapy induced hypogonadism, chronic GVHD and, even more 
important, its treatment with glucocorticosteroids.  
Radiation-induced damage to the epiphyseal growth plate 
Besides radiation-induced GHD, radiation-induced damage to the growth plate 
probably plays an important role in impaired growth after HCT as well, as 
impaired growth also occurs after conditioning for HCT with total lymphoid 
irradiation (TLI) or thoraco-abdominal irradiation (TAI), even though the 
hypothalamic-pituitary axis lies outside the irradiated field in these patients 5. 
For obvious reasons, most data on radiation damage to the growth plates 
comes from animal experiments. Local irradiation of long bones with doses 
comparable to those used in TBI, results in massive structural damage of 
epiphyseal growth plates and permanent impairment of longitudinal growth 
18;19. The cause of this impairment of growth is unknown, but recent evidence 
suggests a role for the parathyroid hormone-related peptide (PTHrP), a 
paracrine/autocrine factor that co-ordinates proliferation, differentiation and 
structural integrity in the growth plate. Irradiation decreases the expression of 
PTHrP in growth plate chondrocytes both in vitro (at mRNA level) 20 and in vivo 
(at protein level) 21;22 (see also chapter 3).  In addition to PTHrP, other factors 
will probably also contribute to the damage of the growth plate; therefore, more 
(animal) studies are needed to clarify the mechanisms of radiation-induced 
growth impairment by damage to the growth plate. 
Radiation-induced damage to the hypothalamic-pituitary region 
Irradiation of the hypothalamic-pituitary region can disturb the regulation of GH 
secretion by a yet unknown mechanism 23, with a decrease in spontaneous GH 
pulse amplitude but with preserved pulsatility and diurnal variation 24;25, 
resulting in GHD or GH neurosecretory dysfunction (GHND). In GHND the 
regulation of GH secretion is disturbed and spontaneous GH secretion is 
impaired. GH secretion in response to pharmacological stimuli, used as 
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diagnostic tool for GHD, however, is intact 26. The incidence of radiation 
induced alterations in GH secretion increases with radiation dose and with time 
interval after irradiation 27;28;28-31, with disturbances at the hypothalamic level 
probably preceding those at the pituitary level 32. 
The underlying mechanism of radiation-induced GHD is unknown. Recently a 
possible role for leptin in radiation induced GHD was suggested 33;34. Apart 
from being a satiety signal that plays an important role in energy balance 
regulation, leptin is thought to influence endocrine axes, including suppression 
of GH secretion 35. Brennan et al. found increased leptin levels in adults treated 
with cranial irradiation for childhood acute lymphoblastic leukaemia (ALL), the 
majority of whom had developed GHD 33. They stated that the increase in leptin 
was either caused by GH deficiency or by radiation-induced damage to the 
hypothalamic region, resulting in leptin insensitivity.  Couto-Silva et al. found a 
negative correlation between leptin and stimulated GH secretion after HCT and 
TBI, and suggested that leptin could be used as a marker for radiation induced 
hypothalamic-pituitary lesions 34. Adan et al. also found increased leptin levels 
in patients with GHD after cranial irradiation during childhood (n=90), but in 
contrast to Brennan and Couto-Silva, they found no relation with GH peak 
response to pharmacological stimuli 36. Whatever the cause of radiation-
induced GHD, however, GH replacement therapy should result in significant 
catch-up growth in the absence of other causes of impaired growth (e.g. 
radiation damage to the growth plate). 
GH secretion after HCT 
There is a large variation in the reported incidence of GHD after HCT 37, which 
can be explained by differences in study populations such as different 
conditioning regimens (TBI doses, fractionation, dose rate), different 
proportions of patients with GVHD or a history of cranial irradiation, and 
differences in duration and structure of follow-up.  In addition, various studies 
have used different criteria for the diagnosis of GHD, and many fail to use 
assay specific references 38. Therefore, comparing the results of different 
studies should be done with caution.  
Although GHD and GHND are often related to cranial irradiation prior to HCT, 
they also occur after TBI without a history of cranial irradiation 6;7;10;13;39-47 (see 
also chapter 8). Sanders 15 gathered information from 8 publications on the 
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results of GH secretion tests in 243 TBI patients (prior cranial irradiation 
excluded) and found that GHD was present in 64% of the patients tested, 
whereas we found GHD only in 9% of our TBI treated patients (chapter 8) 47. 
Possible explanations for the low incidence of GHD in our population are the 
use of strict criteria for GHD 38 and the lower total TBI doses used in our 
transplant centre. 
Radiation-free conditioning and GH secretion 
As already stated, impaired growth is not a well-established complication of 
Bu/Cy-Based conditioning regimens, and decreased GH secretion is rare (GHD 
and GHND is reported in six children without a history of cranial irradiation) 13;14 
(see also chapter 9). The high dose of busulphan (which easily crosses the 
blood-brain barrier) was suggested as probable cause of GHD in these patients 
in one report, as the plasma levels in the two patients with GHD were higher 
compared to other children receiving Bu/Cy 13. Afify et al. 11, however, did not 
encounter impaired growth in any of their 23 Bu/Cy patients, even though their 
unique dosage of busulphan (150 mg/m2 once daily compared to the 
commonly used 4 mg/kg divided in 4 gifts) will have resulted in very high peak 
plasma levels of busulphan. Therefore, more data are needed to establish the 
role, if any, of decreased GH secretion in patients conditioned with Bu/Cy. 
Complications in the evaluation of GH secretion after HCT 
The diagnosis of decreased GH secretion is often based on indirect markers of 
spontaneous GH secretion. The most important marker is the GH response to 
pharmacological stimuli, supported by serum levels of IGF-1 and IGFBP-3 and 
by auxological data such as decreased growth rate and an increased body 
mass index (BMI). The correlation between two consecutive GH provocation 
tests is poor in children treated with HCT 34, and the possibility of GHND makes 
GH provocation tests less sensitive in the diagnosis of decreased GH 
secretion. In addition, failure to use assay-specific references may result in 
false positive diagnosis of GHD 48. Serum IGF-1 and IGFBP-3 levels can be 
used to support the diagnosis, but several studies have shown that plasma 
levels of IGF-1 and IGFBP-3 have only limited value in diagnosing GHD after 
low-dose cranial irradiation and TBI 34;36;43;49. In idiopathic GHD, BMI is an 
indirect marker for the decreased GH secretion. Growth hormone, however, is 
only one of many factors influencing BMI; other important factors are nutritional 
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status and leptin. Poor nutritional status can obscure a possible effect of GHD 
on BMI, but in a combined European study nutritional status after TBI appeared 
to be good 50. Although all indirect markers for decreased spontaneous GH 
secretion have a limited value in diagnosing radiation induced decreases in GH 
secretion, in combination (e.g. stimulated GH secretion and serum levels of 
IGF-1 and IGFBP-3) they could be used as an indicator. The best way to 
diagnose disturbances of GH secretion after cranial irradiation, however, is by 
constructing spontaneous GH secretion profiles, which is a costly and time-
consuming method 30;51.  
Value of evaluating GH secretion after HCT 
The influence of GH on longitudinal growth does not only depend on GH 
secretion, but also on the capacity of epiphyseal chondrocytes to respond to 
stimuli from the somatotrophic axis. As radiation may alter this capacity to 
respond to the growth-promoting stimuli (sometimes referred to as GH 
resistance), the relation between GH secretion and longitudinal growth 
becomes less clear. Indeed, in our experience, GH secretion, IGF-1 and IG-
BP-3 do not correspond well with either the magnitude of impaired growth or 
with growth response to GH therapy. Therefore, evaluation of GH secretion 
after TBI and HCT is not only complicated, it also has limited value in predicting 
the response to GH therapy, as the contribution of partial resistance of 
epiphyseal chondrocytes to GH is not known (chapter 8) 47. However, GH is not 
only involved in longitudinal growth, but also in many other processes (e.g. 
bone mass, body composition, regulation of lipid- and glucose metabolism), 
and the effect of severely decreased GH secretion on these processes 
provides additional arguments for the evaluation of GH secretion. We therefore 
believe that GH secretion should be evaluated (using pharmacological tests) in 
children with impaired growth after HCT, in spite of the limited value in 
predicting growth response to GH therapy.  
GH therapy after HCT 
Effects of GH therapy 
In a multi-centre evaluation of growth and final height after HCT 5, changes in 
HSDS between HCT and final height in patients treated with GH were similar to 
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the changes in patients not treated with GH. The authors’ conclusion that GH 
therapy did not influence final height, however, is open for debate. One must 
assume that patients only received GH therapy on indication (e.g. more 
profound growth retardation or decreased GH secretion). Therefore, GH 
therapy was given to a selected sub-population, in which growth is more likely 
to be impaired, and decrease in HSDS is expected to be greater. One could 
argue, therefore, that similarity in height SDS changes may be interpreted as a 
positive result of GH treatment. Furthermore, many patients were treated at a 
time that GH therapy was not readily available, and GH dosages are likely to 
be lower than those used in the last decade, when recombinant human GH has 
become readily available. Most single-centre reports of GH treatment after 
HCT show some positive effect of GH therapy on growth. Some studies show 
restoration of growth without catch-up growth 45;46, whereas others show catch-
up growth as well. 13;40;42. Recently, several centres have reported final heights 
after GH therapy in children with a history of TBI (chapter 8) 47. Using multiple 
regression analysis, Frisk et al. reported an estimated effect of GH therapy on 
height SDS of approximately 0.2 SD for each treatment year 6, whereas 
Sanders et al. report an estimated effect on final height of +0.86 SD 7. In both 
reports children treated with GH were considered GH deficient. We recently 
analysed the effect of GH therapy on growth after pre-pubertal TBI in 20 
patients using a random effects model, which resulted in an estimated effect of 
+1.2 SDS five years after initiation of GH therapy, even though 16 of them 
(80%) were not GH deficient.  
Safety of GH therapy after HCT 
Recombinant human GH is considered as a safe therapeutic agent and the 
general consensus is that it does not increase the risk of malignancies in 
patients with idiopathic GHD. We reported a relapse leukaemia in one of the 23 
patients receiving GH therapy after HCT, compared to six relapses in the 43 
patients not treated with GH (chapter 8) 47. So far, none of the other single-
centre studies on the effect of GH therapy in BMT-patients have reported a 
relapse of the initial disease after onset of GH therapy 6;7;13;40;42;43;45;46;52-54. We 
also reported two secondary malignancies in patients treated with GH (one 
thyroid carcinoma and one osteosarcoma), compared to one in 43 untreated 
patients (malignant schwannoma) (chapter 8) 47. Sanders et al. reported 6 
secondary malignancies in 42 GH treated patients, compared to 8 in 48 
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untreated patients 7. A large study by Sklar et al. 55 on 5-year survivors of 
childhood cancer revealed no evidence that treating survivors of childhood 
leukaemia or non-Hodgkin lymphoma with GH increased the risk of either 
disease recurrence or death. They did, however, observe a slight increase in 
the risk of secondary solid tumours (not secondary leukaemia) in patients 
receiving GH (n=122) compared to those who did not (n=4545), but the number 
of patients was small (6 solid tumours in 122 patients treated with GH; relative 
risk 4.98, 95% CI 1.95-12.74). In patients with other types of malignancy, no 
significant increase in secondary tumours was found. In addition, all six 
secondary solid tumours occured in patients who had received irradiation, an 
important risk factor for both secondary tumours and GH deficiency. Therefore, 
no definite conclusions can be drawn from these data, and further studies will 
be necessary to assess the clinical importance of these findings. It is important 
that the patient and/or his parents are informed about all possible risks and 
benefits of GH treatment before GH therapy is given to survivors of HCT. 
Ovarian function 
After a fixed maximum at 5 months gestational age, the number of primordial 
follicles in the human ovary progressively decreases with increasing age in a 
bi-exponential fashion, resulting in the menopause at about the age of 50 years 
56. Both chemotherapy and radiotherapy will accelerate oocyte depletion, 
resulting in premature ovarian failure. 
Effects of chemotherapy 
Radiation-free busulphan-based conditioning regimens are very gonadotoxic. 
In pubertal and post-pubertal females, recovery of gonadal function after 
Bu/Cy-based conditioning is reported in 3 of 125 women (2.4%) 57-59. In 
younger women, incidences of recovery are not much higher. Combining our 
data (chapter 9) with several other reports 10;11;60-62, recovery of gonadal failure 
after Bu-based conditioning is seen in 5.3 % of 75 girls. In contrast to these 
data, Shah et al. conclude that long term endocrine side effects of Bu/Cy 
(16/200 mg/kg) conditioning for leukaemia are minimal 63. In this study, 
however, only 13 of 26 relapse-free survivors (both boys and girls) were tested 
for ‘endocrinopathies’ and gonadal failure was reported in 2 girls using age 
Chapter 11 
178 
specific references for LH and FSH. As this report does not mention sex, age 
or pubertal status of the 13 patients tested, we believe the conclusions drawn 
by the authors are premature.  
Effects of TBI 
Depletion of the number of primordial oocytes after a given dose of 
radiotherapy is proportional to the size of the oocyte pool. As younger patients 
have more oocytes, the number of remaining oocytes after radiotherapy is 
higher in younger patients. Therefore, premature ovarian failure will occur after 
longer post-irradiation intervals in younger patients, giving the impression that 
the cytotoxic effect of radiation on the ovary is less severe in younger women 
64. 
Besides the age at HCT and the radiation dose, cumulative dose of 
gonadotoxic chemotherapeutic agents also influence the incidence of ovarian 
failure. The sparing effect of fractionation of TBI is unclear. As the ovary is a 
radiosensitive organ (radiation dose required to kill 50% of oocytes (LD50) is 
less than 2.0 Gy) 65, the theoretical benefit of fractionation is limited, and 
fractionated TBI may be more damaging due to the higher total radiation dose 
required. In girls receiving TBI before onset of puberty, the number of patients 
without a spontaneous onset of puberty can be used as an indicator of gonadal 
failure (provided that age at TBI does not differ largely between patients). 
Combining the results of single centre studies that report incidences of 
spontaneous pubertal development after pre-pubertal TBI-based conditioning, 
using the most recent publication with useful information for each centre, yields 
the following results: the incidence of spontaneous puberty after 10 Gy sf-TBI 
(29 patients) is 41 % 61;66;67, whereas after 12-15.75 Gy f-TBI (63 patients) it is 
43% 17;61;67;68. In our centre, relatively low doses of sf-TBI are used (7-8Gy), 
which resulted in spontaneous onset of puberty in 6 of 10 (60%) patients 
(chapter 6). Frisk et al. also used 7.5 Gy sf-TBI. They reported induction of 
puberty in 3 of 6 girls (50%) receiving TBI before puberty 6. 
In females receiving TBI-based conditioning during or after puberty, recovery of 
ovarian function after TBI can be used as an indicator of gonadal damage. The 
only study correcting for age at TBI in multiple regression analyses, reported a 
4.8 times higher likelihood of recovery from initial ovarian failure after 6 x 2.0 
Gy f-TBI compared to either 10 Gy sf-TBI or 7 x 2.25 Gy f-TBI 69. The number 
of patients in this study, however, is limited, with recovery of gonadal function 
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in patients who received TBI at ages ≤ 25 years only (9 recovered: 7 of 29 after 
12 Gy f-TBI; 2 of 36 after 10 Gy sf-TBI; 0 of 11 after 15.75 Gy f-TBI). In 
addition, the same authors reported recovery in 18 of 61 women (30%) after 8-
10 Gy sf-TBI, 28 of 272 (10%) after 10-12 Gy f-TBI and 11 of 203 (5%) after 
14-15.75 Gy f-TBI 15. Unfortunately, in this report age at TBI was not reported, 
but unless the sf-TBI patients were significantly younger at the time of TBI, 
these data do not support a beneficial role of fractionation of TBI dose for 
gonadal function.  
Based on the available data, there is insufficient evidence for a sparing effect 
of fractionation on the ovaries. A large (multi-centre) study, correcting for age 
at TBI, is needed to clarify this issue. 
Testicular function 
Of the three major cell types in the human testis (germ cells, Leydig cells and 
Sertoli cells), the germ cells are the most sensitive to cytotoxic effects of 
radiation and certain types of chemotherapy, especially alkylating agents, with 
a higher sensitivity in more primitive cell types (i.e. spermatogonia > 
spermatocytes > spermatids) 70;71. 
Recovery of spermatogenesis occurs from surviving stem cells, and duration of 
azoospermia is dose-dependent and may last several years, with only partial 
recovery after higher doses 70;72. There is evidence that recovery of 
spermatogenesis is more likely if males are treated before onset of puberty 
72;73. 
 Effects of Chemotherapy 
In men receiving radiation-free conditioning for HCT, Sanders et al. reported 
evidence of sperm production in 61% of patients receiving cyclophosphamide 
only (Cy, 200 mg/kg, n=109), and in 17% of patients receiving Cy (200 mg/kg) 
and busulphan (Bu, 16 mg/kg, n=46) 57. Although the addition of Bu probably 
accounts for much of this difference in incidence of recovery of 
spermatogenesis, other chemotherapeutic agents could also contribute to the 
difference, as indication for HCT may have influenced the type of conditioning, 
e.g. Cy in patients with severe aplastic anaemia and Bu/Cy in patients with 
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haematological malignancies (the latter group probably had received 
gonadotoxic agents prior to conditioning).  
Grigg et al. reported a higher incidence of recovery of spermatogenesis after 
radiation-free, Bu/Cy-Based conditioning with lower doses of Cy (Bu 16 mg/kg, 
Cy 120 mg/kg) in adults who had not received prolonged therapy with 
alkylating agents 58. In this study, sperm was detectable in semen of 21 of 26 
patients with semen analyses (11 had sperm count >20x106/ml). There was a 
negative correlation between serum levels of FSH and sperm count. In 
addition, in 6 of 21 patients without semen analyses recovery was based on 
successful procreation, with normal FSH levels in 4 of the 15 remaining 
patients. Differences in doses of cytotoxic agents, duration in follow-up (median 
2 versus > 5 years), or gonadotoxic treatment prior to conditioning may 
account for differences in recovery between the two studies. All other studies 
on testicular function after radiation-free, Bu/Cy-Based conditioning have 
limited numbers of patients and do not report semen analysis. In our own 
Bu/Cy population, all 4 boys who had received low dose Bu/Cy (8 mg/kg Bu) 
and 2 of the 5 boys receiving high dose Bu/Cy (16-20 mg/kg Bu) with at least 2 
years of follow-up during puberty, had recovery of gonadal function after 
Bu/Cy-Based conditioning without prior gonadotoxic treatment (chapter 9). 
Leydig cell function is normal in most patients after Bu/Cy (chapter 9), although 
in some patients, LH is slightly elevated and serum testosterone is in the lower 
range of the reference interval, suggesting some Leydig cell dysfunction 10;11. 
Effects of TBI 
The germinal epithelium is one of the most radiosensitive human tissues, and 
azoospermia occurs after a single radiation dose of 0.8 Gy 74. Complete 
recovery of spermatogenesis will take more than 9 months after 1 Gy, with time 
to recovery increasing with increasing radiation dose (e.g. > 5 years after 
doses of 4 Gy and higher). Both animal and human data suggest that 
fractionation increases gonadal toxicity of radiation 71;75. Recently, two reviews 
have addressed the issue of recovery of spermatogenesis after TBI-based 
conditioning, and both report that the chance of recovery is small 37;76. One 
review suggested a higher incidence of recovery after sf-TBI compared to f-TBI 
37. However, Sanders et al. reported comparable incidences of recovery of 
spermatogenesis after sf-TBI and f-TBI: 20% of 71 males receiving 10 Gy sf-
TBI % and 17% of 392 males receiving 12-15.75 Gy f-TBI 57. In theory, patients 
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receiving relatively low dose (7-8 Gy) sf-TBI before onset of puberty should 
have the highest incidence of recovery of spermatogenesis. In our study 
population, however, only 1 of 13 boys receiving TBI before onset of puberty 
showed evidence of recovery of spermatogenesis (chapter 6), even though 10 
of 13 received 7-8 Gy sf-TBI. Three possible explanations for this low incidence 
are 1) the small size of the population, 2) the use of a high instantaneous dose 
rate (0.23 Gy/min) and 3) differences in additional gonadotoxic effects of 
chemotherapy prior to conditioning in our patients compared to those in the 
studies of Sanders et al.  
Leydig cell damage occurs after a single dose of 0.75 Gy or fractionated total 
dose of 2 Gy in adults, resulting in transient elevation of LH but unchanged 
testosterone levels 74;77. After radiation doses of 14-20 Gy to testes of patients 
with carcinoma in situ, Leydig cell dysfunction is often permanent 78;79, with 
elevated LH levels and testosterone at the lower limits of the reference interval. 
After doses of 18 to 20 Gy, 29% of adult patients required permanent 
testosterone substitution 80. Recovery of Leydig cell function, however, can be 
seen after total doses as high as 24 Gy 66. In contrast to germ cells, Leydig 
cells appear to be more radiosensitive in pre-pubertal males compared to adult 
males 73, resulting in severe hypogonadism in most boys receiving 20 Gy 
testicular irradiation before puberty. In our clinic, all patients who had received 
10 Gy testicular irradiation in addition to sf-TBI had severe Leydig cell failure, 
resulting in hypergonadotrophic hypogonadism and absent pubertal 
development or pubertal arrest (chapter 6 and unpublished data). 
Thyroid function 
Both chemotherapy and radiation can result in thyroid dysfunction, with 
compensated primary hypothyroidism in the majority of the patients. The 
incidence of thyroid dysfunction found in the different studies, however, is 
influenced by many other factors besides conditioning regimen, e.g. duration of 
follow-up, definition of compensated hypothyroidism, follow-up protocol 
(standard performance of TRH test at regular times versus symptoms-based 
screening) etcetera. 
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Effects of chemotherapy 
After radiation-free conditioning, (compensated) hypothyroidism occurs in 10-
15 % of both children 10;11;81 and adolescents 59;82-85. In addition, Somali et al. 
describe exaggerated TSH responses to TRH in 61% of patients after 
radiation-free conditioning 85. As they defined exaggerated response as more 
than 5-fold increase in TSH from baseline without any consideration for the 
absolute levels of TSH, this figure is likely to be an over-estimation of thyroid 
dysfunction in these patients. 
Effects of TBI 
There is some evidence that fractionation of TBI has a sparing effect on thyroid 
function, but reported incidences of thyroid dysfunction show a large variation 
between different centres. After fractionated TBI, some centres report 
incidences of 10-20 % 84;86 whereas others report 30-35% 87;88. After sf-TBI 
thyroid dysfunction is more common, with incidences up to 87% reported by 
Borgström et al. 89. In that study, the diagnosis of (compensated) 
hypothyroidism was based on basal values of TSH and free T4 in 48% of 27 
patients after 10 Gy sf-TBI. An additional 41% had exaggerated TSH 
responses to TRH stimulation. Other studies using 9-10 Gy sf-TBI report 
incidences of hypothyroidism of 46-73 % 88;90;91. 
In our single centre evaluation (chapter 4), the incidence of thyroid dysfunction 
after sf-TBI was just 11% in 18 patients. Reviewing the data of all patients in 
the various studies presented in this thesis, thyroid dysfunction after 7-12 Gy 
sf-TBI was diagnosed in 40% of 96 patients (unpublished data). These data 
support a role for fractionation of TBI in the preservation of thyroid function. 
Conclusions and recommendations 
Growth and GH secretion 
In the majority of the patients receiving radiation-free conditioning for HCT, 
growth will not be impaired. Some patients, however, do suffer from impaired 
growth, and GHD could be diagnosed in few of these patients. Therefore, 
growth should be monitored closely after radiation-free conditioning for HCT, 
and further testing for GHD should be performed if growth is impaired. The use 
of radiation-based conditioning regimens in the preparation for HCT often leads 
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to impaired growth, which is a combined result of decrease in GH secretion 
due to radiation-induced damage to the hypothalamic-pituitary region and GH 
resistance due to radiation-induced damage to the epiphyseal growth plate. 
The value of standard tools for the diagnosis of decreased GH secretion is 
limited and the evaluation of GH secretion is not helpful in predicting growth 
responses to GH therapy. As decreased GH secretion has consequences for 
other metabolic processes as well (e.g. peak bone mass), Shalet et al. 
suggested that GH replacement therapy should be considered in all patients 
with GH deficiency, irrespective of auxology 92. In children treated with HCT, 
GH secretion should be analysed by pharmacological tests if impaired growth 
is present. Due to radiation-induced growth plate damage, the results of these 
analyses are not related to the growth response to GH therapy, and patients 
with normal stimulated GH secretion may benefit from GH therapy (chapter 8) 
47. Therefore we would suggest that a one-year trial-period of GH therapy 
should be considered in all patients with impaired growth after TBI, irrespective 
of GH secretion status. 
Gonadal function 
The majority of children receiving TBI and/or high-dose chemotherapy during 
conditioning for HCT will suffer germ cell damage, resulting in premature 
ovarian failure in girls and impaired spermatogenesis in boys. Overt Leydig cell 
failure occurs after higher doses of irradiation and/or chemotherapy. Therefore, 
hypogonadism in boys is generally associated with additional gonadotoxic 
treatment (e.g. prophylactic testicular irradiation). We recommend routine 
screening for hypogonadism after HCT in all patients, with prompt initiation of 
sex hormone replacement therapy in cases with either hypergonadotrophic 
hypogonadism or delayed puberty. In view of the high incidence of infertility, we 
recommend attempts to preserve fertility using semen cryopreservation in all 
adolescent boys before initiation of gonadotoxic treatment. In girls, 
cryopreservation of ovarian cortical strips is an option, but expertise in both 
preservation and re-implantation techniques are very limited, and restoring 
fertility from cryopreserved ovarian tissue is still experimental 64. In addition, in 
patients treated for a haematological malignancy, the risk of re-introducing 
malignant cells by re-implantation of ovarian tissue is of great concern. 
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Thyroid function 
In view of the high risk of (compensated) hypothyroidism, which appears to 
increase with time since HCT, we recommend evaluation of thyroid function at 
regular intervals in all patients after HCT. Although interesting from a scientific 
point of view, standard dynamic testing of the hypothalamus-pituitary-thyroid 
axis is not recommended, as it has no therapeutic consequences. Substitution 
with levothyroxine is indicated in patients with overt hypothyroidism and 
recommended in patients with compensated hypothyroidism (the latter in an 
attempt to reduce the risk of thyroid malignancy and/or developmental delay) 
37. 
Fractionation of TBI 
Endocrine late effects of HCT occur in the majority of patients receiving HCT, 
especially if TBI or busulphan based conditioning regimens are used. 
Fractionation of TBI may decrease the incidence of (compensated) 
hypothyroidism, but a sparing effect of fractionation is not evident for gonadal 
function or final height. As radiation induced thyroid dysfunction is limited to 
compensated hypothyroidism in most patients, and hypothyroidism is easily 
correctable with substitution therapy, we believe that late effects of the 
endocrine system do not offer solid grounds for the introduction of fractionated 
TBI in our clinic. 
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This thesis contains the results of several studies on the long-term 
consequences of the myeloablative conditioning for haematopoietic stem cell 
transplantation (HCT) during infancy and childhood, with the emphasis on late 
effects on endocrine functions.  
 
Chapter 1 gives a general introduction to late effects after HCT. First, the 
etiological roles of chronic graft-versus-host-disease and conditioning regimens 
are discussed, and some background information on the basic aspects of the 
radiobiology of total-body irradiation (TBI) is given. In addition, the most 
important endocrine late effects are briefly introduced. 
Chapter 2 describes the effects of TBI as single toxic agents on growth, 
pituitary and thyroid gland in non-human primates. TBI had a negative effect on 
body fat. There was no evidence of (compensated) hypothyroidism, but dose 
dependent decrease in thyroid weight and changes in follicular structure 
suggest some effect of TBI on the thyroid gland. The decreased IGFI/IGFBP-3 
ratio in the high-dose group may indicate that the somatotrophic axis was 
mildly affected by TBI. 
In chapter 3 the direct effects of radiation on the tibial growth plate of rats are 
studied. Radiation resulted in persistent growth delay of the irradiated tibiae, 
with a difference in length of more than 10% between the irradiated and the 
non-irradiated tibiae 15 weeks or more after irradiation. The growth plate 
architecture was disturbed, and the expression of both PTHrP and IHh was 
decreased in the irradiated tibiae. As PTHrP and IHh are key regulators of both 
the pace and the synchronisation of the differentiation of growth plate 
chondrocytes, the reduced expression of PTHrP and IHh may contribute to the 
changes found after irradiation. 
In chapter 4 results of a cross-sectional study on both endocrine and non-
endocrine late effects of HCT during childhood are presented in a population of 
adult survivors of childhood HCT. Final height was reduced, with a median 
reduction of 1.6 SDS compared to height SDS at time of HCT as well as 
compared to the target height.  The majority of the girls developed gonadal 
failure, with recovery in 2 of them. Reproductive gonadal function was 
decreased in the majority of the men. Hypothyroidism was diagnosed in 10% of 
patients. Osteopenia was found in 68% of patients, osteoporosis in 10%. 
Restrictive lung function was present in 67%; renal function was normal in all 
patients. Cataract was diagnosed in 79 % of patients who had received TBI, 
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the majority of these did not receive eye shielding during TBI. These data give 
some insight in the late effects in our centre. 
Chapter 5 describes results of a large multi-centre study on final height after 
HCT before onset of puberty. Data on 181 patients with aplastic anaemia, 
leukaemia, and lymphoma were analysed. An overall decrease in final height 
standard deviation score (SDS) was found compared to height SDS at HCT 
and to genetic height SDS. Irradiation, male gender and young age at HCT 
were major factors contributing to decreased final height. The combination of 
previous cranial irradiation and single-dose TBI caused the greatest negative 
effect on final height. Fractionation of TBI reduces this effect significantly and 
conditioning with busulphan and cyclophosphamide seems to eliminate it. 
Nevertheless, the majority of patients (140/181) have reached adult height 
within the normal range of the general population. 
In chapter 6 results of a study on the pubertal development and growth of 40 
children receiving TBI and HCT for haematological malignancies are 
presented. In the 19 boys who had not received additional testicular irradiation, 
penile growth and pubic hair development was normal and all had serum 
testosterone levels within the adult range. The majority of them, however, had 
incidental elevations of LH, suggesting minor Leydig cell damage. Testicular 
volume at the last measurement was small (mean: 10.5 ml) and serum FSH 
levels were elevated in all boys, suggesting severe impairment of reproductive 
gonadal function. Normalisation of FSH occurred in one boy. Puberty 
developed spontaneously in 6/10 girls who received HCT before puberty. In the 
remaining four girls, puberty was induced after they had developed 
hypergonadotrophic hypogonadism. Recovery of gonadal function after 
cessation of substitution was seen in one girl, who became pregnant twice 
(both pregnancies ended in spontaneous abortions). Decrease in height SDS 
was seen in the majority of patients and was positively correlated with male 
gender and lower age at the time of HCT. We concluded that careful 
monitoring of both gonadal function and growth after bone marrow 
transplantation and total body irradiation is warranted in order to detect 
disturbances early and ensure normal pubertal development in children treated 
for haematological malignancies.  
Chapter 7 describes patterns of growth and body proportions of 75 children 
receiving TBI and HCT before onset of puberty. Thirty-two patients had 
reached final height (FH). Median change in height SDS between HCT and FH 
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was -1.7 in boys and -1.1 in girls. Peak height velocity (PHV) was decreased in 
the majority of the patients. Decrease in sitting height SDS did not differ 
between boys and girls (0.15 SD/yr). In boys, decrease in leg length SDS was 
of comparable magnitude (0.12 SD/yr), whereas in girls decrease in leg length 
was less pronounced (0.02 SD/yr), leading to a significant decreased sitting 
height/height ratio SDS in girls only. The sex-specific effects of several 
variables on height SDS (e.g. age at HCT, time since HCT, onset of puberty) 
were analysed by linear mixed-effects modelling, showing a slightly faster 
decrease in younger children, and a more pronounced decrease during puberty 
in boys compared to girls. We conclude that 1) younger children are more 
susceptible to growth retardation after TBI and HCT, 2) pubertal growth is more 
compromised in boys, and 3) leg growth is relatively less affected in girls, 
possibly due to a high incidence of gonadal failure in girls. 
In chapter 8 results of evaluation of growth hormone (GH) secretion in 29 
children with impaired growth after TBI and HCT are presented. Impaired GH 
secretion was diagnosed in 8 patients, and GH therapy (1.33 mg/m2) was 
started in 23 of the 29 patients tested. Height SDS increased in the first year of 
treatment in the vast majority of patients receiving GH (mean increase 0.35 
SDS). The effect of GH therapy was estimated by comparing growth of 
individual patients after onset of GH therapy to the predicted growth based on 
individual growth before onset of GH therapy and the model derived from the 
study described in chapter 7. The calculated net effect of GH therapy on height 
SDS was +1.1 SDS. Response to GH therapy did not correlate to the 
parameters of GH secretion, which suggest that variable degrees of GH 
resistance (due to damage to the epiphyseal growth plates inflicted by the 
irradiation) are probably more important than GH secretion status. As GH 
therapy was effective in patients, irrespective of GH secretion status, we 
propose a trial of GH therapy in all children with impaired growth and expected 
low adult height after TBI. 
Chapter 9 describes growth and endocrine function after busulphan (Bu) 
based conditioning in 64 children without a history of irradiation. Mean height 
standard deviation scores remained stable, but unexplained disturbances of 
growth after HCT were found in 17/48 (35%) of the children without growth-
limiting disorders (10/23 in patients treated for haematological malignancies). 
In 10 patients, growth hormone (GH) secretion status was evaluated, and 
insufficient GH secretion was diagnosed in four patients. Thyroid function was 
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evaluable in 52 patients. Two developed antibody-mediated thyroid disorders 
and 10 (19%) compensated primary hypothyroidism. Gonadal function was 
evaluable in 21 patients and was normal in all seven patients treated with low-
dose Bu (8 mg/kg), whereas seven of the 14 children receiving high-dose Bu 
(16–20 mg/kg) developed gonadal failure; the majority of these patients had 
not been exposed to gonadotoxic therapy prior to conditioning. Of the 49 
evaluable patients, 16 developed subclinical hyperparathyroidism. We 
conclude that, besides gonadal and thyroid dysfunction, impaired growth and 
hyperparathyroidism often occur after busulphan based conditioning for HCT 
and that growth impairment may be the result of insufficient GH secretion. 
In chapter 10 Quality of life (QOL) is investigated in 22 adult survivors of 
childhood HCT, using both generic and disease-specific questionnaires. HCT-
related variables were obtained from medical files. Of the generic QOL 
measures, most results fell within the normal range of functioning, although 
some illness-related impairment was reported on subscales for general and 
work-related functioning. Compared to a reference sample of patients who had 
received HCT as adults, patients involved in this study scored significantly 
higher on the ‘emotional well-being’ subscale of the disease specific QOL 
instrument, indicating significantly better emotional functioning. The age at 
HCT and TBI were not related to patients’ QOL. We conclude that on the long 
term, having received HCT during childhood does not negatively affect the 
QOL of patients.  
In chapter 11 the most important long-term endocrine effects of HCT are 
discussed, combining the results presented in this thesis with other data from 
the literature. At the end of this chapter, conclusions and recommendations are 
given. 
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Dit proefschrift bevat de resultaten van meerdere studies naar de gevolgen op 
langere termijn van myeloablatieve conditionering voor hematopoietische cel 
transplantatie (HCT) op de kinderleeftijd, met nadruk op late effecten op 
endocriene functies.  
 
Hoofdstuk 1 geeft een algemene inleiding op de late effecten na HCT. De rol 
van chronische graft-versus-host ziekte en van de verschillende conditionering 
regimes wordt besproken, en er wordt achtergrondinformatie gegeven over 
basale aspecten van de radiobiologie van totale-lichaams bestraling (total-body 
irradiation, ofwel TBI). Daarnaast worden de belangrijkste endocriene late 
effecten van HCT kort geïntroduceerd. 
Hoofdstuk 2 beschrijft de effecten van TBI als unieke noxe op de groei, de 
hypofyse en de schildklier van rhesusapen. TBI had een negatief effect op de 
hoeveelheid lichaamsvet. Er waren geen aanwijzingen voor (gecompenseerde) 
hypothyreoidie, maar de geobserveerde dosis-afhankelijke afname in 
schildkliergewicht alsmede veranderingen de folliculaire structuur van de 
schildklier doen enig effect van TBI op de schildklier vermoeden. De lagere 
IGFI/IGFBP-3 ratio in de groep apen die een hoge dosis TBI hadden gekregen 
kan wijzen op een beperkt effect van TBI op de somatotrope as van deze 
dieren.   
In hoofdstuk 3 worden de directe effecten van bestraling op de epifysaire 
groeischijf van de tibia van de rat beschreven. Bestraling leidde tot 
persisterende groeivertraging van de bestraalde tibiae, hetgeen na 15 weken 
resulteerde in >10% verschil in lengte tussen de bestraalde en de niet-
bestraalde tibiae. De architectuur van de groeischijf was verstoord, en de 
expressie van zowel PTHrP als IHh was verminderd in de bestraalde tibiae. 
Aangezien PTHrP en IHh beide een sleutelrol spelen in zowel het tempo als de 
synchroniciteit van chondrocyt-differentiatie in de groeischijf, lijkt de 
verminderde expressie van deze para/autocriene factoren te kunnen bijdragen 
aan de beschreven veranderingen na bestraling. 
In hoofdstuk 4 worden de resultaten van een cross-sectionele studie naar 
zowel endocriene als niet-endocriene late gevolgen bij volwassenen die als 
kind een HCT ondergingen gepresenteerd. De mediane reductie van de 
relatieve lengte bedroeg bij eindlengte 1.6 standaard deviatie score (SDS) ten 
opzichte van zowel de lengte ten tijde van de HCT als de streeflengte op basis 
van ouderlengte.  De meerderheid van de vrouwen had gonadaal falen 
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ontwikkeld, met herstel van ovariele functie in twee van hen. Reproductieve 
gonadale functie was verminderd in de meerderheid van de mannen. Tien 
procent van de patiënten had een primaire hypothyreoidie, 68% had 
osteopenia en 10% had osteoporose. Restrictieve longfunctieafwijkingen 
waren bij 67% aanwezig, nierfunctie was normaal bij alle patiënten. Van de 
patiënten die een TBI hadden ondergaan had 79 % cataract ontwikkeld; bij de 
meerderheid van deze patiënten waren de lenzen niet afgeschermd tijdens de 
TBI. De reslutaten van deze studie geven inzicht in de ernst en prevalentie van 
late effecten bij patiënten uit ons transplantatie-centrum. 
Hoofdstuk 5 beschrijft de resultaten van een grote multi-center studie naar de 
eindlengte van kinderen die voor de puberteit een HCT ondergingen. De 
gegevens van 181 patiënten met  aplastische anemie, leukemie of lymfomen 
werden geanalyseerd. Eindlengte SDS was verminderd ten opzichte van zowel 
de lengte SDS bij HCT als de gemiddelde ouderlengte-SDS. Bestraling, 
mannelijk geslacht en een lage leeftijd ten tijde van HCT waren de 
belangrijkste factoren die bijdroegen aan de reductie in eindlengte. De 
combinatie van eerdere craniale bestraling en single-dose TBI had het grootste 
negatieve effect op de eindlengte. Fractionering van TBI reduceerde dit effect 
significant en na conditionering met busulfan en cyclofosfamide leek het effect 
op eindlengte afwezig. Bij de meerderheid van de patiënten (140/181) lag de 
eindlengte binnen de normale grenzen voor de populatie (i.e. tussen –2 en +2 
SDS). 
In hoofdstuk 6 worden de resultaten beschreven van een onderzoek naar de 
puberteitsontwikkeling en groei van 40 kinderen die een TBI en HCT 
ondergingen voor hematologische maligniteiten. Puberteitsontwikkeling was 
normaal bij de 19 jongens die geen additionele testiculaire bestraling hadden 
gekregen, en allen bereikten serum-testosteronspiegels binnen de 
referentiewaarden voor volwassen mannen.  In de meerderheid was het LH 
echter incidenteel verhoogd, suggestief voor milde Leydig cel schade. Het 
testikelvolume bij de meest recente meting was klein (gemiddeld 10.5 ml) en 
serumspiegels van FSH waren verhoogd bij alle jongens, wijzend op een 
ernstige vermindering van de reproductieve gonadale functie. Bij één jongen 
trad normalisatie van het FSH op. De puberteit begon spontaan bij 6/10 
meisjes die voor de puberteit een HCT ondergingen. Bij de overige 4 meisjes 
werd de puberteit geïnduceerd nadat zij hypergonadotroop hypogonadisme 
hadden ontwikkeld. Na het staken van oestrogeensubstitutie bleek van 1 
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meisje de gonadale functie te zijn hersteld. Zij werd tweemaal zwanger, maar 
helaas eindigden beide zwangerschappen in een spontane abortus. Bij de 
meerderheid van de patiënten nam de lengte SDS af met de tijd na HCT. 
Afname correleerde positief met mannelijk geslacht en lagere leeftijd ten tijde 
van de HCT. Geconcludeerd wordt dat de groei en puberteitsontwikkeling 
nauwkeurig gevolgd dienen te worden na HCT en TBI, teneinde verstoringen 
hiervan vroeg te kunnen detecteren en te behandelen.  
Hoofdstuk 7 beschrijft de ontwikkeling van lengte en lichaamsverhoudingen 
van 75 kinderen die een TBI en HCT ondergingen vóór de start van de 
puberteit. Tweeëndertig van hen hadden hun eindlengte bereikt. De mediane 
verandering in lengte SDS tussen HCT en het bereiken van de eindlengte was 
-1.7 SD in jongens en -1.1 SD bij meisjes. De maximale groeisnelheid tijdens 
de puberteit was verlaagd bij de meerderheid van de patiënten. Afname van 
zithoogte SDS verschilde niet tussen jongens en meisjes (0.15 SD/jr). Afname 
van beenlengte SDS was van eenzelfde orde van grootte bij jongens, (0.12 
SD/jr), maar bij meisjes was de afname van beenlengte SDS minder 
uitgesproken (0.02 SD/jr), resulterend in een significante afname van de 
zithoogte:lengte ratio SDS bij meisjes. De geslachtsspecifieke effecten van 
verschillende variabelen op lengte SDS (e.g. leeftijd HCT, tijd sinds HCT, start 
puberteit) werden geanalyseerd met behulp van ‘linear mixed-effects’ 
modellering. Afname van lengte SDS bleek sneller bij jongere kinderen, met 
een meer uitgesproken afname bij jongens ten opzichte van meisjes. Onze 
conclusies: 1) jongere kinderen zijn gevoeliger voor groeivertraging na TBI en 
HCT, 2) pubertaire groei is ernstiger gecompromitteerd bij jongens, en 3) groei 
van de benen is relatief gespaard bij meisjes, mogelijk ten gevolge van de 
hoge incidentie van gonadaal falen bij meisjes. 
In hoofdstuk 8 worden resultaten gepresenteerd van een evaluatie van 
groeihormoon (GH) secretie bij 29 kinderen met groeivertraging na TBI en 
HCT. GH secretie was verminderd in 8 patiënten,  en 23 van de 29 geteste 
patiënten werden behandeld met GH (1.33 mg/m2). Bij de overgrote 
meerderheid van deze patiënten nam de lengte SDS toe in het 1e jaar van de 
behandeling (gemiddeld met 0.35 SDS). Het effect van GH therapie werd 
geschat door de groei van individuele patiënten tijdens GH therapie te 
vergelijken met de voorspelde groei op basis van individuele groei voor start 
therapie en het model zoals beschreven in hoofdstuk 7. Het berekende netto 
effect van GH therapie op lengte SDS was +1.1 SDS. De response op GH 
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therapie correleerde niet met parameters van GH secretie, hetgeen suggereert 
dat een variabele mate van GH resistentie (als gevolg van stralingsschade aan 
de groeischijf) mogelijk belangrijker is dan de GH secretie status. Omdat GH 
therapie effectief bleek bij onze patiënten, ongeacht de GH secretie status, 
stellen wij voor een proefbehandeling met GH te overwegen bij alle kinderen 
met groeivertraging en een verwachte lage eindlengte.  
Hoofdstuk 9 beschrijft groei en endocriene functie na conditionering met 
busulfan (Bu) bij 64 kinderen zonder voorafgaande bestraling. De gemiddelde 
lengte SDS bleef stabiel, maar bij 17/48 patiënten (35%) zonder andere 
groeibeperkende factoren werd een onverklaarde verstoring van de lengtegroei 
na HCT gezien. (10/23 patiënten met hematologische maligniteiten). GH 
secretie werd geëvalueerd bij 10 patiënten, en 4 hadden een insufficiënte GH 
secretie. Van 52 patiënten was de schildklierfunctie beschikbaar. Twee van 
hen hadden een antistof-gemedieerde schildklier dysfunctie en 10 (19%) 
hadden een gecompenseerde primaire hypothyreoidie. De gonadale functie 
was beschikbaar van 21 patiënten en was normaal bij alle 7 patiënten die 
behandeld waren met een lage dosis Bu (8 mg/kg), terwijl 7 van de 14 kinderen 
die een hoge dosis Bu hadden ontvangen (16–20 mg/kg) gonadaal falen 
ontwikkelden. De meerderheid van deze patiënten was naast de conditionering 
nooit eerder behandeld met gonadotoxische therapie. Van de 49 evalueerbare 
patiënten ontwikkelden er 16 een subklinische hyperparathyreoidie. Wij 
concludeerden dat, naast gonadale en thyroidale dysfunctie, belemmering van 
groei en hyperparathyreoidie veel voorkomt na conditionering op basis van Bu, 
en dat bij sommige patiënten insufficiënte GH secretie kan bijdragen aan de 
groeivertraging. 
In hoofdstuk 10 wordt de Quality of life (QOL) beschreven van 22 
volwassenen die op de kinderleeftijd een HCT ondergingen (patiënten uit de 
studie in hoofdstuk 4), waarbij gebruik gemaakt is van zowel generieke als 
ziekte-specifieke vragenlijsten. HCT-gerelateerde variabelen werden 
verzameld uit de medische registratie. De meeste resultaten van de generieke 
QOL metingen vielen in het normale bereik, hoewel enige ziekte-gerelateerde 
beperking werd gerapporteerd op subschalen voor algemeen en werk-
gerelateerd functioneren. In vergelijking met een referentiegroep bestaande uit 
patiënten die als volwassenen een HCT ondergingen, scoorden onze patiënten 
significant hoger op de subschaal ‘emotioneel welbevinden’ van de ziekte-
specifieke vragenlijst. Dit duidt op een significant beter emotioneel 
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functioneren. Noch leeftijd ten tijde van HCT, noch TBI waren gerelateerd aan 
de patiënt’s QOL. We concludeerden dat het ondergaan van HCT op de 
kinderleeftijd geen negatieve invloed heeft op de QOL op de lange termijn.  
In hoofdstuk 11 worden de belangrijkste endocriene late effecten besproken, 
waarbij de resultaten uit dit proefschrift worden gecombineerd met overige 
gegevens uit de literatuur. Aan het eind van dit hoofdstuk worden conclusies 
en aanbevelingen gegeven. 
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